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The aim of this study is to investigate the effects of coformers and polymers on the phase 
transformation and release profiles of cocrystals. Pharmaceutical cocrystals of Carbamazepine 
(CBZ) (namely 1:1 carbamazepine-nicotinamide (CBZ-NIC), 1:1 carbamazepine-saccharin (CBZ-
SAC) and 1:1 carbamazepine-cinnamic acid (CBZ-CIN) cocrystals, were synthesized. A Quality by 
Design (QbD) approach was used to construct the formulation.  
Dissolution and solubility were studied using UV imaging and High Performance Liquid 
Chromatography (HPLC). The polymorphic transitions of cocrystals and crystalline properties were 
examined using Differential Scanning Calorimetry (DSC), X-Ray Powder Diffraction (XRPD), 
Raman spectroscopy (Raman) and Scanning Electron Microscopy (SEM). JMP 11 software was 
used to design the formulation. 
It has been found that Hydroxupropyl methylcellulose (HPMC) cannot inhibit the transformation of 
CBZ-NIC cocrystals to Carbamazepine Dihydrate (CBZ DH) in solution or in the gel layer of the 
matrix, as opposed to its ability to inhibit CBZ Form III (CBZ III) phase transition to CBZ DH.  
The selection of different coformers of SAC and CIN can affect the stability of CBZ in solution, 
resulting in significant differences in the apparent solubility of CBZ. The dissolution advantage of 
the CBZ-SAC cocrystal can only be shown for 20 minutes during dissolution because of the 
conversion to its dihydrate form (CBZ DH). In contrast, the improved CBZ dissolution rate of the 
CBZ-CIN cocrystal can be realised in both solution and formulation because of its stability. 
The polymer of Hypromellose Acetate Succinate (HPMCAS) seemed to best augment the extent of 
CBZ-SAC and CBZ-CIN cocrystal supersaturation in solution. At 2 mg/ml of HPMCAS 
concentration, the apparent CBZ solubility of CBZ-SAC and CBZ-CIN cocrystals can increase the 
solubility of CBZ III in pH 6.8 phosphate buffer solutions (PBS) by 3.0 and 2.7 times respectively. 
All pre-dissolved polymers in pH 6.8 PBS can increase the dissolution rates of CBZ cocrystals. In 
the presence of a 2 mg/ml HPMCAS in pH 6.8 PBS, the cocrystals of CBZ-NIC and CBZ-CIN can 
dissolve by about 80% within five minutes in comparison with 10% of CBZ III in the same 
dissolution period. Finally, CBZ-NIC cocrystal formulation was designed using the QbD principle. 
The potential risk factors were determined by fish-bone risk assessment in the initial design, after 
which Box-Behnken design was used to optimize and evaluate the main interaction effects on 





tablets meeting the required Quality Target Product Profile (QTPP) were produced. The tablets’ 
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QbD                                      Quality by Design 
QbT                                       Quality by Testing 
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SDG                                    Solvent Drop Grinding 
SDS                                     Sodium Dodecyl Sulphate 
SLS                                     Sodium Lauryl Sulphate 
SMPT                                 Solution Mediate Phase Transformation 
SSNMR                              Solid State Nuclear Magnetic Resonance Spectroscopy 
TGA                                   Thermal Gravimetric Analysis 
TPDs                                  Ternary Phase Diagrams 
XRD                                   X-Ray Diffraction 






Chapter 1 Introduction 
1.1 Research background 
In the pharmaceutical industry, it is poor biopharmaceutical properties (low biopharmaceutical 
solubility,  dissolution rate and intestinal permeability) rather than toxicity or lack of efficacy that 
are the main reasons why less than 1% of active pharmaceutical compounds eventually get into the 
marketplace [1, 2]. Enhancing the solubility and dissolution rates of poorly water soluble 
compounds has been one of the key challenges to the successful development of new medicines in 
the pharmaceutical industry. Although many methods including prodrug, solid dispersion, 
micronisation and salt formation have been developed to answer this purpose, pharmaceutical 
cocrystals have been recognised as an alternative approach with the enormous potential to provide 
new and stable structures of active pharmaceutical ingredients (APIs) [1, 3]. Apart from offering 
potential improvements in solubility, dissolution rate, bioavailability and physical stability, 
pharmaceutical cocrystals frequently enhance other essential properties of APIs such as 
hygroscopicity, chemical stability, compressibility and flowability [4]. These behaviours have been 
rationalised by the crystal structure of the cocrystal vs. the parent drug [5]. Different coformers can 
form different packing styles and hydrogen bonds with an API, conferring significantly different 
physicochemical properties and in vivo behaviours on the resultant cocrystals [6, 7].  
Although pharmaceutical cocrystals can offer the advantages of higher dissolution rates and greater 
apparent solubility to improve the bioavailability of drugs with poor water solubility, a key 
limitation of this approach is that a stable form of the drug can be recrystallized during the 
dissolution of the cocrystals, resulting in the loss of the improved drug properties. For example, in 
the previous study of the Mingzhong’s lab, they investigated the dissolution and phase 
transformation behaviour of the CBZ-NIC cocrystal using the in situ technique of the UV imaging 
system and Raman spectroscopy, demonstrating that the enhancement of the apparent solubility and 
dissolution rate has been significantly reduced due to its conversion to CBZ DH [8]. In order to 
inhibit the form conversion of the cocrystals in aqueous media, the effects of various coformers and 
polymers on the phase transformation and release profiles of cocrystals in aqueous media and 
tablets were studied. Most research work on coformer selection is currently focused on the 
possibility of cocrystal formation between APIs and coformers. Only a small amount of work has 
been carried out to identify a coformer to form a cocrystal with the desired properties, and there has 




1.2 Research aim and objectives 
The Biopharmaceutics Classfication System (BCS) has been introduced as a scientific framework 
for classifying drug substances according to their aqueous solubility and intestinal permeability [9]. 
CBZ is classified as a Class II drug, with the properties of low water solubility and high 
permeability. This class of drug is currently estimated to account for about 30% of both commercial 
and developmental drugs [10]. The aim of this study is to investigate the influence of coformers and 
polymers on the phase transformation and release profile of CBZ cocrystals in solution and tablets. 
The QbD approach was used to develop a formulation that ensures the quality, safety and efficacy 
of the tablets. The specific objectives of this research can be summarised as follows: 
Objective 1: A brief review of strategies to overcome poor water solubility is presented. The 
definition of pharmaceutical cocrystal is introduced together with the relevant basic theory, as well 
as recent progress in the field. The formulation of tablets designed by QbD is introduced.  
Objective 2: Three pharmaceutical cocrystals, CBZ-NIC, CBZ-SAC and CBZ-CIN, were prepared 
using solvent evaporation and cooling crystallisation methods. Various techniques were used to 
characterize the prepared CBZ cocrystals. 
Objective 3: The effect of coformers and polymers on the phase transformation and release profiles 
of CBZ cocrystals is investigated. The mechanism of the phase transformation of pharmaceutical 
cocrystals in aqueous media for the selection of lead cocrystals to ensure the success of product 
development is explored in order to acquire an understanding of the process. 
Objective 4: QbD principles and tools were used to design the CBZ-NIC cocrystal tablets. DOE was 
used to optimize and evaluate the main interaction effects on the quality of formulation. 
Mathematical models are established to predict the dissolution performance of the tablet.  
1.3 Thesis structure 
This thesis is organized into nine chapters: 
Chapter 1 briefly describes the research background, research aim, objectives and structure of Shi’s 
PhD research. 
Chapter 2 reviews the mechanisms used to overcome poor water solubility. One of these, the 




recent progress is outlined. The drug delivery system of tablets is introduced, together with some 
definitions and the principles of QbD. Finally, CBZ, including CBZ cocrystals and CBZ 
formulation, is summarized. 
Chapter 3 introduces all the materials and methods used in this study. The principles underlying the 
analytical techniques used are given in this chapter. Operation and methods developments are 
described in detail, as are the preparation of dissolution media and the various test samples. 
Chapter 4 characterises all CBZ samples used in this study. The characterization results of the 
various forms of CBZ samples, which include CBZ III and CBZ DH, three cocrystals of CBZ, 
which include CBZ-NIC cocrystal, as well as the CBZ-SAC and CBZ-CIN cocrystals, are presented, 
together with the molecular structures of the CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals. 
Chapter 5 covers the influence of HPMC on the phase transformation and release profiles of the 
CBZ-NIC cocrystal in solution and in sustained release matrix tablets. The examination by DSC, 
XRPD, Raman spectroscopy and scanning electron microscopy of polymorphic transitions of the 
CBZ-NIC cocrystal and its crystalline properties is described, as well as the investigation by UV-
imaging of the intrinsic dissolution rate of the CBZ-NIC cocrystal and an investigation by HPLC of 
the release profiles of the CBZ-NIC cocrystal in solution and sustained release matrix tablets. 
Chapter 6 covers the influence of coformers on the phase transformation and release profiles of 
CBZ-SAC and CBZ-CIN cocrystals in HPMC solution and in sustained release matrix tablets. The 
examination by DSC, XRPD and SEM of the polymorphic transitions of the CBZ-SAC and CBZ-
CIN cocrystals and their crystalline properties, the investigation of the powder dissolution studies of 
CBZ-SAC and CBZ-CIN cocrystals in HPMC solutions and the investigation by HPLC of solubility 
and release profiles of the CBZ-SAC and CBZ-CIN cocrystals in solution and sustained release 
matrix tablets are all detailed. 
Chapter 7 deals with the influence of the polymers of HPMCAS, Polyethylene Glycol 4000 (PEG) 
and Polyvinvlpyrrolidone K30 (PVP) on the phase transformation and release profiles of CBZ 
cocrystals in solution and in tablets, and with the examination by DSC, XRPD and SEM of the 
polymorphic transition of the CBZ cocrystals and their crystalline properties, together with the 
investigation of the powder dissolution tests of CBZ cocrystals in polymer solutions and the 




In Chapter 8, QbD principles and tools were used to develop a tablet formulation that ensures the 
quality, safety and efficacy of CBZ-NIC cocrystal sustained release tablets.  
Chapter 9 summarizes the present work and the results obtained from my research. Further work in 




Chapter 2 Literature Review 
2.1 Chapter overview 
In this chapter, some basic termaqueos in pharmaceutical physical chemistry are defined. A brief 
review of strategies to overcome poorly-water solubility are then presented, including prodrug, salt 
formation, high-energy amorphous forms, particle size reduction, cyclodextrin complexation and 
pharmaceutical cocrystals, the last of which are presented in detail. Secondly, the formulation of 
tablets using the QbD method was introduced [11], including the drug delivery system-tablets and 
some definitions and basic concepts of QbD. This presents general knowledge about QbD, the 
advantages and the types of tablets, tablet excipients and tablet production via direct compression. 
Finally, a brief review of CBZ incorporates a CBZ pharmaceutical cocrystal case study and a 
summary of CBZ sustained/controlled release formulations. 
2.2 Definitions of basic concepts relating to pharmaceutical physical chemistry  
Equilibrium Solubility 
The extent to which dissolution proceeds under a given set of experimental conditions is referred to 
as the solubility of the solute in the solvent. Thus, the solubility of a substance is the amount that 
passes into solution when equilibrium is established between the solution and excess substance  
[12]. 
Apparent solubility 
Apparent solubility refers to the concentration of material at apparent equilibrium (supersaturation). 
Apparent solubility is distinct from true thermodynamic solubility, which is reached at infinite 
equilibrium time [13].  
Polymorphism and transformation  
Polymorphism is a solid crystalline phenomenon of a given compound that results from the ability 
of at least two crystal structures of that compound’s molecules in its solid state. There are two types 
of polymorphism: the monotropic system, in which the transition between different polymorphs is 
irreversible, and the enantiotropic system, where the two polymorphs can repeatedly interchange 





Two aspects of drug absorption are important in clinical practice: the rate at which, and the extent to 
which, the administered dose is absorbed. The fraction of an administered dose of drug that reaches 
the systemic circulation in an unchanged form is known as the bioavailable dose. Bioavailability is 
concerned with the quantity and rate at which the intact form of a particular drug appears in the 
systemic circulation following administration of that drug [14]. 
2.3 Strategies to overcome poor water solubility 
The drugs are classified by the biopharmaceutics classification system (BCS) into four categories 
based on their aqueous solubility and permeability [15], as shown in Fig.2.1. 
 
Fig.2.1 Four classes drugs: ClassI, Class II, Class III and Class IV [15] 
For Class II and Class IV drugs, the bioavailability can be improved by the enhancement of 
solubility, especially for Class II drugs. It is reported that nearly 40%-70% of newly developed 
chemical compounds are not aqueous soluble enough to ensure therapeutic efficacy in 
gastrointestinal (GI) absorption [15]. The poor solubility that may obstruct development of 
parenteral products and limit bioavailability of oral ones has been of concern regarding 
formulations. There are generally two methods for changing Active Pharmaceutical Ingredient (API) 
solubility or dissolution: material engineering of the API (prodrug, salt formation and 
pharmaceutical cocrystal) and formulation approaches (high-energy amorphous formation, particle 




2.3.1 Prodrug strategy 
Prodrug strategy is applied as a chemical/biochemical method to overcome many barriers to drug 
delivery [16]. A prodrug is a medication that is administered in an inactive or less than fully active 
form, and is then converted to its active form through a normal metabolic process. An example 
would be hydrolysis of an ester form of the drug [17]. 
Fosamprenavir provides an illustration of this process. A prodrug of the HIV protease inhibitor, 
amprenavie, fosamprenavir takes the form of a calcium salt which is about 10 times more soluble 
than amprenavir. Because of this superior solubility, patients need just two tablets twice a day 
instead of eight capsules of amprenavir twice a day. It is more convenient for patients, and provides 
a longer patent clock [18-22].  
2.3.2 Salt formation 
The most common method of increasing the solubility of acidic and basic drugs is salt formation. 
Salts are formed through proton transfer from an acid to a base. In general, if the difference of pKa 
is greater than 3 between an acid and a base, a stable ionic bond could be formed [23]. For example, 
the dissolution rate and oral bioavailability of celecoxib, a poorly water-soluble weak acidic drug, is 
greatly enhanced by being combined with sodium salt formation [24]. 
2.3.3 High-energy amorphous forms 
Because of the higher energy of amorphous solids, they are generally up to 10 times more soluble 
[25]. Many solid dispersion techniques such as the melting and solvent methods could be used to 
achieve a stable amorphous formulation. The intrinsic dissolution rate of Ritonavir, a Class IV drug 
with low solubility and permeability, for example, is 10 times that of crystalline solids [26]. 
2.3.4 Particle size reduction 
A drug’s dissolution rate rises as the surface area of its particles increases [24]. A reduction in 
particle size is thus the most common method of improving the bioavailability of drugs in the 
pharmaceutical industry. The micronized drug particles, which are 2-3 μm, can be achieved by 
conventional milling. However, the nanocrystal particles, which are smaller than 1 μm, are 
produced by wet-milling with beads. Particle size reduction can result in an increase in surface area 




8.7-fold and 5.5-fold enhancements in Cmax and AUC were found in nitrendipine’s nanocrystal 
formulation compared with micro-particle size crystal formulation, for example [27-29]. 
2.3.5 Cyclodextrin complexation 
Cyclodextrins (CD) are oligosaccharides containing a relatively hydrophobic central cavity and a 
hydrophilic outer surface. A lipophilic microenvironment is provided by the central CD cavity, into 
which any suitably-sized drug may enter and include. There are no covalent bonds formed or 
broken between the API/CD complex formation and in aqueous solutions. The apparent solubility 
of poorly water-soluble drugs, and consequently their dissolution rate, is improved. CD intervention 
is thus well suited to Class II and IV drugs, of which 35 marketed formulations already exist [30]. 
2.3.6 Pharmaceutical cocrystals 
A pharmaceutical cocrystal is a crystalline single phase material containing two or more 
components, one of which is an API, generally in a stoichiometric ratio amount [8].  
2.3.6.1 Design of cocrystals 
The components in a cocrystal exist in a definite stoichiometric ratio, and are assembled via non-
convalent interactions such as hydrogen bonds, ionic bonds, π-π and van der Waals interactions 
rather than by ion pairing [31]. Hydrogen bonding is the most common bonding for cocrystals. 
Some commonly found synthons are shown in Fig.2.2 [32]. 
 
Fig.2.2 Common synthons between carboxylic acid and amide functional groups [32] 
A design strategy is required to obtain the desired cocrystals. A practical screening paradigm is 





Fig.2.3 Cocrystal screening protocol [5] 
Computational screening of cocrystals uses summative surface interaction via electrostatic potential 
surfaces to predict of the H-bond propensity based on Cambridge Structural Database (CSD) 
statistics [5]. Charges across the surface of the molecule can interact in pairwise fashion, as a result 
of which the a strongest hydrogen bond donor to strongest hydrogen bond accepter interaction takes 
place (Fig.2.4) [5, 33]. This summative energy is then compared to the sum of self:self interactions 
for both components. The lower energy, more likely structure is then ranked against others to 
predict the most likely cocrystals or lack of them [5].  
 
Fig.2.4 Summary surface energy approach to screening [5] 
The solvent-assisted grinding is the most common method for cocrystal physical screening due to 
the inherent propensity of the technique to function in the region of ternary phase space, where  
cocrystal stability is readily accessible [33, 34]. 
The aim of the selection is to investigate the physiochemical and crystallographic properties. The 
physicochemical properties included stability, solubility, dissolution rate and compaction 
behaviours. Both in vitro and in vivo tests were used to evaluate the performance of formed 




2.3.6.2 Cocrystal formation methods 
Cocrystals can be prepared using the solution method or by grinding the components together. 
Sublimation, cocrystals using supercritical fluid, hot-stage microscopy and slurry preparation have 
also been reported [26, 36]. 
Solution methods 
Slow evaporation from solutions with equimolar or stoichiometric concentrations of cocrystals is 
one of the most important solution methods. There is, however, a risk of crystallizing the single 
component phase [1]. 
The grinding method [37] 
Patil et als’ preparation of quinhydrone cocrystal products was the first time cocrystals were 
prepared by cocrystallization without a solution. Instead, reactants were ground together [37, 38]. 
There are two techniques for cocrystal synthesis by grinding. The first is dry grinding [39], in which 
the mixtures of cocrystal components are ground mechanically or manually [40], and the second is 
liquid-assisted grinding [41]. 
Other methods 
Several new methods relating to pharmaceutical cocrystals have also been proposed. Sjoljar et al. 
prepared 1:1 or 1:2 molar ratio CBZ and NIC cocrystals by a gas anti-solvent method of 
supercritical fluid process [42]. Lehmann was the first to describe the mixed fusion method in 1877 
[43], a methodology refined by Kofler [44]. Because of its use in screening, it is recognized as an 
effective method by which to identify phase behaviour in a two-component system [45]. David used 
hot-stage microscopy to screen a potential cocrystal system [45], employing NIC as coformer with a 
range of APIs with the functionalities of carboxylic acid and amide. Cocrystallization by the slurry 
technique has been used as a new method for several cocrystals [46]. Noriyuki et al. successfully 
utilized it for the cocrystal screening of two pharmaceutical chemicals with 11 coformers [47]. 
2.3.6.3 Properties of cocrystals 
Physical and chemical properties of cocrystals are the most important for drug development. The 




properties in order to improve the stability and efficacy of a dosage form [1, 48]. The main 
properties of pharmaceutical cocrystal are as follows: 
Melting point 
The melting point of a compound is generally used as a means of characterization or purity 
identification; however because hydrogen bonding networks along with intermolecular forces are 
known to contribute to physical properties of solids such as enthalpy of fusion, it is also valuable in 
the pharmaceutical sciences. It is thus very advantageous to tailor the melting point toward a 
particular coformer of a cocrystal before it is synthesized by the melting point. For example, AMG 
517 was selected as the model drug (API) and 10 cocrystals with respective coformers were 
synthesized. The authors compared their melting points and the results show that those of 10 
cocrystals are all between that of AMG 517 (API) and their correspondent coformers [49].  
Stability 
Physical and chemical stability is very important during storage. Water must also be added in some 
processes such as wet granulation. The stability of a drug in high humidity is therefore very 
important. Pharmaceutical cocrystals have an obvious advantage over other strategies. The 
synthesis of most cocrystals is based on hydrogen bonding, so solvate formation that relies on such 
bonding will be inhibited by the formation of cocrystals if the interaction between the drug and 
coformer is stronger than between the drug and solvent molecules. Taking CBZ as an example, 
even though it is transformed to CBZ dihydrate when exposed to high relative humidity, the 
cocrystals of CBZ-NIC and CBZ-SAC are not [50], as shown in Fig.2.5. 
 
Fig.2.5 Moisture uptake of  CBZ III, CBZ-NIC and CBZ-SAC  cocrystals at room temperature for three weeks at 100% 





Pharmaceutical cocrystals have been shown to be a valid method for the improvement of tablet 
performance. For example, tablet strength was demonstrably improved for ibuprofen and 
flurbiprofen when cocrystallised with NIC [25]. 
Dissolution 
A dissolution improvement in ibuprofen-nicotinamide cocrystals is shown in Fig.2.6. Based on the 
spring and parachute model, if the transient improvement in concentration is great and is maintained 
over a bio-relevant timescale for administration, pharmaceutical cocrystals will be a potential 
method by which to improve drug bioavailability [25].  
 
Fig.2.6 Comparison of dissolution of ibuprofen, Nicotinamideand ibuprofen-nicotinamide cocrystals [25] 
2.3.6.4 Cocrystal characterization techniques 
In generally, the most common techniques used to characterize cocrystal are Raman, Differential 
Scanning Salorimetry (DSC), Infrared Spectroscopy (IR), XRPD, SEM and Solid State Nuclear 
Magnetic Resonance Spectroscopy (SSNMR). 
2.3.6.5 Theoretical development in the solubility prediction of pharmaceutical cocrystals 
Prediction of cocrystal solubility 
Pharmaceutical cocrystals can improve the solubility, dissolution and bioavailability of poorly 
water-soluble drugs. However, true cocrystal solubility is not readily measured for highly soluble 




solubility of cocrystals has been the subject of much research. Rodríguez-Hornedo’s research group 
has contributed greatly to the study of cocrystal solubility [9] investigating inter alia the solubility 
advantage of pharmaceutical cocrystals and the predicted solubility of cocrystals based on eutectic 
point constants, [9, 51]. 
Cocrystal eutectic point 
The cocrystal transition concentration or eutectic point is a key parameter that establishes the 
regions of thermodynamic stability of cocrystals relative to their components. It is an isothermally 
invariant point where two solid phases coexist in equilibrium with the solution [9].  
Prediction of solubility behaviour by cocrystal eutectic constants [9, 51] 
The cocrystal to drug solubility ratio (ɑ) is shown to determine the excess eutectic coformer 
concentration and the eutectic constant (Keu), which is the ratio of solution concentrations of 
cocrystal components at the eutectic point. The composition of the eutectic solution and the 
cocrystal solubility ratio are a function of component ionization, complexation, solvent and 
stoichiometry.  
For cocrystal AyBz, where A is the drug and B the coformer, its solubility, eutectic composition and 
solution complexation from the eutectic of the solid drug A and the cocrystal are predicted by three 
equations and equilibrium constants 
𝐴𝑠𝑜𝑙𝑖𝑑 ⇌ 𝐴𝑠𝑜𝑙𝑛        𝑆𝑑𝑟𝑢𝑔 = 𝑎𝑑𝑟𝑢𝑔                                                Equ.2.1 
𝐴𝑦𝐵𝑧𝑠𝑜𝑙𝑖𝑑 ⇌ 𝑦𝐴𝑠𝑜𝑙𝑛 + 𝑧𝐵𝑠𝑜𝑙𝑛    𝐾𝑠𝑝 = 𝑎𝑑𝑟𝑢𝑔
𝑦
𝑎𝑐𝑜𝑓𝑜𝑟𝑚𝑒𝑟                        
𝑧
Equ.2.2 
𝐴𝑠𝑜𝑙𝑛 + 𝐵𝑠𝑜𝑙𝑛 ⇌ 𝐴𝐵𝑠𝑜𝑙𝑛       𝐾11 =
𝑎𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑎𝑑𝑟𝑢𝑔𝑎𝑐𝑜𝑓𝑜𝑟𝑚𝑒𝑟
                                 Equ.2.3 
where 𝑆𝑑𝑟𝑢𝑔, 𝐾𝑠𝑝 and 𝐾11 are the intrinsic drug solubility in a pure solvent, the cocrystal solubility 
product and the complexation constant respectively. Activity coefficients are relatively constant for 
the dilute solution. By combining Equations 2.1, 2.2 and 2.3, the concentration of the complex at 
eutectic can be written in Equ.2.4. 









As described in the definition of the cocrystal eutectic point, for poorly water-soluble drugs and 
more soluble coformers, the eutectic should be for solid drugs and cocrystals in equilibrium with the 
solution. The solubility, stability and equilibrium behaviour are all relevant to the eutectic constant 
(𝐾𝑒𝑢), which is the concentration ratio of total coformer to total drug that satisfies equilibrium 




















1/𝑧 ]                                     Equ.2.5 
The cocrystal 𝐾𝑠𝑝 and drug solubility represent the eutectic concentrations of free components. 
Considerations of ionization for either component can be added to this equation. For a monoprotic 





[𝐵]𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 + [𝐵]𝑖𝑜𝑛𝑖𝑧𝑒𝑑 + [𝐴𝐵]
[𝐴]𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 + [𝐴]𝑖𝑜𝑛𝑖𝑧𝑒𝑑 + [𝐴𝐵]
 






























                               Equ.2.6       
where [H+] is the hydrogen ion concentration and𝐾𝑎  is the dissociation constant for the acidic 
conformer or the conjugate acid of the basic drug. Considering the case of components with 








































                   Equ.2.7 
where g and m are the total number of acidic groups for each component and j and q are the total 
number of basic groups. In this case the eutectic constant is a function of the cocrystal solubility 
product, drug solubility and ionization. Letting the ionization terms for drug and coformer equal 














                                               Equ.2.8 
Keu can also be expressed as a function of the cocrystal to drug solubility ratio (α) in pure solvent 
using the previously described equation for cocrystal solubility [9] 
𝐾𝑒𝑢 = 𝑧𝑦
𝑦/𝑧𝛼(𝑦+𝑧)/𝑧                                                       Equ.2.9 
𝑤ℎ𝑒𝑟𝑒   𝛼 =
𝑆𝑐𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙
𝑆𝑑𝑟𝑢𝑔𝛿𝑑𝑟𝑢𝑔
                                                Equ.2.10 





                  Equ.2.11 
For a drug with known solubility, Equ.2.9 allows the cocrystal solubility to be predicted from the 
eutectic constant or vice versa. For a 1:1 cocrystal (i.e. y=z=1), Equ.2.9 becomes 𝐾𝑒𝑢 = 𝛼
2 , 
indicating that 𝐾𝑒𝑢 is the square of the solubility ratio of cocrystal to drug in a pure solvent. A 𝐾𝑒𝑢 
greater than 1 thus indicates that the 1:1 cocrystal is more soluble than the drug, while a less soluble 
one would have 𝐾𝑒𝑢 values of less than 1. 
The prediction solubility of cocrystals CBZ-NIC, CBZ-SAC and CBZ-CIN is discussed in the 
Appendiceses. 
Cocrystal Solubility (Scc) and the Phase Solubility Diagram (PSD) [9, 51] 
The solubility and stability of cocrystals can be explained by phase solubility diagrams. One stable 
cocrystal (Case 1) and one metastable cocrystal (Case 2) in solvent are shown in Fig.2.7. The 
solubility product behaviour of the cocrystal with the drug concentration as a function of the 




 from Equ.2.2. The 
drug solubility, shown by the horizontal line, is assumed to be much lower than the ligand 
(coformer) solubility, which is not shown. A dashed line represents stoichiometric solution 
concentrations or stoichiometric dissolution of cocrystals in pure solvent, and their intersection with 
the cocrystal solubility curves (marked by circles) indicates the maximum drug concentration 
associated with the cocrystal solubilities. For a metastable cocrystal (Case 2), the drug 
concentration associated with the cocrystal solubility is greater than the solubility of the stable drug 
form (the horizontal line). The solubility of a metastable cocrystal is not typically a measurable 




cocrystal dissolves, the drug released into the solution can crystallize because of supersaturation. 
This supersaturation is a necessary, but not sufficient condition for crystallization. In certain 
instances, slow nucleation might delay crystallization of the favoured thermodynamic form and 
enable measurement of the true equilibrium, solubility. In Case 1, a congruently saturating cocrystal 
has a lower drug concentration than the pure drug form at their respectively solubility values. The 
solubility of congruently saturating cocrystals can therefore be readily measured from solid 
cocrystals dissolved and equilibrated in solution.  
For both congruently and incongruently saturating cocrystals, eutectic points, indicated by Xs in 
Fig.2.8, are the points where both solid drug and cocrystal are in equilibrium with a solution 
containing drug and coformer. The drug and conformer solution concentrations at the eutectic point 
are together referred to as the transition concentration (𝐶𝑡𝑟). 
The solubility product expresses all possible solution concentrations of the drug and the ligand 
(coformer) in equilibrium with the solid cocrystal, and is directly related to cocrystal solubility by 
Equ.2.11. Inserting the cocrystal transition concentration ([A]tr and [B]tr) into Equ.2.11 allows 
Equ.2.12 to be rewritten as 










                                                   Equ.2.12 
 
Fig.2.7 Schematic phase solubility diagram of two different cocrystals based on the 𝐾𝑠𝑝  for a stable (Case 1) or 




Methods used to determine the transition concentration 𝐶𝑡𝑟 have been investigated [9]. A flowchart 
of two methods used to determine cocrystal transition concentrations is shown in Fig 2.8. Method 1: 
Cocrystal 𝐶𝑡𝑟 was measured by adding the drug to a near saturated coformer solution and slurring 
for 24 hours. Method 2: The same cocrystal was measured by dissolving it in a saturated drug 
solution and then slurring it for 24 hours. There should be two solid phases (cocrystal and drug) in 
the collected samples after this period. The drug and coformer (ligand) concentration were analysed 
by High-Performance Liquid Chromatography (HPLC). 
 
Fig.2.8 Flowchart of method used to establish the invariant point and determine equilibrium solubility transition 
concentration of cocrystal components [9] 
Solution Mediated Phase Transformation (SMPT) 
Many approaches have been used to improve the solubility of poorly water-soluble drugs. However, 
these approaches all result in a phenomenon called “Solution Mediated Phase Transformation” 
(SMPT), the crystallization of a stable solid phase during dissolution of a metastable phase caused 
by supersaturation conditions in solution or at the surface of the dissolving solid, as shown in 
Fig.2.9. The dissolution advantage is therefore lost during dissolution resulting from the 
crystallization of a stable phase.  
Method 1 Method 2 
Add drug to a near-
saturated coformer 
solution 
Add cocrystal and 
drug to saturated 
drug solution 
Does XRPD indicate 
a mixed solid phase? 
Sample liquid for 
HPLC analysis 
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Slurry for 24 hours 
or 
Add coformer (Method 1) 
or cocrystal (Method 2) & 




Many important properties of solid materials are determined by crystal packing, so crystal 
polymorphism has been increasly recognized. For example, more than one crystalline polymorph 
may exist in pharmaceutical supramolecular isomers. The dissolution rate, equilibrium solubility 
and absorption may differ significantly [52].  
In a monotropic polymorphic system this compound has two forms, Phases I and II. As the 
metastable solid (Phase I) dissolves, the solution is supersaturated with respect to Phase II, leading 
to precipitate Phase II and growth [53]. SMPT has been extensively examined for many years as 
regards amorphous solids, polymorphs and salts [54-56]. However, only a few studies have focused 
on the SMPT of cocrystals during dissolution.  
 
Fig.2.9 Phase diagram for a monotropic system [57] 
In our previous lab works, different forms of CBZ (Form I, Form III and CBZ DH, CBZ-NIC 
cocrystals and physical mixtures) were studied in situ using UV imaging techniques. Within the 
first three minutes all intrinsic dissolution rates (IDRs) of the test samples reached their maximum 
values. During the three-hour dissolution test the IDR of CBZ DH was almost constant at 0.0065 
mg/min/cm
2
. The IDR profiles of CBZ I and CBZ III were similar, with the maximum IDRs being 
reached in two minutes and then decreasing quickly to relatively stable values. The greatest 
variability in IDR of the CBZ-NIC mixture is shown in Fig.2.10. Its IDRmax is the highest of the 
five test samples due to the effect of a very high concentration of NIC in the solution. Compared 
with CBZ I, CBZ III and the CBZ-NIC mixture, the IDR of CBZ-NIC cocrystals decreased slowly 





Fig.2.10 Intrinsic dissolution rates as a function of dissolution time obtained by UV imaging at a flow rate of 0.2 
mL/min (n=3) [8] 
Studies of the effects of surfactants and polymers on cocrystal dissolution has shown that they can 
impart thermodynamic stability to cocrystals that otherwise convert to a stable phase in aqueous 
solution [58]. 
Effects of polymers and surfactants on the transformation of cocrystals 
The means of maintaining the solubility advantage of cocrystals is very important. The “spring and 
parachute model” has been widely used in cocrystal systems. This behaviour is characterised by a 
transient improvement in concentration and a subsequent drop, normally to the solubility limits of 
the free form in that pH environment [5]. The usefulness of pharmaceutical cocrystals depends on 
the timescale and extent of any improvement in concentration [25]. If such improvement occurs 
over a bio-relevant timescale, it is believed to improve bioavailability [5].  
Mechanisms for stabilizing supersaturation cocrystals in a polymer solution may result from the 
stabilization of its supersaturation by intermolecular H-bonding between drug and polymers [59], 
and the prevention of transformation by delaying nucleation or inhibiting crystal growth [60]. The 
effect of polymers on the dissolution behaviour of indomethacin-saccharin (IND-SAC) cocrystals 
has been investigated by Amjad [61]. Predissolved PVP was used to examine polymer inhibition of 
indomethacin crystallization. PVP was chosen because it forms hydrogen bonds with solid forms of 
IND [62]. The dissolution behaviour of IND-SAC cocrystals was studied in buffer, predissolved 
250 ug/mL PVP and 2% w/v PVP as shown in Fig.2.11. The results indicate that conversion of 
cocrystals takes place, but that PVP can kinetically inhibit indomethacin crystallization at higher 




The maintenance of supersaturation is of great importance in order to avoid erratic absorption of the 
drug [61].   
 
Fig.2.11 The concentration of indomethacin resulting from indomethacin-saccharin cocrystals at various times in PB at 
pH3. (△) in buffer only (○) in predissolved 250 ug/mL PVP (□) in predissolved 2% w/v PVP [61] 
The mechanism for stabilizing supersaturation cocrystals in surfactant solution differs from polymer 
solution. The solubility of poorly soluble drugs was increased by micellar surfactant solubilisation 
through micelle formation [61]. This approach is based on the differential solubilisation of the 
cocrystal components, where the surfactant preferentially increase the solubility of the poorly 
soluble component through micelle formation, resulting in the stabilization or minimization of the 
thermodynamic driving force behind conversion of the cocrystal. The effect of the surfactant on the 
dissolution behaviour of IND-SAC cocrystals was also investigated by Amjad [61].  The surfactant 
SLS was predissolved at various concentration in the range of 0-800 mM, and the eutectic points 
were determined. The Fig.2.12 shows the concentration of IND and SAC as a function of SLS 
concentration at the eutectic points. It can be seen that concentration of IND dramatically increased 
relatively to that of SAC with increasing SLS concentrations.  
 
Fig.2.12 Keu values (○) as a function of SLS concentration, The dotted line represents the theoretical presentation of Keu 




The dissolution behaviour of CBZ-SAC cocrystals in predissolved 25 mM SLS and 100 mM SLS is 
shown in Fig.2.13. The results indicate that the concentration of IND increases dramatically with 
increased SLS concentrations. The concentrated IND exhibited a parachuting effect with 25 mM 
SLS, dropping after the first measurement (two minutes) and continuing to decrease. With 100 mM 
SLS, IND reached a supersaturated state in 10 minutes [61]. 
 
Fig.2.13 The concentration of indomethacin resulting from indomethacin-saccharin cocrystals at various times in PB at 
pH3 (△) in buffer only (○) in predissolved 25 mM SLS (□) in predissolved 100 mM SLS [61] 
2.4 The formulation of tablets by QbD 
2.4.1 Drug delivery system-Tablets  
Tablets were the most common form of dosage. It has many advantages over other forms, including 
simplicity of administration, ease of portability by the patient, simplicity and speed of mass 
production and markedly lower manufacturing cost [14]. 
2.4.1.1 Types of tablets [14] 
The commonest type is those intended to be swallowed whole. Many tablets are formulated to be 
effervescent because of their more rapid release of medicament and reduced chance of causing 
gastric irritation. Some tablets are designed to be chewed and used where buccal absorption is 
desired. There are now many types of tablets that provide for the release of the drug to be delayed 




2.4.1.2 Tablet excipients 
A tablet does not contain only the active ingredient, but also other substances known as excipients, 
which have specific functions.  
Diluents 
Diluents are inert substances that are added to the active ingredient in sufficient quantity to make a 
reasonably sized tablet. Lactose, dicalcium phosphate and microcrystalline cellulose are used 
extensively as tablet diluents. 
Binder agents  
The substances that act as adhesives to bind powders together in the wet granulation process are 
known as binders. They are also used to bind granules together during compression. If the binding 
is too little in a formulation, soft granules result. Conversely, too much binding produces large, hard 
granules. The most common binders are glucose, starch and polyvinylpyrrolidone.  
Glidants 
Glidants are materials added to tablet formulations to improve the flow properties of the 
granulations. The most commonly used and effective glidant is colloidal silica.  
Lubricants 
These agents are required to prevent adherence of the granules to the punch faces and dies. They 
also ensure smooth ejection of the tablet from the die. Talc and magnesium stearate appear to be 
effective as punch lubricants. 
Disintegrants 
Disintegrants are always added to tablets to promote their breakup when they are placed in an 
aqueous environment. The object of a disintegrant is to cause the tablet to disintegrate rapidly so as 
to increase the surface area of the tablet fragments and so promote rapid release of the drug. Starch, 




2.4.1.3 Tablet preparation 
The two methods of tablet preparation are dry and wet, with direct compression and wet granulation 
being the most common respective examples. Their details are as follows:  
Direct compression 
The steps involved in direct compression are shown in Fig.2.14. The potential of this method lies in 
the discovery of directly compressible fillers or diluents which produce good quality tablets without 
prior manipulation. The direct compression diluents include microcrystalline cellulose, lactose, 
modified starch and dicalcium phosphate.  
 
Fig.2.14 Tablet production by direct compression [14] 
Direct compression offers several advantages: the small number of stages involved, the low cost of 
appliances and handling, and stability due to the fact that no heat and water are involved. Although 
it is a simple method, there are, however, limitations to its use. The difference in particle size and 
bulk density between the diluent and the drug may result in variations in the drug content of the 
tablets. 
Wet granulations 
This is the traditional method of giving a particulate solid those properties needed for it to produce 
satisfactory tablets. The process essentially consists of sticking the particles together using an 
adhesive material, thereby increasing particle size and improving flow properties. The enlarged 
particles are termed granules. Other additives are usually also incorporated at some stage. The 












Fig.2.15 Tablet production by wet granulation [14] 
2.4.2 QbD 
2.4.2.1 Introduction of QbD  
Pharmaceutical development involves traditional and systematic approaches. The former mainly 
depends on empirical evaluation of product and process performance. Product quality is tested at 
the end of the process or sometimes at a specific stage during production, rather than being 
designed into the process [63]. The aim of QbD, on the other hand, is to make more effective use of 
the latest pharmaceutical science and engineering principles and knowledge throughout the lifecycle 
of a product [64]. The difference between traditional approach and systematic (QbD) approaches 
are summarized in Table 2.1. 
Table 2.1 Difference between traditional and QbD approaches [65] 
Aspects Traditional QbD 
Pharmaceutical 
development 
Empirical Systematic; multivariate experiments 
Manufacturing 
process 
Fixed Adjustable within design space; 
opportunities for innovation 
Process control In process testing for go/on-go; offline 
analysis wide or slow response 
PAT utilized for feedback and feed 
forward at real time 



















specification on batch data on the desired product performance 
Control strategy Mainly by intermediate product and end 
product testing 
Risk based; controlled shifted up stream, 
real time release 
Lifecycle 
Management 
Reactive time problem; Post approval 
changes needed 
Continual improvement enabled within 
design space 
QbD should include some basic elements. The Quality Target Product Profile (QTPP) forms the 
basis of design for the development of the product; it is a summary of the quality characteristics of 
product. Critical Quality Attributes (CQAs) are physical, chemical, biological or microbiological 
properties or characteristics that should fall within an appropriate limit range or distribution to 
ensure the desired product quality. Table S.2.1 in the Appendices summarizes the quality attributes 
of Example sustained release tablets and indicated which attributes were classified as drug product 
CQAs. For this product, physical attributes, assay, content uniformity and drug release are 
investigated and discussed in detail. Risk Assessment (RA) is a valuable science-based process used 
in quality risk management that can help identify which material attributes and critical process 
parameters (CPPs) could affect product CQAs [66]. Fig.2.16 presents a simplified flow-chart of the 
QbD process.  
Statistical Design of Experiment (DoE) is a valuable tool with which to establish in mathematical 
form the relationships between CQAs and CPPs. The main purpose of DoE is to find the design 
space (DS). Regardless of how a DS is developed, it is expected that operation within it will result 
in a product matching the defined quality [65]. A control strategy is designed to ensure that a 
product of the required quality will produced consistently. Such a strategy can include, but is not 
limited to, the control of input material attributes, in-process or real-time release testing in lieu of 
end-product testing, and a monitoring program for verifying multivariate prediction models [66]. 





Fig.2.16 Simplified flow-chart of the QbD process  
2.4.2.2 Design of Experiments (DoE) 
Design of Experiments (DoE) techniques enable designers to determine simultaneously the 
individual and interactive effects of the factors that could affect the output results in any design. 
These techniques therefore help pinpoint the sensitive parts and areas in designs that cause 
problems in yield. Designers are then able to fix these problems and produce robust and higher-
yield designs prior to going into production [68].  
Basically, there are two kinds of DoE: screening and optimization. The former is the ultimate 
fractional factorial experiments, which assume that the interactions are not significant. Critical 
variables which will affect the output are determined by literally screening the factors [69]. 
Optimization DoE aims to determine the range of operating parameters for design space and to 
consider more complex simulations such as the quadratic terms of variables.  
Full Factorials Design 
As the name implies, full factorials experiments examine all the factors involved completely, 
together with all possible combinations associated with those factors and their levels. They look at 
the effects of the main factors and all interactions between them on the responses [69]. The sample 
size is the product of the numbers of levels of the factors. For example, a factorial experiment with 
two-level, three-level and four-level factors has 2 x 3 x 4 = 24 runs. Full factorial designs are the 
Quality target product profile 
(QTPP) 
Critical Quality Attributes 
(CQAs) 
 
 Critical Process Parameters  
(CPPs) 
Design space definition and 
control strategy establishment 
Risk Assessment 
(RA) 





most conservative of all design types. There is little scope for ambiguity when all combinations of 
the factors’ settings are tried. Unfortunately, the sample size grows exponentially according to the 
number of factors, so full factorial designs are too expensive to run for most practical purposes  [70]. 
Response Surface Methodology (RSM) [71] 
Response surface designs are useful for modelling curved quadratic surfaces to continuous factors. 
A response surface model can pinpoint a minimum or maximum response, if one exists inside the 
factor region. It includes three kinds of central composite designs together with the Box-Behnken 
design, as shown in Fig.2.17.  
 
(a)                                                                                (b) 
 
     (c)                                                                                (d) 
Fig.2.17 Response surface designs: (a) Circumscribed (b) Inscribed (c) Faced (d) Box-Behnken [72] 
The Box-Behnken statistical design is one type of RSM design. It is an independent, rotatable or 
nearly rotatable, quadratic design having the treatment combinations at the midpoints of the edges 
of the process space and at the centre [73, 74]. The present author used it to optimize and evaluate 




her research. Because fewer experiments are run and less time is consequently required for the 
optimization of a formulation compared with other techniques, it is more cost-effective. 
One distinguishing feature of the Box-Behnken design is that there are only three levels per factor; 
another is that no points at the vertices of the cube are defined by the ranges of the factors. This is 
sometimes useful when it is desirable to avoid these points because of engineering considerations.  
For the response surface methodology involving Box-Behnken design, a total of 15 experiments are 
designed for 3 factors at 3 levels of each parameter shown in Table 2.2. 
Table 2.2  Box-Behnken experiment design 
Run Independent variables (levels) 
Mode X1 X2 X3 
1 −−0 -1 -1 0 
2 −0− -1 0 -1 
3 −0+ -1 0 1 
4 −+0 -1 1 0 
5 0−− 0 -1 -1 
6 0−+ 0 -1 1 
7 000 0 0 0 
8 000 0 0 0 
9 000 0 0 0 
10 0+− 0 1 -1 
11 0++ 0 1 1 
12 +−0 1 -1 0 
13 +0− 1 0 -1 
14 +0+ 1 0 1 
15 ++0 1 1 0 
The design is equal to the three replicated centre points and the set of points are lying at the 
midpoint of each surface of the cube defining the region of interest of each parameter, as described 
by the red points in Fig.16 (d). The non-linear quadratic model generated by the design is given as 
below 
        𝑌 = 𝑏0 + 𝑏1𝑋1 + 𝑏2𝑋2 + 𝑏3𝑋3 + 𝑏12𝑋1𝑋2 + 𝑏13𝑋1𝑋3 + 𝑏23𝑋2𝑋3 + 𝑏11𝑋1
2 + 𝑏22𝑋2
2 + 𝑏33𝑋3
2                Equ.2.13 
where, Y is a measured response associated with each factor level combination; 𝑏0 is an intercept; 
𝑏1 to 𝑏33 are regression coefficients calculated from the observed experimental values of Y; and 𝑋1, 
𝑋2 and 𝑋3 are the coded levels of independent variables. The terms 𝑋1𝑋2,  𝑋1𝑋3, 𝑋2𝑋3 and 𝑋𝑖
2 (i=1, 




2.5 CBZ studies 
2.5.1 CBZ cocrystals 
2.5.1.1 Introduction 
CBZ  was discovered by chemist Walter Schindler in 1953 [75], and now is a well-established drug 
used in the treatment of epilepsy and trigeminal neuralgia [76]. CBZ is a white or off-white powder 
crystal. The molecule structure of CBZ is shown in Fig.2.18. It has at least four anhydrous 
polymorphs: triclinic (Form I), trigonal (Form II), monoclinic (Form III and IV) and a dihydrate as 
well as other solvates [55, 77]. Form I crystallizes in a triclinic cell (P-1) having four inequivalent 
molecules with the lattice parameters a=5.1706(6), b=20.574(2), c=22.452(2)  Å , α = 84.12(4), 
β = 88.01(4) and γ = 85.19(4)°. The asymmetric unit consists of four molecules (Fig.2.19) that 
each form hydrogen-bonded anti dimers through the carboxamide donor and carbonyl acceptor, as 
in the other three modifications of the drug [52]. Graph set analysis [78] reveals that these are 
R2,2(8) dimers. However, only two dimers are centrosymmetric, formed between identical residues 
(Fig.2.20), whereas the other unique dimer is pseudocentrosymmetric and consists of inequivalent 
1,3 residue pairs, where the two N-H⋯O hydrogen bonds differ by <0.1 Å [52]. 
NH2
 
Fig.2.18 Molecular structure of CBZ 
 





Fig.2.20 Packing diagrams of all four forms of CBZ showing hydrogen-bonding patterns. The notation indicates the 
position of important hydrogen-bonding patterns, and is as follows: R1=R2,2(8); R2=R2,4(20); C1=C3,6(24); 
C2=C1,2(8); C3=C(7). The Arabic numbers on Form I correspond to the respective residues [52] 
2.5.1.2 Current research  
Given that pharmaceutical scientists are always seeking to improve the quality of their drug 
substances, it is not surprising that cocrystal systems of pharmaceutical interest have begun to 
receive extensive attention [79]. In recent years there has been much research into improving CBZ 
solubility and dissolution rates [80-82]. The database of 50 crystal structures containing the CBZ 
molecule are summarized in Table 2.3 [83]. 
Table 2.3 A summary of CBZ cocrystals [52] 
 CBZ cocrystals references 
1 CBZ Form I  
2 CBZ Form II  
3 CBZ Form III  
4 CBZ Form IV  
5 CBZ/actone (1:1) [84] 
6 CBZ/water (1:2) [85] 
7 CBZ./furfural (1:0.5) [86] 
8 CBZ/trifluoroacetic acid (1:1) [87] 
9 CBZ/10,11-dihydrocarbamazepine (1:1) [88] 
10 CBZ/N,N-dimethylformamide (1:1) [89] 
11 CBZ/2,2,2-trifluoroethanol (1:1) [90] 
12 CBZ/aspirin (1:1) [91] 
13 CBZ/dimethylsulfoxide (1:1) [84] 




15 CBZ/terepthalaldehydr (1:0.5) [84] 
16 CBZ/saccharin (1:1) [84] 
17 CBZ/nicotinamide (1:1) [84] 
18 CBZ/acetic acid (1:1) [84] 
19 CBZ/formic acid (1:1) [84] 
20 CBZ/butyric acid (1:1) [84] 
21 CBZ/trimesic acid/water (1:1:1) [84] 
22 CBZ/5-nitroisophthalic acid/methanol (1:1:1) [84] 
23 CBZ/adamantine-1,3,5,7-tetracarboxylic acid (1:0.5) [84] 
24 CBZ/formamidine (1:1) [84] 
25 CBZ/quinoxaline-N,N’-dioxide (1:1) [92] 
26 CBZ/hemikis (pyrazine-N,N’-dioxide) (1:1) [92] 
27 CBZ/ammonium chloride (1:1) [93] 
28 CBZ/ammonium bromide (1:1) [93] 
29 CBZ/4,4’-bipyridine (1:1) [94] 
30 CBZ/4-aminobenzoic acid (1:0.5) [94] 
31 CBZ/4-aminobenzoic acid/water (1:0.5:0.5) [94] 
32 CBZ/2,6-pyridinedicarboxylic acid (1:1) [94] 
33 CBZ/N,N-dimethylacetamide (1:1) [95] 
34 CBZ/N-methylpyrrolidine (1:1) [95] 
35 CBZ/nitromethane (1:1) [95] 
36 CBZ/benzoic acid (1:1) [83] 
37 CBZ/adipic acid (2:1) [83] 
38 CBZ/succinic acid (1:0.5) [96] 
39 CBZ/4-hydroxybenzoic acid (1:1) form A [83] 
40 CBZ/4-hydroxybenzoic acid (1:0.5) form C [83] 
41 CBZ/4-hydroxybenzoic acid (1:X) form B [83] 
42 CBZ/glutaric acid (1:1) [83] 
43 CBZ/malonic acid (1:0.5) form A [96] 
44 CBZ/malonic acid (1:X) form B [83] 
45 CBZ/salicylic acid (1:1) [83] 
46 CBZ-/L-hydroxy-2-naphthoic acid (1:1) [83] 
47 CBZ/DL-tartaric acid (1:X) [83] 
48 CBZ/maleic acid (1:X) [83] 
49 CBZ/oxalic acid (1:X) [83] 
50 CBZ/(+)-camphoric acid (1:1) [83] 
The tree diagram (Fig.2.21) was generated using the Crystal Packing Similarity tool, based on the 
size of the cluster that relates them as a group. The data in Fig.2.21 indicates that all the structures 




similar clusters of three CBZ molecules, while 32, 25, 16, 33 and 34 each contain a third unique 
cluster of three CBZ molecules. The remaining eight structures do not have clusters of three CBZ 
molecules that match any other structures [52]. 
 
Fig.2.21 A tree diagram based on the results of the Crystal Packing Similarity tool [52] 
2.5.1.3 CBZ cocrystal preparation methods 
CBZ cocrystals have been prepared by a variety of methods. In Rahman’s study [97], CBZ-NIC 
cocrystals were prepared by solution cooling crystallization, solvent evaporation and melting and 
cryomilling methods. Solvent drop grinding (SDG) is a new method of cocrystal preparation. For 
example, CBZ was chosen as a model drug to investigate whether SDG could prepare CBZ 
cocrystals. The results indicate that eight CBZ cocrystals could be prepared by SDG methods. SDG 
therefore appears to be a cost-effective, green and reliable method for the discovery of new 
cocrystals as well as for the preparation of existing ones [98]. 
2.5.2 CBZ sustained/controlled release tablets/capsules  
CBZ sustained/extended release tablets can be formulated by direct compression, wet granulation 
methods and the oral osmotic system. Table 2.4 summarizes the research and patents on CBZ 
sustained/extended release formulation. 
The tablets were prepared by direct compression, and hydroxypropyl methylcellulose (HPMC) was 
used as the matrix excipient in U.S. Patent 5980942 [99] and the research by Soravoot [100].  
In U.S. Patent 5284662, CBZ was prepared using the osmotic system. An oral sustained release 
composition for slightly-soluble pharmaceutical active agents comprises a core with a wall around it 




comprises a slightly soluble active agent, optionally a crystal habit modifier, at least two osmotic 
driving agents, at least two different versions of hydroxyalkyl cellulose, and optionally lubricants, 
wetting agents and carriers. The wall is substantially impermeable to the core components but 
permeable to water and gastro-intestinal fluids. It was found CBZ from an oral osmotic dosage form 
approximately zero-order release of active agent [101].   
In both U.S. Patent 20070071819 A1 and U.S. Patent 20090143362 A1, CBZ is prepared by the wet 
granulation method. In the two patents, extended release and enteric release units in ratio by weight 
are mixed and filled into a capsule [102, 103]. 
In U.S. Patent WO 2003084513 A1 and U.S. Patent 6162466 and the papers published by Barakat 
and Mohammed, CBZ is prepared by wet granulation followed by direct compression [104-107]. 








U.S. Patent 5980942 HPMC different grade USP basket Apparatus I;700 
ml1% SDS aqueous solution; 100 
rev/min 





Tablet core: Ludipress, magnesium 
state. 
Tablet: core above, different grade 
of HPMC 
Drug release was studied in a 
paddle apparatus at 37±0.1 °C, 












250HNF, Mannitol, Dextrates NF, 
Na Lauryl sulphate NF, Iron Oxide 
yellow, Magnesium Stearate NF 
Semipermeable wall: Cellulose 
acetate 320S NF, Cellulose acetate 
398-10NF, Hydroxypropylmethyl 










U.S. Patent 20070071819 
A1  
Coated with enteric polymer 
Coated with extended polymer, 
acceptable excipients 
Not mentioned 
U.S. Patent 20090143362 
A1 
Granulation: microcrystalline 
cellulose, lactose, citric acid, 
sodium lauryl sulfate, 
hydroxypropylcellulose and a part 
of polyvinylpyrrolidone were 
mixed and granulated with 
granulating dispersion 
0.1N HCL for 4 hours and 
phosphate buffer, pH6.8 with 
0.5% sodium lauryl sulfate for 
remaining time using USP-2 










U.S. Patent WO 
2003084513 A1 
Core: polyethylene glycol (PEG), 
magnesium Stearate   
Tablet: core above, granulated 
lactose, Carbopol 71 G polymer and 
sodium lauryl sulfate 
The dissolution test was 
performed in USP Apparatus 1, 
900ml water 
U.S. Patent 6162466 coated with Eurdrgit RS and RL 
and then in a disintegrating tablet 
Dissolution testing was 
performed in 1% Sodium Lauryl 
Sulphate (SLS) water 
“Controlled-release 
carbamazepine matrix 
granules and tablets 
comprising lipophilic and 
hydrophilic components” 
Compriol 888 ATO  
HPMC and Avicel 
 
900 mL of 1% sodium lauryl 
sulphate (SLS) aqueous solution 





release release tablets USP 
200 mg” 
HPMC E5, PVP K30 were prepared 
by wet granulation. The 
granulations, Talc and Magnesium 
state were mixed uniformly and 
then prepared by direct 
compression. 
USP II apparatus at 37 
o
C and 




Chapter 3 Materials and Method 
3.1 Chapter overview 
This chapter covers materials and analytical methods used in the present research. Firstly, all 
materials were introduced in detail, including the name, level of purity and the manufacturers. 
Secondly, analytical methods including Raman, DSC, IR, XRPD, SEM, Thermal Gravimetric 
Analysis (TGA), UV-imaging system, HPLC and Hot Stage Polarized optical Microscopy (HSPM). 
These methods were used to identify the cocrystals and characterise their physicochemical 
properties. DSC, TGA, FTIR and Raman were used to perform qualitative analysis of formed 
samples, and the Raman spectrometer was also used for quantitative analysis of the phase transition 
of samples during the dissolution process. SEM and HSPM were used to characterize the 
morphology of solid compacts. HPLC was used to measure the dissolution rate, solubility and 
release profiles. The UV-imaging system was used to measure the intrinsic dissolution rate. In this 
chapter, the principles of the most methods are outlined and the methods for the measurement of 
intrinsic dissolution, powder dissolution and solubility of cocrystals described. Finally, the 
preparation work for the present research is presented. The preparation of dissolution media 
included double-distilled water, pH 6.8 phosphate buffer solution (PBS) and 1% (w/v) sodium 
lauryl sulphate (SLS) pH 6.8 PBS. Three coformers (NIC, SAC and CIN) were used to form CBZ 
cocrystals. Four polymers HPMC, HPMCAS AS-MF, PEG 4000 and PVP K30 were utilized to 
investigate the phase transformation and release profiles of CBZ cocrystals. These are 
microcrystalline cellulose (MCC), lactose, colloidal silicon dioxide and stearic acid, which were 
used as excipients in the CBZ sustained release tablets. 
3.2 Materials 
All materials were used as received, without further processing. Table 3.1 summarizes these 
materials. 
Table 3.1 Materials 
Materials Purity/grade Manufacturer 
carbamazepine form III ≥99.0% Sigma-Aldrich Company Ltd.,Dorset , UK 
NIC  ≥99.5% Sigma-Aldrich Company Ltd.,Dorset , UK 
SAC ≥98% Sigma-Aldrich Company Ltd.,Dorset , UK 




Ethyl acetate ≥99% Fisher Scientific, Loughborough, UK 
Ethanol ≥99% Fisher Scientific, Loughborough, UK 
Methanol HPLC grade Fisher Scientific, Loughborough, UK 
Double distilled water  Bi-Distiller (WSC044. Fistreem 
International Limited, Loughborough, 
UK) 
Sodium lauryl sulfate >99% Fisher Scientific, Loughborough, UK 
Potassium phosphate monobasic ≥99% Sigma-Aldrich Company Ltd.,Dorset , UK 
Sodium hydroxide 0.2M Fisher Scientific, Loughborough, UK 
HPMC K4M  Shin-Etsu Pharma&Food Materials 
Distribution GmbH (Stevenage, UK) 
HPMCAS (AS-MF)  Shin-Etsu Pharma&Food Materials 
Distribution GmbH (Stevenage, UK) 
HPMCP (HP-55)  Shin-Etsu Pharma&Food Materials 
Distribution GmbH (Stevenage, UK) 
PEG 4000  Fisher Scientific, Loughborough, UK 
PVP K30  Fisher Scientific, Loughborough, UK 
MCC  Blackbum Distributions Ltd,UK 
Lactose  Blackbum Distributions Ltd,UK 
Stearic acid  Sigma-Aldrich Company Ltd.,Dorset , UK 
Colloidal silicon dioxide  Degussa 
0.45 um nylon syringe filter  Thermo Scientific Naglene, Rochesterm, 
NY, USA 




In this study, three coformers with different solubilities were selected to make CBZ cocrystals. 
NIC is generally recognized as a safe Class I chemical and is often utilized in much larger doses 
than seen in cocrystal formation to treat high cholesterol [97]. It has four known polymorphs, I-IV, 
with the room temperature stable and a Phase I melting point of 129.5
o
C [108]. The molecular 
structure for NIC is shown in Fig.3.1. NIC has been utilized as a coformer for the cocrystallization 
of theophylline [4], ibuprofen [45] and 3-hydroxybenzoic acid, 4-hydroxybenzoic acid and gentisic 








Fig.3.1 Molecular structure of NIC 
SAC is a white crystalline solid and a sulphonic acid derivation used as an artificial sweetener in 
pharmaceutical formulation because it is a GRAS category excipient. Its melting point is about 
228.8-229.7
o
C [109]. Its molecular structure is shown in Fig.3.2. Many SAC cocrystals such as 
indomethacin-SAC [110], CBZ-SAC [109] and ethenzamide-saccharin [111] have been 




Fig.3.2 Molecular structure of SAC 
CIN is an organic, white crystalline compound that is slightly soluble in water, at about 0.4 mg/ml 
at 37
o
C. Its melting point is 133
o
C [112]. CIN possesses anti-bacterial, antifungal and anti-parasitic 
capabilities. A derivative of CIN is an important pharmaceutical excipient for high blood pressure 
and stroke prevention and possesses antitumour activity [113]. Its molecular structure is shown in 
Fig.3.3. CIN is used as a coformer for many cocrystals such as CBZ-CIN [114] and AMG-571-
cinnamic acid [49]. 
 
Fig.3.3 Molecular structure of CIN 
3.2.2 Polymers 




HPMC is the most widely used of the cellulosic controlled-release agents. It is a well-known 
excipient with an excellent safety record. HPMC polymers are non-ionic, so they minimize 
interaction problems when used in acidic, basic or other electrolytic systems. HPMC polymers work 
well with soluble and insoluble drugs and at both high and low dosage levels. To achieve controlled 
release through the use of HPMC, the polymer must quickly hydrate on the outer tablet skin to form 
a gelatinous layer, the rapid formation of which is critical to prevent wetting of the interior and 
disintegration of the tablet core. Once the original protective gel layer is formed, it controls the 
penetration of additional water into the tablet. As the outer gel layer fully hydrates and dissolves, a 
new inner layer cohesive and continuous enough to retard the influx of water and control drug 
diffusion must replace it. HPMC K4M’s apparent viscosity at 2% in water at 20
o
C is 4000 mPa.s. 
Its pH value of 1% in water is 5.5-8.0. 
Hypromellose Acetate Succinateby AS-MF (HPMCAS) [116] 
The appearance of HPMCAS is a white powder with a faint, acetic acid-like odour, but tasteless. 
The average molecular weight is 18000. The pH solubility of HPMCAS AS-MF is no less than 6.0. 
The labelled viscosity is 3 mPa.s. HPMCAS is used as an enteric coating material, and was first 
approved in Japan in 1987. Recently, HPMCAS was also used to play the role of taste masking and 
sustained release [117]. 
Polyethylene Glycol 4000 (PEG 4000) [118] 
PEG is designated by a number that roughly equates to average molecular weight. As the molecular 
weight increases, so does PEG’s viscosity. PEG 4000 has a melting point of 53-56
o
C and is easily 
extracted by common solvents. Its molecular weight is about 3500-4500 and its solubility in water 
is 50 mg/ml at 25
o
C. PEG has been extensively used as carriers for solid dispersion due to its 
favourable solution properties. Its pH value of 50 mg/ml in water at 25
o
C is 5.5-7.0. 
Polyvinvlpyrrolidone K30 (PVP K30) [119] 
Polymerization of vinylpyrrolidone leads to polyvinylpyrrolidone (PVP) of molecular weights 
ranging from 2500-3000000. The can be classified according to the K value, which is calculated 
using Fikentsche’s equation. The average molecular weight of PVP K30 is about 50000. Due to its 
good solubility in a wide variety of organic solvents, it is particularly suitable for the preparation of 
solid dispersions by the solvent method. PVP is widely used in the pharmaceutical sector as an 




absorbed from the GI tract. Its viscosity of 1% solution at 25
o
C is 26-35 mPa.s and its pH value of 5% 
aqueous solution is 3 to7. 
3.3 Methods 
3.3.1 Raman spectroscopy 
Raman spectroscopy is a technique used to observe vibrational, rotational and other low-frequency 
modes in systems. It relies on inelastic, or Raman, scattering of monochromatic light, usually from 
a laser in the visible, near-infrared or near-ultraviolet ranges. The Raman effect occurs when 
electromagnetic radiation impinges on a molecule and interacts with the polarisable electron density 
and the bonds of the molecule. For the spontaneous Raman effect, which is a form of inelastic light 
scattering, a photon excites the molecule from the ground state to a virtual energy state for a short 
period of time shown in Fig.3.4. When the molecule relaxes it emits a photo and it returns to a 
different rotation or vibration state. The resulting inelastically scattered photon which is “emitted” 
or “scatted” can be of either higher (anti-Stokes) or lower (Stokes) energy than the incoming photon. 
In Raman scattering the final vibrational state of the molecule is in a different rotational or 
vibrational state than the one in which the molecule was originally, before interacting with the 
incoming photon. The difference in energy between the original state and this final state gives 
information about the vibration modes in the system, since the vibration information is specific to 
the chemical bonds and symmetry of molecules. It therefore provides a fingerprint by which the 
molecule can be identified  [120].  
 




EnSpectcter R532® Raman spectrometer (Enhanced Spectrometry, Inc., Torrance, USA), shown in 
Fig.3.5, is used for measuring the Raman spectra of solids. The equipment includes a 20-30 MW 
output powder laser source with a wavelength of 532 nm, a Czerny-Turner spectrometer, a scattered 
light collection and analysis system. In the present study, Raman spectra were obtained using an 
EnSpectcter R532® Raman spectrometer. The integration time was 200 milliseconds and each 




 Raman spectrometer 
Raman spectroscopy quantitative characterisation [8] 
In order to quantify the percentage of CBZ DH crystallised during the dissolution of CBZ III and 
CBZ-NIC cocrystal, Raman calibration is done as follows: CBZ III and CBZ-NIC cocrystal were 
blended with CBZ DH separately to form binary physical mixtures at 20% (w/w) intervals from 0 to 
100% of CBZ DH in the test samples. Each sample was prepared in triplicate and measured by 
Raman spectroscopy. Ratios of characteristic peak intensities were used to construct the calibration 
models. For CBZ III and CBZ DH mixture, the ratio of peak intensity at 1040 to 1025 cm
-1
 were 
used to make calibration curve; for CBZ-NIC cocrystal and CBZ DH mixture, the ratio of peak 
intensity at 1035 to 1025 cm
-1
 were used to make calibration curve. Calibration curves for CBZ III 
and CBZ DH mixture, CBZ-NIC cocrystal and CBZ DH mixture were obtained and shown in 
Fig.3.6. Equation fitted for the calibration curves were shown in Table 3.2. The calibration equation 









Fig.3.6 Raman calibration curve for (a) mixture of CBZ III and CBZ DH; (b) mixture of CBZ-NIC cocrystal and CBZ 
DH [8] 
Table 3.2 Raman calibration equations and validations [8] 








CBZ III and CBZ DH 
y = -0.0053x + 0.9057 
R² = 0.9894 
70 73 4 
CBZ-NIC cocrystal and CBZ DH 
y = -6E-05x
2
 + 0.0004x + 0.8171 
R² = 0.896 
70 82 17 
y: characteristic peak ratio of 1040/1025 for CBZ III and CBZ DH mixture, and 1035/1025 for  CBZ-NIC cocrystal and 
CBZ DH mixture 
x: percentage of CBZ DH in the mixture  
P𝐷𝐻
𝑟 : real DH percentage 
P𝐷𝐻





DSC is a thermoanalytical technique in which the amount of heat required to increase the 
temperature of a sample and a reference is measured as a function of temperature. Both the sample 
and reference are maintained at nearly the same temperature throughout the experiment. Generally, 
the temperature program for a DSC analysis is designed so that the sample holder temperature 
increases linearly as a function of time. The reference sample should have a well-defined heat 
capacity over the range of temperatures to be scanned [122].  
In the present study a Perkin Elmer Jade DSC (PerkinElmer Ltd, Beaconsfield, UK) was used to test 
samples. The Jade DSC was controlled by Pyris Software. The temperature and heat flow of the 
instrument were calibrated using an indium and zinc standards. The samples (8-10 mg) were 
analysed in crimped aluminium pans with pin-hole pierced lids. Measurements were carried out at a 
heating rate of 20
o
C/min under a nitrogen flow rate of 20 ml/min. 
3.3.3 IR 
IR is the spectroscopy that deals with the infrared region of the electromagnetic spectrum, namely 
light with a longer wavelength and lower frequency than visible light. The theory of infrared 
spectroscopy is that molecules absorb specific frequencies that are characteristic of their structures. 
These absorptions are resonant frequencies, i.e. those in which the frequency of the absorbed 
radiation matches the transition energy of the bond or group that vibrates. The energies are 
determined by the shape of the molecular potential energy surfaces, the masses of the atoms and the 
associated vibronic coupling. The infrared spectrum of a sample is recorded by passing a beam of 
infrared light through the sample. When the frequency of the IR is the same as the vibrational 
frequency of a bond, absorption occurs. Fourier Transform Infrared Spectroscopy (FTIR) is a 
measurement technique that allows one to record infrared spectra infrared light guided through an 
interferometer and then through the sample. A moving mirror inside the apparatus alters the 
distribution of infrared light that passes through the interferometer. The signal directly recorded, 
called an “interferogram”, represents light output as a function of mirror position. A data-processing 
technique called Fourier Transform turns this raw data into the desired result: light output as a 
function of infrared wavelength [123]. 
The current study used an ALPHA A4 sized Benchtop ATR-FTIR spectrometer for IR spectra 
measurement. ATR is the abbreviation of Attenuated Total Reflectance. It is a sampling technique 




without further preparation. Measurement settings are a resolution of 2 cm
-1
 and a data range of 
4000-400 cm
-1
. The ATR-FTIR spectrometer was equipped with a single-reflection diamond ATR 
sampling module, which greatly simplifies sample handing.  
3.3.4 X-ray diffraction 
X-ray crystallography is used to identify the atomic and molecular structure of a crystal. It is a tool 
in which the crystalline atoms cause a beam of incident X-rays to diffract in many specific 
directions. By measuring the angles and intensities of these diffracted beams, a crystallographer can 
produce a three-dimensional picture of the density of the electrons within the crystal, from which 
the mean positions of the atoms in the crystal can be determined as well as their chemical bonds, 
their states of disorder and a variety of other information [124]. 
Crystals are regular arrays of atoms, and X-rays can be considered waves of electromagnetic 
radiation. Atoms scatter X-ray waves, primarily through the atoms’ electrons. Just as an ocean wave 
striking a lighthouse produces secondary circular waves emanating from the lighthouse, so an X-ray 
striking an electron produces secondary spherical waves emanating from the electron. This 
phenomenon is known as elastic scattering, and the electron is known as the scatter. A regular array 
of scatterers produces a regular array of spherical waves. Although these waves cancel one another 
out in most direction through destructive interference, they add constructively in a few directions, 
determined by Bragg’s Law: 
2d sin 𝜃 = 𝑛𝜆                                                                       Equ.3.1 
Here d is the spacing between diffracting planes, θ is the incident angle, n is any integer, and λ is 
the wavelength of the beam. These specific directions appear as spots on the diffraction pattern 
called reflections. Thus, X-ray diffraction results from an electromagnetic wave impinging on a 
regular array of scatterers [125].  
XRPD patterns of the samples were recorded at a scanning rate of 0.5° 2Θmin −
1
 by a 
Philipsautomated diffractometer. Cu K radiation was used with 40 kV voltage and 35 mA current. 
3.3.5 SEM 
A scanning electron microscope (SEM) is a type of electron microscope that produces images of a 
sample by scanning it with a focused beam of electrons. The electrons interact with atoms in the 




topography and composition. The electron beam is generally scanned in a raster scan pattern, and 
the beam’s position is combined with the detected signal to produce an image [126]. 
In this study, SEM micrographs were photographed by a ZEISS EVO HD 15 scanning electron 
microscope (Carl Zeiss NTS Ltd., Cambridge, UK). The sample compacts were mounted with Agar 
Scientific G3347N carbon adhesive tab on Agar Scientific G301 0.5” aluminium specimen stub 
(Agar Scientific Ltd., Stansted, UK) and photographed at a voltage of 10.00 kV. The manual sputter 
coating S150B was used for gold sputtering of SEM samples. 
3.3.6 TGA 
The principle underlying TGA is that of a high degree of precision when making three 
measurements: mass change, temperature and temperature change. The basic parts of the TGA 
apparatus are thus in precise balance with a pan loaded with the sample, a programmable furnace. 
The furnace can be programmed in two ways: heating at a constant rate or heating to acquire a 
constant mass loss over time. For a thermal gravimetric analysis using the TGA apparatus, the 
sample is continuously weighed as it is heated. As the temperature increases, components of the 
samples are decomposed so that the weight percentage of each mass change can be measured and 
recorded. TGA testing results are plotted with mass loss on the Y-axis versus temperature on the X-
axis [127]. 
In this study, a Perkin Elmer Pyris 1 TGA (PerkinElmer Ltd, Beaconsfield UK) was used. Samples 
(8-10 mg) in crucible baskets were used for TGA runs from 25-190
o
C with a constant heating rate 
of 20
o
C/min under a nitrogen purge flow rate of 20 ml/min. 
3.3.7 Intrinsic dissolution study by UV imagine system 
The ActiPix SDI 300 UV imaging system comprises a sample flow cell, syringe pump, temperature 
control unit, UV lamp and detector and a control and data analysis system, as shown in Fig.3.7. The 
instrumentation records absorbance maps with a high spatial and temporal resolution, facilitating 
the collection of an abundance of information on the evolving solution concentrations [128]. With 
spatially resolved absorbance and concentration data, a UV imaging system can give information on 





Fig.3.7 ActiPis SDI 200 UV surface imaging dissolution system 
The dissolution behavior of CBZ III and CBZ-NIC cocrystals in pure water and different 
concentrations of HPMC solutions was studied using an ActiPis SDI 300 UV imaging system 
(Paraytec Ltd., York, UK). A UV imagine calibration was performed by imagining a series of CBZ 












mM. A standard curve was constructed by 
plotting the absorbance against concentration of each standard solution based on three repeated 
experiments as shown in Fig.3.8. The calibration curve was validated by a series of CBZ standard 
solutions with different HPMC concentrations, showing that HPMC did not affect the accuracy of 
the model and that the calibration curve was applicable for the dissolution test with HPMC 
solutions. The sample compact in a dissolution test was made by filling around 5 mg of the sample 
into a stainless steel cylinder with an inner diameter of 2 mm and compressed by a Quickset 
MINOR torque screwdriver (Torqueleader, M.H.H. engineering Co. Ltd., England) for one minute 
at a constant torque of 40 cNm. All dissolution tests were performed at 370.5C and the flow rate 
of a dissolution medium was set at 0.4 ml/min. The concentrations of HPMC solutions were 0, 0.5, 
1, 2 and 5 mg/ml. Each sample had been been tested for one hour in triplicate. A UV filter with a 





Fig.3.8 UV-imagine calibration of CBZ 
UV-imaging calibration curves were validated by standard solutions of CBZ with known 
concentrations and by running the standard solutions and calculating their concentrations using 
calibration curves. The calculated concentrations were compared with real ones; the results are 
shown in Table 3.3. 
Table 3.3 UV-imagine calibration equations of CBZ 
test sample calib equations 
validation  
𝑪𝒓 𝑪𝒎 |𝑪𝒎 − 𝑪𝒓|/𝑪𝒓% 
CBZ 






 mM 2.76 
3.3.8 HPLC 
In this study, the concentrations of samples were analysed using the Perkin Elmer series 200 HPLC 
system. A HAISLL 100 C18 column (5 µm, 250×4.6 mm, Higgins Analytical, Inc. USA) at 
ambient temperature was set. The mobile phase was composed of 70% methanol and 30% water, 
and the flow rate was 1 ml/min using an isocratic method. Concentrations of CBZ, NIC, SAC and 
CIN were measured using a wavelength of 254 nm. HPLC calibration was performed for the four 
chemicals. The standard curves are shown in Fig.3.9. HPLC calibration curves were validated by 
standard solutions of CBZ, NIC, SAC and CIN with known concentrations, the standard solutions 
run and their concentrations calculated using calibration curves. The calculated concentrations were 
















Table 3.4 Calibration equations of CBZ, NIC, SAC and CIN 
test sample calib equations 
validation  
𝑪𝒓 𝑪𝒎 |𝑪𝒎 − 𝑪𝒓|/𝑪𝒓% 
CBZ 
y = 48163x+140224, R² = 
0.9997 
100 98 2 
NIC 
y = 30182x+205634, R² = 
0.9991 
100 102 2 
SAC y = 10356x+7865.5, R² = 1 100 103 3 
CIN 
y = 134938x+131567, R² = 
0.9997 
100 98 2 
3.3.9 HSPM 
In this study, HSPM studies were conducted on a Leica polarizing optical microscope (Leica 
Microsystems DM750). The samples were placed between a glass slide and a cover glass and then 
fixed on a METTLER TOLEDO FP90 hot stage. The sample was then heated from 35
o
C to 240°C 
at 10°C/min. The morphology changes during the heating process were recorded by camera for 
further analysis. 
3.3.10 Equilibrium solubility test 
In this study, all solubility tests were determined using an air-shaking bath method. Excess amounts 
of samples were added for 20 seconds into a small vial containing a certain volume of media and 
vortexes. The vials were placed in a horizontal air-shaking bath at 37
o
C at 100 rpm for 24 hours. 
Aliquots were filtered through 0.45 um filters and diluted properly for determination of the 
concentration of samples by HPLC. Solid residues were retrieved from the solubility tests, dried at 
room temperature for one day and analyzed using DSC, Raman and SEM. 
3.3.11 Powder dissolution test 
In this study, powder dissolution rates were investigated. In order to reduce the effect of particle 
size on the dissolution rates, all powders were slightly ground and sieved through a 60 mesh sieve 
before the dissolution tests. Powders with a 20 mg equivalent of CBZ III were added to beakers 
containing 200 ml of dissolution media. The dissolution tests were conducted at 37±0.5C with the 




75 and 90 minutes. The samples were filtered and measured using HPLC to determine the 
concentrations of samples. Each dissolution test was carried out in triplicate.      
3.3.12 Dissolution studies of formulated tablets 
The dissolution tests of the tablets were carried out by the USP 1 basket or USP II paddle methods 
for six hours. The rotation speed was 100rpm and the dissolution medium was 700 ml of 1% SLS 
aqueous solution (in Chapters 5 and 6) and 1% (w/v) SLS pH 6.8 PBS (in Chapters 7 and 8) to 
achieve sink conditions, maintained at 37
o
C. Each profile is the average of six individual tablets. 
After a dissolution test, the solid residues were collected and dried at room temperature for at least 
24 hours for the further analysis of XRPD, DSC and SEM.  
3.3.13 Physical tests of tablets 
The diameter, hardness and thickness of tablets were tested in the Dual Tablet Hardness/Thickness 
tester (Pharmacist/IS0 9001/ Germany). 
Friability testing is a laboratory technique used by the pharmaceutical industry to test the likelihood 
of a tablet breaking into smaller pieces during transit. It involves repeatedly dropping a sample of 
tablets over a fixed time, using a rotating wheel with a baffle, and afterwards checking whether any 
tablet are broken and what percentage of the initial mass of the tablets has been lost [129]. 
The friability test was conducted using a friabilator (Pharma test/ 1S09001/ Germany). Six tablets 
of each formulation were initially weighed and placed in the friabilator, the drum of which was 
allowed to run at 30 rpm for one minute. Any loose dust was then removed with a soft brush and the 




× 100                                            Equ.3.2 
3.3.14 Preparation of tablets 
Cylindrical tablets were prepared by direct compression of the blends, using a laboratory press 
fitted with a 13 mm flat-faced punch and die set and applying one ton of force. All tablets contained 




3.3.15 Statistical analysis 
The differences in solubility and release profiles of the samples were analysed by one-way analysis 
variance (ANOVA) (the significance level was 0.05) using JMP 11 software. 
3.4 Preparations 
3.4.1 Media  
pH 6.8 PBS: Mix 250 ml of 0.2 M potassium dihydrogen phosphate (KH2PO4) and 112 ml of 0.2 M 
sodium hydroxide and dilute to 1000.0 ml with water [130]. 
1% (w/v) SLS aqueous solution: dissolve 10 g SLS in 1000.0 ml water. 
1% (w/v) SLS pH 6.8 PBS: dissolve 10 g SLS in 1000.0 ml pH 6.8 PBS. 
0.5, 1.0, 2.0, 5.0 mg/ml HPMC aqueous solution: dissolve 50, 100, 200, 500 mg HPMC in four 
beakers with 100 ml of water respectively, and stir the four solutions until all are clear.   
0.5, 1.0, 2.0, 5.0 mg/ml HPMCAS/PVP/PEG pH 6.8 PBS: dissolve 50, 100, 200, 500 mg 
HPMCAS/PVP/PEG in four beakers with 100 ml pH 6.8 PBS respectively, and stir the four 
solutions until all are clear.   
3.4.2 Test samples  
Preparation of CBZ DH  
Excess amount of anhydrous CBZ III was added to double distilled water and stirred for 48 hours at 
a constant temperature of 37
o
C. The suspension was filtered and dried for 30 minutes on the filter. 
TGA was used to determine the water content in the isolated solid and confirm complete conversion 
to the hydrate. 
Preparation of CBZ-NIC 1:1 cocrystal  
CBZ-NIC cocrystals were prepared by the reaction crystallisation method. A 1:1 molar ratio 
mixture of CBZ III and NIC was completely dissolved in Ethyl Acetate (EtOAc) by stirring at 70°C. 
The solution was put in an ice bath for two hours and the suspension was then filtered through 0.45 




Preparation of physical mixture of CBZ III and NIC (CBZ-NIC mixture) 
A 1:1 molar ratio mixture of CBZ III and NIC was prepared by thoroughly mixing 1 mmol CBZ III 
(23.6 mg) and 1 mmol NIC (12.2 mg). 
Preparation of CBZ-SAC 1:1 cocrystal 
A CBZ-SAC cocrystal was prepared by the reaction crystallisation method. A 1:1 molar ratio 
mixture of CBZ III and SAC was completely dissolved in Ethyl Acetate (EtOAc) by stirring at 
70°C. The solution was put in an ice bath for two hours and the suspension was then filtered 
through 0.45µm filters (thermo Scientific Nalgene) to collect the solid residue of CBZ-SAC 
cocrystals. 
Preparation of physical mixture of CBZ III and SAC (CBZ-SAC mixture) 
A 1:1 molar ratio mixture of CBZ III and SAC was prepared by thoroughly mixing 1 mmol CBZ III 
(23.6 mg) and 1 mmol SAC (18.3 mg). 
Preparation of CBZ-CIN 1:1 cocrystals 
Carbamazepine and cinnamic acid (CBZ-CIN) cocrystals were prepared using the slow evaporation 
method. A 1:1 molar ratio mixture of CBZ and CIN was completely dissolved in methanol by 
stirring and slight heating. The solutions were allowed to evaporate slowly in a controlled fume 
hood (room temperature, air flow 0.50-1.0 m/s). When all the solvent had evaporated, the solid 
product was obtained from the bottom of the flask. 
Preparation of physical mixture of CBZ III and CIN (CBZ-CIN mixture) 
A 1:1 molar ratio mixture of CBZ III and CIN was prepared by thoroughly mixing 1 mmol CBZ III 
(23.6 mg) and 1 mmol CIN (14.6 mg). 
3.5 Conclusion 
This chapter introduced all the materials, methods and sample preparations used in this study. 
Details of all the materials were firstly presented, including their names, purities and producers. 
Secondly, the research methods including analytical techniques and experiments were introduced.  
DSC, TGA, ATR-FTIR, Raman and SEM were used to identify the formation of test samples. The 




powder dissolution test was carried out to study the dissolution rates of CBZ-SAC and CBZ-CIN 
cocrystals. The air-shaking bath method was used in the equilibrium solubility test. Finally, test 
samples and dissolution media preparation methods were outlined. Several media were used in this 
study: water, 1% SLS water, pH 6.8 PBS, 1% SLS pH 6.8 PBS, different concentrations of HPMC 
aqueous solutions and different concentrations of HPMCAS/PVP/PEG pH 6.8 PBS. The 
preparation methods for CBZ samples, which are, CBZ DH, CBZ-NIC, CBZ-SAC and CBZ-CIN 




Chapter 4 Sample Characterisations 
4.1 Chapter overview 
In this chapter, test samples prepared for this study were characterised. These are CBZ III and CBZ 
DH, and the CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals. Various techniques such as TGA, DSC, 
IR spectroscopy, Raman, XRPD and HSPM were used to characterise these products. 
4.2 Materials and methods 
4.2.1 Materials 
Anhydrous CBZ III, NIC, SAC, CIN, EtOAc, methanol and distilled water were used in this chapter; 
details of these materials can be found in Chapter 3. 
4.2.2 Methods 
ATR-FTIR, Raman, DSC, TGA, HSPM, XPRD were used for the characterisation.  Details of these 
techniques can be found in Chapter 3. 
4.3 Results 
4.3.1 TGA analysis of CBZ DH 
The TGA thermograph of CBZ DH is shown in Fig.4.1. The result shows that the water content of 
CBZ DH is 13.286%. This is similar to the theoretical stoichiometric water content of 13.2% w/w. 
The TGA result demonstrates the formation of CBZ DH. 
 




4.3.2 DSC analysis of CBZ III, CBZ cocrystals and physical mixtures 
4.3.2.1 CBZ-NIC cocrystals and a mixture 
DSC curves patterns of CBZ III, NIC, CBZ-NIC cocrystals and a CBZ-NIC mixture are shown in 
Fig.4.2 and DSC data shown in Table 4.1.  






CBZ III 160;189 167;195 
NIC 128 133 
CBZ-NIC cocrystals 159 162 
CBZ-NIC mixture 121;158 128;162 
The DSC curve shows that CBZ III melted at around 167
o
C and then recrystallized in the more 
stable form CBZ I, which melted at around 195
o
C; NIC melted at around 133
o
C; CBZ-NIC 
cocrystals had a single melted point of around 162
o
C; and the CBZ-NIC mixture exhibited two 
major thermal events: the first endothermic-exothermic one was around 120-140
o
C because of the 
melting of NIC and the cocrystallisation of CBZ-NIC cocrystals, while the second endothermic 
peak, at around 162
o
C, resulted from the melting of newly formed CBZ-NIC cocrystals under DSC 
heating. These results are identical to those reported [8, 52].  
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4.3.2.2 CBZ-SAC cocrystals and a mixture 
DSC curves patterns of CBZ III, SAC, CBZ-SAC cocrystals and CBZ-SAC a mixture are shown in 
Fig.4.3 and DSC data shown in Table 4.2. 






CBZ III 160;189 167;195 
SAC 227 231 
CBZ-SAC cocrystals 173 177 
CBZ-SAC mixture 166 177 
The DSC curve shows that SAC melted at around 231
o
C, while CBZ-SAC cocrystals showed a 
sharp endothermic peak at around 177
o





C because of the melted CBZ III for cocrystallisation of CBZ-SAC 
cocrystals and the newly formed cocrystals melting again under DSC heating. 
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Fig.4.3 DSC thermograms of CBZ III, CBZ-SAC cocrystals and a mixture, and SAC 
4.3.2.3 CBZ-CIN cocrystal and mixture 
DSC curves patterns of CBZ III, CIN, CBZ-CIN cocrystals and the CBZ-CIN mixture are shown in 










CBZ 160;189 167;195 
CIN 134 137 
CBZ-CIN cocrystals 142 145 
CBZ-CIN mixture 121;139 125;142 
The DSC curve shows that CIN melted at around 137
o
C and that CBZ-CIN cocrystals had a single 
endothermic peak at around 145
o
C. For the CBZ-CIN physical mixture, the first endothermic peak 
was at approximately 125
o
C because of the melting of CIN and the second endothermic peak was at 
around 142
o
C, a result of the melting of the newly formed CBZ-CIN cocrystal. 
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Fig.4.4 DSC thermograms for CBZ III, CBZ-CIN cocrystals and a mixture, and CIN 
4.3.3 IR analysis of CBZ III, CBZ cocrystals and physical mixtures 
4.3.3.1 CBZ-NIC cocrystals 
The structure of CBZ, NIC and CBZ-NIC cocrystals has been the subject of study. It has an amide-









Fig.4.5 Structure of CBZ, NIC and CBZ-NIC cocrystals [132] 
CBZ-NIC cocrystals are formed via hydrogen bonds in which the carboxamide groups from both 
CBZ and NIC provide hydrogen bonding donors and acceptors. The IR spectra for CBZ, NIC, 
CBZ-NIC cocrystals and the physical mixture are shown in Fig.4.6.  


































Fig.4.6 IR spectrum of CBZ III, NIC, CBZ-NIC cocrystals and a mixture 
The IR spectrum for CBZ III has peaks at 3463 and 1674 cm
-1
, corresponding to carboxamide N-H 




stretch at 3353 cm
-1
 and a peak at around 1673 cm
-1
 for C=O stretch. The spectrum of CBZ-NIC 
cocrystals is different from those of CBZ and NIC, suggesting that both molecules are present in a 
new phase. CBZ’s carboxamide N-H and C=O stretching frequencies shifted to 3444 and 1656 cm
-1
 
respectively. While NIC’s N-H stretching frequency shifted to a higher position at 3387 cm
-1
, the 
C=O stretching peak frequency moved to 1681 cm
-1
. The spectrum of the CBZ-NIC physical 
mixture peaked at 3463 and 1674 cm
-1
 as a result of CBZ III, and 3356 cm
-1
 from NIC. A summary 
of IR peak identities for CBZ III, NIC and CBZ-NIC cocrystals and a mixture is shown in Table 4.4. 
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4.3.3.2 CBZ-SAC cocrystal 
The structure of CBZ III, SAC and CBZ-SAC cocrystals, the structure of which is shown in Fig.4.7, 









Fig.4.7 Structure of CBZ, SAC and CBZ-SAC cocrystals 
The IR spectrum of CBZ III, SAC, CBZ-SAC cocrystals and a physical mixture are shown in 
Fig.4.8. 



































Fig.4.8 IR spectrum of CBZ III, SAC, CBZ-SAC cocrystals and a mixture 
The IR spectrum of pure SAC demonstrates the peaks resulting from secondary amide and carbonyl 
stretching at 3091 and 1715 cm
-1




asymmetric stretching of the -SO2 group in the SAC was also observed at 1332 and 1175 cm
-1
 
respectively [134]. The IR spectra of CBZ-SAC cocrystals exhibited a shift in peaks of carbonyl, 
amide and –SO2 regions that indicated the hydrogen bonding interaction between CBZ III and SAC. 
A shift in the carbonyl stretching of CBZ III was observed at 1644 cm
-1
 and the stretching due to 
the primary –NH group of CBZ III had shifted to 3498 cm
-1
, a return that agrees with its report data 
[136]. Similarly, the peak of the free carbonyl group had shifted to 1724 instead of 1715 cm
-1
, as 
seen in the SAC result. This also exhibited a shift in the asymmetric stretching from 1332 to 1320 
cm
-1
because of the –SO2 group of SAC. All these change in the IR spectra indicated interaction 
between the SAC and CBZ molecules in their solid state, and hence the formation of cocrystals 
[134]. The IR spectra of the CBZ-SAC physical mixture peaked at 3463 and 1674 cm
-1
 as a result of 
CBZ III, 1715, 1332 and 1175 cm
-1
 from SAC. These IR peak identities of CBZ III, SAC, CBZ-
SAC cocrystals and a mixture is shown in Table 4.5. 


















N-H of CBZ 
-(C=O)- of CBZ 
O=S=O of SAC 






1332 and 1175 
-NH2 of CBZ 
-(C=O)- of CBZ 
-(C=O)- of SAC 
-SO2- of SAC 
4.3.3.3 CBZ-CIN cocrystals 











Fig.4.9 Structure of CBZ, CIN and CBZ-CIN cocrystals 
The IR spectrum of CBZ III, CIN, CBZ-CIN cocrystals and a physical mixture are shown in 
Fig.4.10. 





































Fig.4.10 IR spectrum of CBZ III, CIN, CBZ-CIN cocrystals and a mixture 
CIN’s IR spectrum exhibited medium strong and broad peaks at around 2542-2985 cm
-1 
corresponding to -OH- stretch. Peaks corresponding to the stretching of C=O and C=C in CIN were 
also observed at around 1668 and 1626 cm
-1




[137]. The cocrystals’ IR spectra peaks showed shifts in the C=O, C=C and –NH regions. Shifts in 
CBZ III’s amide-NH stretching were observed at 3424 cm
-1
. The peak of CBZ III and CIN’s C=O 
stretch had shifted to 1697 cm
-1
. It also exhibited a shift in the stretching from 1626 to 1633 cm
-1
 
because of the C=C group of CIN. All these changes in the IR spectra indicated interaction between 
the CIN and CBZ III molecule in their solid state, and hence the formation of cocrystals. The CBZ-
CIN cocrystals can be characterized by any one or more of the IR peaks including, but not limited 
to, 1658, 1633, 1574, 1489 and 1449 cm
-1
. This agrees with the published data [138]. The CBZ-CIN 
physical mixture’s IR spectra showed peaks of 3463 and 1674 cm
-1
 resulting from CBZ III, and 
1626 cm
-1
 from CIN. The IR peak identities of CBZ III, CIN, the CBZ-CIN cocrystals and a 
mixture are summarized in Table 4.6. 











-OH- of carboxylic acid 
-C=O- 
-C=C- conjugated with aromatic rings 





-NH2 of CBZ 
-C=C- of CIN 
-(C=O)- of CBZ, CIN 
 
CBZ-CIN  mixture 3463 
1675 
1626 
-NH2 of CBZ 
-(C=O)- of CBZ 
-C=C- of CIN 
 
4.3.4 Raman analysis of CBZ III, CBZ cocrystals and physical mixtures 
4.3.4.1 CBZ-NIC cocrystals 
Raman spectra of CBZ III, NIC, CBZ-NIC cocrystals and a physical mixture are shown in Fig.4.11, 




Several characteristic peaks can identify CBZ samples. CBZ III’s double peak at 272 cm
-1
 and 253 
cm
-1
 is caused by lattice vibration. CBZ III exhibits triple peaks in the range of wavenumbers 3070-
3020 cm
-1
 and one aromatic asymmetric stretch peak around 3071 cm
-1
. The two most significant 
peaks for NIC are the pyridine ring stretch peak at 1042 cm
-1
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Fig.4.11 Raman spectra for CBZ III, NIC, CBZ-NIC cocrystals and a mixture 
Characteristic peaks of CBZ and NIC both showed in the Raman spectrum of the CBZ-NIC 
physical mixture. This double peak, at 272 and 253 cm
-1
, as a result of CBZ; the ratio of the peak 
intensity at 1040 cm
-1
 to that at 1025 cm
-1
 increases due to NIC’s strong ring stretch peak at 1042 
cm
-1
. The CBZ-NIC cocrystals’ Raman spectrum has a single peak at around 264 cm
-1
 and a 
spectrum pattern in the ranges of 1020-1040 cm
-1
 and 2950-3500 cm
-1
. Differences among the 
Raman spectra of CBZ, NIC, CBZ-NIC cocrystals and a physical mixture demonstrate that CBZ-
NIC cocrystals are not just a physical mixture of the two components; rather, a new solid-state 




4.3.4.2 CBZ-SAC cocrystals 
Raman spectra of CBZ III, SAC, CBZ-SAC cocrystals and a physical mixture are shown in Fig.4.12, 
and the spectra data is shown in Table 4.7. 
A strong band characteristic of SAC’s C=O stretching mode was observed near 1697 cm
-1
, which 
agrees with published data [139]. The Raman spectrum for the CBZ-SAC physical mixture shows 
both characteristic peaks CBZ III and SAC. Its double peak at 272 and 253 cm
-1
 results from CBZ 
III, and its single peak near 1697 cm
-1
 from SAC. The Raman spectrum of CBZ-SAC cocrystals 
contained a single peak at around 1715 cm
-1
, which differs from SAC’s stretching frequency 1697 
cm
-1
. The pattern of spectrum in the ranges of 2950-3500 cm
-1 
is different from those of the physical 
mixture. Differences among the Raman spectra of CBZ III, SAC, CBZ-SAC cocrystals and a 
physical mixture demonstrate that CBZ-SAC cocrystals are not just a physical mixture of the two 
components; rather, a new solid-state formation has been generated. 
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4.3.4.3 CBZ-CIN cocrystals 
The Raman spectra of CBZ III, CIN, CBZ-CIN cocrystals and a physical mixture are shown in 
Fig.4.13 and the spectra data in Table 4.7. 
A very strong characteristic of CIN’s C=C stretching mode was observed near 1637 cm
-1
 and a 
weak characteristic of CIN’s C-O stretch near 1292 cm
-1
, both of which agree with published data 
[137]. The Raman spectrum of the CBZ-CIN physical mixture demonstrates the characteristic peaks 
of both CBZ III and CIN. It exhibits a double peak at 272 and 253 cm
-1
 as a result of CBZ III, and 
single peaks near 1637 cm
-1
 and 1292 cm
-1
 as a result of CIN. The Raman spectrum of CBZ-CIN 
cocrystals show a single peak at around 255 cm
-1 
instead of a double one at 272 and 253 cm
-1
. The 
spectrum pattern in the range 2950-3500 cm
-1
 is different from that of the physical mixture. A 
single peak near 1699 cm
-1
 was observed in the cocrystals but not in CBZ III or CIN. Differences 
among the Raman spectra of CBZ III, CIN, CBZ-CIN cocrystals and a physical mixture 
demonstrate that the CBZ-CIN cocrystals are not just a physical mixture of the two components; 
rather, as before, a new solid-state formation has been generated. 
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The Raman spectra data of CBZ III, NIC, SAC, CIN and the CBZ-NIC, CBZ-SAC and CBZ-CIN 
cocrystals is summarized in Table 4.7. 
Table 4.7 Raman peaks for CBZ III, NIC, SAC, CIN and CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals 
Compound Peak position (cm
-1
) Assignment 
CBZ III double peaks at 272 and 253 
1040,1025, peak intensity ratio 0.97 
triple peaks at 3020, 3043 and 3071 
lattice vibration 
C-H bending 
non-aromatic C-H stretch 
aromatic C-H stretch 
aromatic asymmetric stretch 
NIC 1042 
3060 
pyridine ring stretch 
C-H stretch 





CBZ-NIC cocrystals single peak at 264 
distinctive peaks at 1020-1040 
distinctive peaks at 2950-3500 
lattice vibration 
C- H bending 
C-H stretch 
CBZ-SAC cocrystals 1715 C=O stretch 
CBZ-CIN  cocrystals 255 lattice vibration 
 1700-1720 C=O 
4.3.5 XRPD analysis of CBZ III, CBZ cocrystals and physical mixtures 
4.3.5.1 CBZ-NIC cocrystals 
Fig.4.14 presents the corresponding XRPD patterns of the crystals of CBZ III, NIC, CBZ-NIC 









, all of which are identical to those of the reported data [52, 140-142]. NIC’s 




. CBZ-NIC cocrystals show the 
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Fig.4.14 XRPD of CBZ III, NIC, CBZ-NIC cocrystals and a mixture 
4.3.5.2 CBZ-SAC cocrystals 
Fig.4.15 presents the corresponding XRPD patterns of the crystals of CBZ III, SAC, CBZ-SAC 


















, all of which agrees with the reported data [144]. The physical mixtures showed the 
characteristic peaks of both CBZ III and SAC. 






































4.3.5.3 CBZ-CIN cocrystals 
Fig.4.16 presents the corresponding XRPD patterns of the crystals of CBZ III, CIN, CBZ-CIN 




















 which are identical to the reported data [146]. The physical mixtures showed 
characteristic peaks of both CBZ III and CIN. 














































Fig.4.16 XRPD of CBZ III, CIN, CBZ-CIN cocrystals and a mixture 
4.3.6 HSPM analysis of CBZ III, CBZ cocrystals and physical mixtures 
4.3.6.1 CBZ-NIC cocrystals 
The crystallization pathways of CBZ III and NIC were investigated using HSPM and the 
photomicrographs obtained are shown in Fig.4.17. For CBZ, the agglomerates of prismatic crystal 
corresponding to Form III converted to small needle-like crystal corresponding to Form I from 
176°C [147], which finally melted at 193°C as shown in Fig.4.17 (a). For NIC, the crystalline 
completely melted at 130°C, as shown in Fig.4.17 (b). For CBZ-NIC cocrystals, the crystalline 
completely melted at 161°C as shown in Fig.4.17 (c). For CBZ-NIC physical mixture, NIC melted 
from 130°C and CBZ dissolved into this melt. The CBZ-NIC cocrystals then began to grow until 
157°C and completely melted at 162°C. The results of HSPM analysis indicated that physical 
mixture of CBZ and NIC could form cocrystals during the heating process. The newly generated 




      
(a) CBZ III 
      
(b) NIC 
      
(c) CBZ-NIC cocrystals 
       
(d) CBZ and NIC mixture 
Fig.4.17 HSPM micrographs of phase transition during heating processes: (a) CBZ III; (b) NIC; (c) CBZ-NIC 




4.3.6.2 CBZ-SAC cocrystals 
The crystallization pathways of CBZ III and SAC were investigated using HSPM and the 
photomicrographs obtained are shown in Fig.4.18. For SAC, the crystalline completely melted at 
230°C, as shown in Fig.4.18 (a). For CBZ-SAC cocrystals, the crystalline completely melted at 
177°C as shown in Fig.4.18 (b). For CBZ-SAC physical mixture, new crystalline was generated 
from 130°C; this began to grow until 150°C and completely melted at 178°C as shown in Fig.4.18 
(c). The results of the HSPM analysis indicated that the physical mixture CBZ and SAC could form 
cocrystal during the heating process. 
     
(a) SAC 
     
(b) CBZ-SAC cocrystals 
       
(c) CBZ-SAC mixture 





4.3.6.3 CBZ-CIN cocrystals 
The crystallization pathways of CBZ III and CIN were investigated using HSPM and the 
photomicrographs obtained are shown in Fig.4.19. For CIN, the crystalline completely melted at 
136°C as shown in Fig.4.19 (a). For CBZ-CIN cocrystals, the crystalline completely melted at 
147°C as shown in Fig.4.19 (b). For CBZ-CIN physical mixture, some crystalline melt from 110°C 
and new crystalline was generated from 120°C. This then began to grow until 127°C and 
completely melted at 144°C, as shown in Fig.4.19 (c). The results of HSPM analysis indicated that 
CBZ and CIN could form cocrystal during the heating process.  
     
(a) CIN 
     
(b) CBZ-CIN cocrystal 
     
(c) CBZ-CIN mixture 





4.4 Chapter conclusions 
In this chapter, various samples of CBZ DH, cocrystals of CBZ-NIC, CBZ-SAC and CBZ-CIN 
were successfully prepared. The CBZ-NIC cocrystals were prepared using the solvent evaporation 
method and the CBZ-SAC and CBZ-CIN cocrystals using the cooling crystallization method. All 
the prepared samples were the characterized using a variety of techniques. The DSC results indicate 
that the physical mixtures of CBZ and the coformer formed CBZ cocrystals during the heating 
process. The Raman and FTIR results indicate that the CBZ cocrystals had formed through the H-
bonding acceptors and donors of groups –NH2 and –(C=O)-. The patterns of the CBZ cocrystals 
were different from the physical mixtures of CBZ and the coformer by XRPD, indicating that the 
CBZ cocrystals were not just a physical mixture of the two components but rather that a new solid-
state formation had been generated. The HSPM micrographs further prove that the physical 
mixtures of CBZ and the coformer form a new solid-state formation during the heating process. The 
molecular structure of the cocrystals CBZ-NIC, CBZ-SAC and CBZ-CIN were also described in 




Chapter 5 Investigation of the effect of Hydroxypropyl 
Methylcellulose on the phase transformation and release profiles of 
CBZ-NIC cocrystals 
5.1 Chapter overview 
In this chapter the effect of Hydroxypropyl Methylcellulose (HPMC) on the phase transformation 
and release profile of CBZ-NIC cocrystals in solution and in sustained release matrix tablets were 
investigated. The polymorphic transitions of the CBZ-NIC cocrystals and their crystalline 
properties were examined using DSC, XRPD, Raman spectroscopy and SEM. The intrinsic 
dissolution study was investigated using the UV imaging system. The release profiles of the CBZ-
NIC cocrystals in solution and sustained release matrix tablets were investigated using the 
dissolution method. 
5.2 Materials and methods 
5.2.1 Materials 
Anhydrous CBZ III, NIC, Ethyl acetate, double distilled water, HPMC K4M, SLS and methanol 
were used in this chapter; details of these materials can be found in Chapter 3. 
5.2.2 Methods 
5.2.2.1 Formation of the CBZ-NIC cocrystals 
This chapter describes the preparation of the CBZ-NIC cocrystals. The details of the formation 
method can be found in Chapter 3 
5.2.2.2 Preparation of tablets 
The formulations of the matrix tablets are provided in Table 5.1. The details of the method can be 







Table 5.1 Matrix tablet composition (mg) 
Component Formulation 
F1 F2 F3 F4 F5 F6 
CBZ III 200   200   
CBZ-NIC cocrystals  304   304  
Equal molar mixture of CBZ III and NIC   304   304 
HPMC K4M 100 100 100 200 200 200 
5.2.2.3 Intrinsic dissolution study by the UV imaging system 
The dissolution behaviours of CBZ III and CBZ-NIC cocrystals in pure water and different 
concentrations of HPMC solutions were studied in this study. The details of this method can be 
found in Chapter 3. The media used for the tests included water and 0.5, 1, 2 and 5 mg/ml HPMC 
aqueous solutions. 
5.2.2.4 Solubility analysis of CBZ-NIC cocrystals and mixture, CBZ III in HPMC solutions 
The equilibrium solubilities of CBZ-NIC cocrystals and a mixture, as well as CBZ III in HPMC 
aqueous solution, were tested in this chapter. The details of this method can be found in Chapter 3. 
The media used for the tests included water and 0.5, 1, 2 and 5 mg/ml HPMC aqueous solutions.  
5.2.2.5 Dissolution studies of formulated HPMC matrix tablets 
The results of dissolution studies of formulated HPMC tablets are presented in this chapter. The 
details of this method can be found in Chapter 3. The medium used for the test was 1% SLS water. 
5.2.2.6 Physical properties characterisation techniques 
HPLC and statistical analysis were used to study the solubility and dissolution behaviour of tablets. 
UV imaging was used to study the intrinsic dissolution rate. SEM, XRPD and DSC were used in 





5.3.1 Phase transformation  
Fig.5.1 shows the CBZ solubility of CBZ-NIC cocrystals, CBZ III and a physical mixture of CBZ 
III and NIC at different HPMC concentration solutions at equilibrium after 24 hours. In pure water, 
there was no significant difference in equilibrium solubility between CBZ III, CBZ-NIC cocrystals 
and a physical mixture of CBZ III and NIC (P>0.05).  
It was found that a small amount of HPMC in solution can increase the CBZ solubility of CBZ III 
and a physical mixture of CBZ III and NIC significantly, indicating a higher degree of interaction 
between CBZ and HPMC to form a soluble complex. No difference in the equilibrium solubility of 
CBZ III and the physical mixture (P>0.05) at different HPMC concentration solutions was observed, 
indicating that NIC had no effect on the solubility of CBZ because of the low concentration of NIC 
in the solution, which is consistent with the present researchers’ previous results [148]. The 
solubility of CBZ III and a physical mixture of CBZ III and NIC increased initially with increasing 
HPMC concentration in solution to a maximum at 2 mg/ml HPMC concentration, and then 
decreased slightly. This suggests that the soluble complex of CBZ and HPMC reached its solubility 
limit at 2 mg/ml HPMC in solution.  
 
Fig.5.1 CBZ concentration of CBZ-NIC cocrystals, CBZ III, and a physical mixture of CBZ III and NIC in different 
HPMC solution concentration solutions 
The CBZ solubility of CBZ-NIC cocrystals exhibits behaviour different to those of CBZ III and a 
































nearly constant with increasing HPMC concentrations, indicating that the amount of a soluble 
complex of CBZ-HPMC formed in solution was not significant. 
Solid residues retrieved from each of the solubility tests were analysed using DSC, Raman and 
SEM. The DSC thermographs of individual components are given in Fig.5.2 (a) for comparison, 
showing that the dehydration process of CBZ DH occurred in the range 80-120
o
C. After a 
dehydration process under DSC heating conditions, CBZ DH converted back to CBZ III which 
melted at around 175
o
C and recrystallized to CBZ I, which in turn melted at around 195
o
C. The 
DSC thermographs of the solid residues from different HPMC concentration solutions were 
examined as shown in Fig.5.2 (b). It can clearly be seen that the CBZ DH crystals were found in the 
solid residues of CBZ-NIC cocrystals in different HPMC concentration solutions because there was 
a clear dehydration process with a sharp endothermic between 80-120°C in each DSC thermograph. 
This is analogous to that seen with CBZ DH in Fig.5.2 (a), indicating that HPMC did not inhibit the 
crystallisation of CBZ DH from solution. As expected, the solid residues of CBZ III and a physical 
mixture in water were converted to CBZ DH after 24 hours, showing the same DSC thermographs 
as that of CBZ DH alone. It can be seen that at 2 mg/ml of HPMC concentration and above, CBZ 
III alone or in physical mixture did not convert to dihydrate after 24 hours because no dehydration 
event occurred in the DSC thermographs, indicating that HPMC completely inhibited the 





C; the present researchers believe that this was caused by the CBZ IV 
melting and simultaneously recrystallizing to CBZ I. This is discussed in greater depth in the 
following section. 
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Fig.5.2 DSC thermographs of solid residues obtained from different HPMC concentration solutions: (a) original 
samples; (b) solid residues of CBZ III, CBZ-NIC cocrystals and a physical mixture of CBZ and NIC 
Fig.5.3 illustrates the influence between various HPMC concentrations on the degree of conversion 




cocrystals and a physical mixture in water were completely converted to CBZ DH after 24 hours. 
HPMC did not show any influence on the transformation of CBZ-NIC cocrystals to CBZ DH at any 
concentrations between the 0.5 to 5 mg/ml studied, showing the same conversion rate of around 95% 
CBZ DH in the solid residues. At 2 mg/ml of HPMC concentration and above, the conversion rate 
of CBZ DH for anhydrous CBZ III alone or in physical mixture was zero, which was consistent 
with the DSC results. The conversion rates of CBZ DH for CBZ III alone and in physical mixture 
were also same at the other HPMC concentrations – i.e. around 10% in the 0.5 mg/ml HPMC 
concentration solution and 5% in the 1mg/ml HPMC concentration solution – indicating that 
HPMC partly inhibited the transformation to CBZ DH. It is also interesting to note that NIC did not 
affect the conversion rate for CBZ III in a physical mixture.  
 
Fig.5.3 Influence of HPMC concentration on conversion of CBZ to CBZ DH after 24 hours 
Fig.5.4 shows SEM photographs of solid residues obtained from different HPMC concentration 
solutions. CBZ III samples used appeared to be prismatic, showing a wide range of size and shape. 
Small cylindrical NIC particles could be seen to mix with CBZ III particles in the physical mixture 
samples. CBZ-NIC cocrystals show a thin needle-like shape in a wide range of sizes. It can be seen 
that HPMC has a significant influence on the morphology of the crystals shown in the SEM 
photographs. In water, prism-like CBZ III crystals have become transformed into needle-like CBZ 
DH crystals. At different HPMC concentration solutions there was no significant change in 
morphology for most residual crystals compared with the starting materials of CBZ III. However, it 
can clearly be seen that some spherical aggregates appeared to be amorphous in the residuals, all of 
which are consistent with previous findings [149]. The morphology of the residues for the physical 
mixture of CBZ III and NIC was similar to those of CBZ III in different concentrations of HPMC 
solutions, indicating that all NIC samples had dissolved and that NIC had no effect on the phase 




concentration solutions show the needle-like shape as that of pure CBZ DH, whose size distribution 
is much more even and narrow than that of the CBZ-NIC cocrystals. This indicates that HPMC did 
not inhibit the crystallisation of CBZ DH from the solution. At concentrations of 2 and 5 mg/ml 
HPMC solution, the CBZ DH crystals were thicker than the CBZ DH crystals precipitated from 
pure water, and some aggregates composed of small crystals also appeared with the needle-like 
shape of the CBZ DH crystals. 
 CBZ-NIC cocrystals CBZ III CBZ III and NIC mixture 
original material    
water    
0.5 mg/ml HPMC    
1 mg/ml HPMC    
2 mg/ml HPMC    
5 mg/ml HPMC    
Fig.5.4 SEM photographs of solid residues obtained from CBZIII, CBZ-NIC cocrystal and physical mixture at different 
HPMC concentration solutions 
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The IDR profiles of the compacts of the CBZ III (dashed lines) and CBZ-NIC cocrystals (solid lines) 
at different HPMC concentration dissolution medium are shown in Fig.5.5. It can be seen that all 
IDRs decreased quickly within 10 minutes, reaching their static values after 30. No differences 
between the IDR profiles of the CBZ-NIC cocrystals at different HPMC concentration dissolution 
medium (P>0.05) were found. Prior to the dissolution tests, all the compact surfaces of CBZ-NIC 
cocrystals were smooth. After those tests, the SEM photographs (Fig.S5.1 in the Appendices) show 
that small needle-shaped CBZ DH crystals had appeared on the compact surfaces of the CBZ-NIC 
cocrystals, indicating that HPMC did not inhibit the recrystallization of CBZ DH crystals from the 
solutions. Different dissolution behaviours (P<0.05) of CBZ III at different HPMC concentration 
dissolution medium were observed. When the dissolution medium was water, the IDR of CBZ III 
decreased quickly because of the precipitation of CBZ DH on the compact surface (shown in the 
SEM photographs in Fig.S5.1 in the Appendices). The IDR of CBZ III increased significantly when 
the HPMC was added in the dissolution medium, as shown in Fig.5.5, and there were no CBZ DH 
crystals on the compact surfaces in Fig.S5.1 in the Appendices, indicating that HPMC inhibited the 
recrystallization of CBZ DH crystals from the solutions. It can be also shown that the CBZ-NIC 
cocrystals had an improved dissolution rate in water when compared with CBZ III, but also that this 
advantage was completely lost (when compared with CBZ III) when HPMC was included in a 
dissolution medium.   
 
Fig.5.5 Intrinsic dissolution rates obtained by UV imaging (n=3) 
The results of IDR have the same ranking as the solubility – i.e. in different HPMC solutions, CBZ 
III> CBZ-NIC cocrystals (Fig.5.1). The turning point on the IDR curves indicates where the slope 
changed from the dissolution of CBZ III or CBZ-NIC cocrystals to that of CBZ DH. The highest 




form [150].  The results of the IDR curves indicate that CBZ-NIC cocrystals transformed into CBZ 
DH faster than CBZ III in HPMC solutions.  
5.3.2 CBZ release profiles in HPMC matrices 
Fig.5.6 (a) presents the CBZ release profiles of CBZ-NIC cocrystals, CBZ III and a physical 
mixture of CBZ III and NIC from the 100 mg HPMC matrices. This demonstrates that the release of 
CBZ from the CBZ-NIC cocrystal formulation is significant different from those of the CBZ III and 
physical mixture formations (P<0.05). It is interesting to note that the significantly higher release of 
CBZ from the CBZ-NIC cocrystal formulation occurred at the early stage of the dissolution (up to 
one hour). However, the CBZ release rate from the cocrystal formulation changed significantly, 
gradually decreasing to a lower value than that of the CBZ III and physical mixture formulations 
after 2.5 hours, indicating significant changes to the cocrystal properties in the matrix. The 
difference in the CBZ releases from the CBZ III and physical mixture formulations was significant 
during dissolution up to three hours (P<0.05), after which both formulations’ CBZ release profiles 
were identical (P>0.05). It can be seen that during the first hour of the dissolution test the CBZ 
release rate from the CBZ III formulation was the lowest, which is explained by HPMC’s initially 
slower hydration and gel layer formation processes. Once the tablet’s hydration process was 
completed, the CBZ release rate remained constant. For the physical mixture of CBZ and NIC 
formulations, HPMC’s hydration and gel layer formation processes was much faster than that of the 
CBZ III formulation alone because the quickly dissolved NIC acted as a channel agent to speed up 
the water uptake process, resulting in a higher release rate. Once all of NIC had dissolved, both 
formations showed similar dissolution profiles.   
Fig.5.6 (b) presents the CBZ release profiles of CBZ-NIC cocrystals, CBZ III and a physical 
mixture of CBZ III and NIC from the 200 mg HPMC matrices. Overall, the results show that 
increasing HPMC in all three formulations resulted in reduced CBZ release rates, indicating that 
HPMC slowed down drug dissolution. It shows that the CBZ release from the CBZ-NIC cocrystal 
formulation is much higher than those of the other two formulations of CBZ III and a physical 
mixture, demonstrating the advantage of CBZ-NIC cocrystal formulation. Incorporation of NIC in 
the formulation produced no change in CBZ III release rate (P>0.05), thereby demonstrating NIC’s 
complete lack of effect on the enhancement of CBZ III dissolution in the formation. The CBZ 








Fig.5.6 CBZ release profiles of CBZ-NIC cocrystals, CBZ III and a physical mixture of CBZ III and NIC formulations: 
(a) in a 100 mg HPMC matrix; (b) in a 200 mg HPMC matrix 
The solid crystal properties in the gel layer were examined using XRPD, SEM and DSC in order to 
understand the mechanisms involved in the CBZ release of CBZ-NIC cocrystals from a HPMC 
Fig.5.7 (e)-(j) illustrates the corresponding XRPD patterns of the crystals in the gel layers of 
different formulations. The XRPD patterns of the individual components of CBZ III, CBZ DH, NIC 
and CBZ-NIC cocrystals are also shown in Fig.5.7 (a)-(d). The characteristic diffraction peaks of 
CBZ III are at 2=13.1°, 15.3°, 19.6° and 20.1°, being identical to those in published data [52, 140-
142]. The molecular of CBZ III arrangements along the three crystal faces [(100), (010) and (001)] 
was carried out: fewer polar groups were exposed on the (100) face than on the (001) and (010) 
faces, which explains the comparatively weak interaction of the (100) face with water during 




of CBZ DH. NIC shows the characteristic diffraction peaks at 2=14.9° and 23.5°. The 
characteristic diffraction peaks of CBZ-NIC cocrystals were exhibited at 2=6.7°, 9.0°, 10.3°, 13.5° 
and 20.6°, which agrees with previous reports [140, 143]. 
The significant, characteristic peaks of CBZ III, without any characteristic peaks of CBZ DH, were 
observed in the gels of CBZ III tablets in both 100 mg and 200 mg HPMC matrices, implying that 
there was no change in CBZ III’s crystalline state. In the gel layers of the physical mixture of CBZ 
III and NIC in both 100 mg and 200 mg matrices, only the characteristic peaks of CBZ III appear; 
no diffraction peaks of NIC or CBZ DH are evident, indicating that NIC had dissolved completely 
and that its existence had no effect in the formulation on CBZ III’s crystalline properties. 
Furthermore, the XRPD diffraction patterns of CBZ III obtained from the formulations of CBZ III 
and a physical mixture of CBZ III and NIC in Fig.5.7 (e), (f), (i) and (j) revealed the characteristic 
peaks of CBZ IV at 2=14.4 and 17.4°  [52], indicating that a new form of CBZ IV crystal had been 
crystallised during the dissolution of the tablets. In the meantime, those XRPD diffraction patterns 
showed the significantly weaker and broader peaks compared with that of CBZ III powder in 
Fig.5.7 (a), which can be attributed to smaller particle size and increased defect density of CBZ 
crystals. 
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Both CBZ-NIC cocrystals and CBZ DH characteristic peaks were observed in the CBZ-NIC 
cocrystal formulations of the 100 mg and 200 mg HPMC matrices, indicating recrystallization of 
CBZ DH from the solution. However, diffraction peaks of CBZ DH in the 100 mg HPMC matrix 
are stronger, indicating that more CBZ DH had been recrystallized. The broad peaks of CBZ DH 
compared with the X-ray patterns of pure CBZ DH indicate a decrease in crystallinity of the 
crystals with the formation of a less ordered structure.   
The gels’ SEM morphologies after the dissolution tests are shown in Fig.5.8. These make it clear 
both that there are many CBZ DH particles dispersed in the gels for the CBZ-NIC cocrystal 
formulations in both 100 mg and 200 mg HPMC matrices, and that needle-shaped CBZ DH 
particles were not found in a formulation of either CBZ III or a physical mixture of CBZ III and 
NIC. 
 CBZ-NIC cocrystals CBZ III CBZ III and NIC mixture 
Gel of 100 mg 
HPMC matrix 
after dissolution 
   
Gel of 200 mg 
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Fig.5.8 SEM photographs of layers after dissolution tests 
DSC results are also similar to those in Fig.S5.2 in the Appendices, which supports XRPD and 
SEM analysis. 
5.4 Discussion 
The inhibition of CBZ III phase transition to CBZ DH and the amorphism induced in the presence 
of low concentrations of HPMC and in the gel layer of hydrated tablets has been extensively studied 
[149]. It is known that hydroxyl groups of HPMC attach to CBZ at the site of water binding and 
therefore that its transformation to the dihydrate form is inhibited. HPMC was also expected to 
inhibit the transformation of CBZ-NIC cocrystals to CBZ DH during dissolution because the 
change in crystalline properties of CBZ-NIC cocrystals during this process can reduce the 
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advantages of the improved dissolution rate and solubility, resulting in poor drug absorption and 
bioavailability [8, 148]. Unfortunately, this study shows that HPMC did not inhibit the phase 
transformation of CBZ-NIC cocrystals to CBZ DH in either the aqueous solutions or the sustained-
release HPMC matrix tablets. It also indicated that the CBZ release profile of CBZ-NIC cocrystals 
was significantly affected by the percentage of HPMC in the formulation. 
In fusion, the competition mechanism between CBZ and NIC with HPMC to form hydrogen bonds 
has been proposed [140]. When the physical mixture of CBZ III, NIC and HPMC was heated, NIC 
melted first, allowing both CBZ III and HPMC subsequently to dissolve in molten NIC and form 
intermolecular hydrogen bonds between the three components [152].  
The solubility study of CBZ III in different concentrations of HPMC solutions found that CBZ’s 
apparent solubility initially increased with the increasing concentration of HPMC in solution, as 
shown in Fig.5.1, implying a soluble complex formation between CBZ and HPMC in solution. 
When the concentration of HPMC was higher than 1mg/ml, the solubility limit of the complex 
formed was reached and the total apparent solubility of CBZ in solution did not change 
significantly, as represented by the plateau in Fig.5.1. The sole phase of CBZ III appears as solid 
residues when the concentration of HPMC was above 1 mg/ml, as is evident from the results of the 
DSC and Raman spectroscopy in Fig.5.2 and Fig.5.3. This indicates that HPMC can inhibit the 
precipitation of CBZ DH. The most reasonable explanation is probably two-fold:. a stronger 
interaction between CBZ and HPMC involving hydrogen bonding interaction occurring at the site 
where water molecules attack CBZ to form a CBZ-HPMC association, resulting in inhibition of the 
formation of CBZ DH in solution, and the formation of a soluble complex of CBZ-HPMC in the 
solution being faster than the rate of CBZ III dissolution.  
The formation of the soluble complex CBZ-HPMC in solution has been studied extensively [149, 
153-155]. The molecular structure of CBZ DH and a part of the hydrogen bond system is shown in 
Fig.5.9. Like the crystalline structure of the non-hydrated form, intermolecular hydrogen bonding 
between carboxamide groups builds centrosymmetric dimers with N17-H…O18’. The two 
independent water molecules, W1 and W2, are linked to the CBZ molecules by the bridge N17-
H…OW1 and OW2-H…O18. The structural formula of HPMC is present in Fig.5.10, which has a 
high content of OH groups. The formation of CBZ-HPMC association which hydrogen bonding 
interaction occurs at the site where water molecules are attached to CBZ, thus inhibit the 
transformation of CBZ to CBZ DH. This interaction may occur at different sites on HPMC 





Fig.5.9 The structure of CBZ DH [149] 
 
Fig.5.10 HPMC’s molecular structure, possible sites of interaction are indicated by * [149] 
When the HPMC concentration was higher than 2 mg/ml, the solubility limit of the complex of 
CBZ-HPMC formed was exceeded, resulting in the precipitation of the complex of CBZ-HPMC 
showing induction of amorphism of CBZ III crystals in the solid residues. The apparent CBZ 
solubility therefore decreased, as shown in Fig.5.1. The SEM images in Fig.5.4 illustrate larger 
agglomerated particles in the solid residuals of the 5 mg/ml HPMC solution. The UV imaging 
intrinsic dissolution study of CBZ III compacts also supports this explanation. When the dissolution 
medium was water, the IDR of CBZ III decreased quickly because of precipitation of CBZ DH on 
the compact surface. This in turn was caused by supersaturation of the CBZ solution around the 
compact surface. CBZ III’s IDR increased with increasing HPMC concentration and no CBZ DH 
was precipitated on the sample compact surface when HPMC was included in the dissolution 
medium. The CBZ solubility profile was the same as the physical mixture of CBZ III and NIC, 
suggesting that NIC had not been incorporated into the complex with CBZ or HPMC in solution. 
The reason is that the interaction force between NIC and water is much stronger than between the 
other two components as a result of the large incongruent solubility difference between NIC and 
CBZ or HPMC in water. This is consistent with the authors’ previous report [148], which found no 




The apparent CBZ solubility of CBZ-NIC cocrystals was same as the solubility of CBZ III alone or 
a physical mixture of CBZ III and NIC because the interaction force of CBZ and NIC was much 
weaker than that of NIC with water, resulting in the failure in formation of the soluble complex of 
CBZ-NIC at a low NIC concentration. The apparent CBZ solubility of CBZ-NIC cocryrstals at 
different concentrations of HPMC solutions was constant, increasing slightly compared with that of 
CBZ-NIC cocrystals in water. This can be explained by the rate differences between the cocrystal 
dissolution and formation of a soluble complex of CBZ and HPMC in solution. The solubility of the 
CBZ-NIC cocrystals was higher and their dissolution rate faster, making it possible to generate a 
higher supersaturation of CBZ in solution during dissolution. Although the soluble complex of 
CBZ-HPMC can be formed to stabilize CBZ in the solution, the rate of CBZ from the dissolved 
CBZ-NIC cocrystals entering the solution was much faster than the rate of CBZ-HPMC complex 
formation, leading to precipitation of CBZ DH. The Raman analysis shown in Fig.5.3 indicates that 
nearly 95% of the CBZ DH crystals in the solid residues and SEM images in Fig.5.4 show the 
needle-shaped particles precipitated on the surfaces of sample compacts. Previous studies have 
shown that CBZ IV (C-monoclinic) can be crystallized by the slow evaporation of an ethanol 
solution in the presence of polymers such as hydroxypropyl cellulose, poly(4-methylpentene), 
poly(α-methylstyrene), and poly(p-phenylene ether-sulfone) [52, 156]. The present study finds that 
CBZ IV can also be crystallized by dissolving CBZ III in HPMC solution. The DSC results of the 
solid residues from the both CBZ III and a physical mixture of CBZ III and NIC in different 
concentrations of HPMC solutions, as shown in Fig.5.2 (b), reveal an additional endothermic-




C corresponding to the melting point of CBZ IV 
[52], indicating that HPMC has been docked on the surfaces of CBZ III crystals, as heteronucleito 
induces defects in crystallinity. Although some aggregates appeared in the solid residuals of CBZ-
NIC cocrystals at different concentrations of HPMC solution, the DSC thermograms are same as 
those shown in Fig.5.2, indicating that HPMC was not crystallised in the crystal units of CBZ 
dihydrate. It did, however, affect the morphology of CBZ DH crystals.  
When the CBZ-NIC cocrystals were formulated into sustained release HPMC matrix tablets, the 
change in the cocrystals’ crystalline properties was affected not only by interaction forces among 
the components in solution but also by the matrix hydration and erosion characteristics of the drug 
delivery system. The reduction in CBZ-NIC cocrystal dissolution through HPMC was affected by 
drug loading: higher drug loading resulted in a weaker reduction effect, exhibiting high CBZ 




In a lower percentage of 100 mg HPMC matrixes the CBZ release profiles of CBZ-NIC cocrystals, 
CBZ III and a physical mixture display behaviour similar to that of their IDRs in solution, as found 
in the authors’ previous study [8]. The CBZ-NIC cocrystals in a 100 mg HPMC matrix exhibits the 
highest release rate compared with the other two formulations at the early stage of the dissolution 
(up to two hours) because of the improved dissolution rate and the solubility of CBZ-NIC 
cocrystals. The study has shown that the solubility of CBZ-NIC was approximately 130 to 319 
times that of CBZ III alone in water [148]. However, the dissolution profile of CBZ-NIC cocrystals 
was nonlinear and the release rate declined over time, as shown in Fig.5.6 (a). The slope of the 
CBZ-NIC cocrystal release rate was 17.454 for the first 0.5 hours, decreasing to 9.0702 thereafter. 
The XRPD analysis of the gel layer showed that CBZ DH crystals recrystallized from the solution. 
Similar as the solubility study of CBZ-NIC cocrystals, HPMC in solution failed to stabilize CBZ in 
solution because the formation rate of the soluble complex of CBZ-HPMC was slower compared 
with the dissolution rate of CBZ-NIC cocrystals. Because of solid phase transformation of CBZ-
NIC cocrystals, the CBZ release rate from the cocrystal formation was lower than that of the 
formation of CBZ III alone, or of a physical mixture after two hours in the dissolution tests.   
By contrast, the CBZ release rate of the physical mixture in the HPMC matrix was linear. When the 
more soluble component of NIC dissolved rapidly from the matrix, pores could be formed to bring 
more water into the matrix to increase the dissolution rate of both HPMC and CBZ, resulting in 
higher CBZ dissolution rates compared with that of the pure CBZ III formulation. A significant 
delay in the release stage of the pure CBZ III formulation was observed because of the hydration of 
the HPMC matrix. When NIC dissolved and the HPMC matrix was hydrated, the two formulations 
exhibited the same CBZ release rates. 
With an increased HPMC (200 mg) content in the tablets, it was observed that the release rate of 
CBZ from various formulations was reduced. The CBZ release profiles of CBZ-NIC cocrystals, 
CBZ III and a physical mixture in the 200 mg HPMC matrix tablets were controlled mainly by the 
matrix bulk erosion, indicating that the kinetics of the CBZ release rate were of zero order. 
Although the XRPD diffraction patterns of the gels of the CBZ-NIC cocrystal formulation indicate 
the crystallisation of CBZ DH crystals, the CBZ release is less influenced by the change of the 
crystalline properties of CBZ-NIC cocrystals. When a matrix tablet is immersed in the dissolution 
medium, wetting occurs at the surface and then progresses into the matrix to form an entangled 
three-dimensional gel structure in HPMC. Molecules undergoing chain entanglement are 
characterized by strong viscosity dependence on concentration. An increase in the HPMC 




the CBZ-NIC cocrystals. Dissolution of most of CBZ-NIC cocrystals can occur only at the outer 
surface of the matrix when HPMC undergoes a process of disentanglement in order to be released 
from the matrix. A similar hydration process also occurred for the CBZ III and physical 
formulations in 200 mg HPMC matrices. The CBZ release from the CBZ-NIC cocrystal 
formulation is therefore much higher than those of the other two formulations.  
The matrices of the six formulations maintained their structural integrity after six hours of 
dissolution tests. CBZ III’s XRPD diffraction patterns produced by the formulations of CBZ III and 
a physical mixture of CBZ III and NIC revealed the defect of crystallinity, because CBZ IV 
appeared in the gel layers, indicating weaker and broader peaks compared with CBZ III powder. 
The broad peaks of CBZ dihydrate obtained from the gel of CBZ-NIC cocrystal formulations 
compared with those of pure CBZ DH indicated a change in the crystallinity of crystals with the 
formation of less ordered structures.   
5.5 Chapter conclusion 
The influence of HPMC on the phase transformation and release profiles of CBZ-NIC cocrystals in 
solution and in sustained release matrix tablets was investigated using DSC, XRPD, Raman 
spectroscopy and SEM. The results indicate that HPMC cannot inhibit the transformation of CBZ-
NIC cocrystals to CBZ DH in solution or in the gel layer of the matrix, by contrast with its ability to 
inhibit CBZ III phase transition to CBZ DH. Based on this conclusion, we propose a possible 
mechanism for HPMC’s inability to inhibit CBZ dihydrate during CBZ-NIC cocrystal dissolution: 
it is caused by the rate differences between CBZ-NIC cocrystal dissolution and formation of a 
CBZ-HPMC soluble complex in the solution. For CBZ III, alone or in a physical mixture of CBZ 
III and NIC, the rate of CBZ III dissolution was slower than the rate of formation of a CBZ-HPMC 
association in solution, involving a hydrogen bonding interaction at the site where water molecules 
attach CBZ. The supersaturation level of the soluble complex of CBZ-HPMC was exceeded first, 
causing the precipitation of CBZ IV crystals because HPMC had been docked on the surfaces of 
CBZ III crystals as heteronuclei to induce defects of crystallinity. Because of the significantly 
improved dissolution rate of CBZ-NIC cocrystals, the rate at which CBZ entered the solution was 
significantly faster than the rate of formation of the CBZ-HPMC soluble complex, leading to high 
supersaturation levels of CBZ and subsequently precipitation of CBZ DH. Therefore, the apparent 
solubility and dissolution rates of CBZ of CBZ-NIC cocrystals were constant at different 
concentrations of HPMC solutions. In a lower percentage of 100 mg HPMC matrixes, the CBZ 




affected significantly by the change of the crystalline properties of CBZ-NIC cocrystals. With an 
increased HPMC content in the tablets, dissolution of CBZ-NIC cocrystals can only occur at the 
outer surface of the matrix when HPMC undergoes a process of disentanglement, resulting in a 
significantly higher CBZ release rate in comparison with the other two formulations of CBZ III and 
a physical mixture. In conclusion, there can be no doubt that cocrystals offer great advantages with 
regard to the fine-tuning of physicochemical properties of drug compounds, and in particular to 
improved solubility and dissolution rates of poorly water-soluble drugs. However, the means by 
which to maintain drug supersaturation level after the cocrystals are dissolved is a different matter, 




Chapter 6 Effects of coformers on phase transformation and release 
profiles of CBZ-SAC and CBZ-CIN cocrystals in HPMC based matrix 
tablets 
6.1 Chapter overview 
This chapter investigates the effects of coformers on the phase transformation and release profiles 
of CBZ-SAC and CBZ-CIN cocrystals in both HPMC solution and sustained release matrix tablets. 
The polymorphic transitions of the CBZ-SAC and CBZ-CIN cocrystals and their crystalline 
properties were examined using DSC, XRPD and SEM. The release profiles of the CBZ-SAC and 
CBZ-CIN cocrystals in solution and sustained release matrix tablets were investigated using the 
dissolution method. 
6.2 Materials and methods 
6.2.1 Materials 
Anhydrous CBZ III, SAC, CIN, HPMC K4M, SLS, methanol, EtOAc and doubly-distilled water 
were used in this chapter. Details can be found in Chapter 3. 
6.2.2 Methods 
6.2.2.1 Formation of the CBZ-SAC and CBZ-CIN cocrystals 
CBZ-SAC and CBZ-CIN cocrystals were used in this chapter. The details of the formation method 
can be found in Chapter 3. 
6.2.2.2 Preparation of tablets 
The formulations of the matrix tablets are provided in Table 6.1. The details of the method can be 







Table 6.1 Matrix tablet composition (mg) 
Component   Formulation 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
CBZ III 200     200     
CBZ-SAC cocrystals  355     355    
equal molar mixture 
of CBZ III and SAC 
  355     355   
CBZ-CIN cocrystals    325     325  
equal molar mixture 
of CBZ III and CIN  
    325     325 
HPMC K4M 100 100 100 100 100 200 200 200 200 200 
6.2.2.3 Powder dissolution study  
The powder dissolution rates of CBZ-SAC and CBZ-CIN cocrystals and CBZ III were studied. The 
details of this method can be found in Chapter 3. The concentrations of HPMC solutions were 0, 0.5 
and 2 mg/ml. Each dissolution test was carried out in triplicate.     
6.2.2.4 Solubility analysis of CBZ-SAC cocrystal, CBZ-CIN cocrystal and CBZ III in HPMC 
solutions 
The equilibrium solubility of CBZ-SAC and CBZ-CIN cocrystals and of CBZ III in HPMC aqueous 
solutions was tested in this chapter. The details of this method can be found in Chapter 3. The 
medium used for the tests included 0, 0.5, 2 and 5 mg/ml HPMC aqueous solutions. 
6.2.2.5 Dissolution studies of formulated HPMC matrix tablets 
Dissolution studies of formulated HPMC tablets were studied. The details of this method can be 
found in Chapter 3. The medium used for the test was 1% SLS water. 
6.2.2.6 Physical properties characterisation techniques 
HPLC and statistical analysis were used to study the solubility, powder dissolution rates and 
dissolution behaviour of tablets. SEM, XRPD and DSC were used in this chapter for 





6.3.1 Phase transformation  
Fig.6.1 (a)-(b) shows the CBZ and coformer concentrations after the solubility tests of CBZ III, 
SAC and CIN and of CBZ-SAC and CBZ-CIN cocrystals at various concentrations of HPMC 
solutions at equilibrium after 24 hours. 
The solubility of CBZ III as shown in Fig.6.1 (a) increased significantly with increasing HPMC 
concentrations in solution as the result of the formation of the soluble complex CBZ-HPMC, 
reaching its maximum at 2 mg/ml HPMC in solution and then decreasing slightly because of the 
inhibition effect of HPMC on the phase transformation of CBZ DH, as discussed in Chapter 5 [157]. 
SAC’s solubility decreased slightly in different concentrations of HPMC solutions, as shown in 
Fig.6.1 (b), indicating that there was no complex formation between SAC and HPMC in solution. 
Similarly to SAC, there was no interaction between CIN and HPMC in solution because the 
solubility of CIN in water or in different concentrations of HPMC solutions was almost constant 
(p>0.05). 
For CBZ-SAC cocrystals, the concentration of CBZ was the same as that of CBZ III in water 
(p>0.05). It increased slightly (from 1.19 mM to 1.56 mM) with increasing HPMC concentration up 
to 2 mg/ml, after which point it remained constant as shown in Fig.6.1 (a). The SAC concentration 
of CBZ-SAC cocrystals decreased slightly in solution as HPMC concentrations rose, as shown in 
Fig.6.1 (b).  
For CBZ-CIN cocrystals, the concentration of CBZ in water was significantly lower than that of 
CBZ III alone. The CBZ concentrations of CBZ-CIN cocrystals in various concentrations of HPMC 
solutions remained constant (p>0.05), as shown in Fig.6.1 (a). The CIN concentration profile of 
CBZ-CIN cocrystals was similar to that of CBZ, as shown in Fig.6.1 (b). Fig.6.1 (c) shows the 
eutectic constant Keu of CBZ-SAC and CBZ-CIN cocrystals decreasing with an increase in HPMC 
concentrations in solution, indicating that HPMC can change the stability of the cocrystals in 










Fig.6.1 Concentration of solubility tests: (a) CBZ concentrations; (b) coformer concentrations; (c) Eutectic constant 
Keu as a function of HPMC concentration 
Solid residues retrieved from each of the solubility tests were analysed using DSC and SEM. The 




solid residuals retrieved from the solubility tests are shown in Fig.6.2 (b). CBZ DH crystals were 
found in the solid residues of HPMC solutions up to 1 mg/ml after the solubility test of CBZ III 
alone, but the dehydration peak decreased significantly with increased HPMC concentrations in 
solution, indicating a reduction in the percentage of CBZ DH in the solid residue due to HPMC’s 
inhibition effects. There was no CBZ DH in the solid residuals retrieved from the solubility tests of 
a higher HPMC solution of 2 mg/ml, indicating that HPMC can completely inhibit the 
transformation of CBZ to CBZ DH in solution during the dissolution of CBZ III.   
It is clear that CBZ DH crystals were found in the solid residues of CBZ-SAC cocrystal solubility 
tests at different HPMC concentration solutions. This can be explained by the existence of a clear 
dehydration process of CBZ DH with a sharp endothermic peak between 80 and 120°C in each 
DSC thermograph, indicating that HPMC cannot inhibit the crystallisation of CBZ DH from 
solution during the dissolution of CBZ-SAC cocrystals. It also shows that the solid residues left by 
the solubility tests of CBZ-SAC cocrystals in various dissolution medium were a mixture of CBZ 
DH and CBZ-SAC cocrystals: the peak melting point of CBZ-SAC cocrystals occurred between 
174C and 177C, as shown in the DSC thermographs in Fig.6.2 (b). It seems that there was no 
significant change in the percentage of CBZ DH in the solid residues, indicating that HPMC has no 
significant effect on the transformation of CBZ to CBZ DH in solution during dissolution of CBZ-
SAC cocrystals.  
The DSC thermographs for the solid residuals retrieved from the solubility tests of CBZ-CIN 
cocrystals (Fig.6.3 (b)) show a single peak between 143C and 150C, corresponding to the melting 
point of CBZ-CIN cocrystals, as shown in Fig.6.2 (a). This illustrates that there was no change of 
the solid form of CBZ-CIN cocrystals after the solubility tests. There was a small change in the 
DSC thermographs of the solid residuals retrieved from the CBZ-CIN cocrystal solubility tests at 
around 75C, which the authors believe resulted from the evaporation of free water in the solid 
residues. HPMC in solution therefore had no effect on the solid form change of CBZ-CIN 
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Fig.6.2 DSC thermographs: (a) original samples; (b) solid residues of solubility test 
Fig.6.3 shows the SEM photographs of the solid residuals. In water, CBZ III has completely 
transformed into needle-like CBZ DH crystals. A large amount of CBZ DH crystals were found in 
the solid residuals after the tests of CBZ-SAC cocrystals in water. Needle-like CBZ DH crystals 
were clearly observed in the solid residues of the CBZ-SAC cocrystal solubility tests in different 
concentrations of HPMC solutions, but the amount of CBZ DH was significantly reduced. Some 
CBZ-SAC cocrystals can clearly be seen in the solid residuals after solubility tests, indicating that 
HPMC can partly inhibit the transformation of CBZ-SAC cocrystals into CBZ DH. CBZ-CIN 
cocrystals did not change their form after the solubility tests. 
The XRPD results shown in Fig.S6.1 in the Appendices also support the above analysis. 
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Fig.6.3 SEM photographs of solid residues of soubility tests at different HPMC concentration solutions 
6.3.2 Powder dissolution study 
Fig.6.4 (a)-(c) show the results of the powder dissolution studies of CBZ III alone and of CBZ-SAC 
and CBZ-CIN cocrystals in various dissolution medium including water and 0.5 mg/ml and 2 
mg/ml HPMC solutions. It was observed that the CBZ release profile of CBZ III alone was 
significantly affected by the concentration of HPMC in solution (p<0.05), as shown in Fig.6.4 (a). 
Increasing the HPMC concentration in the dissolution medium can reduce the amount of CBZ 
dissolved in solution from CBZ III powders. By contrast, the CBZ release profile of CBZ-CIN 
cocrystal was insensitive to HPMC in solution, remaining constant in different concentrations of 
HPMC solutions for up to 30 minutes (p>0.05). The effect of HPMC in solution on the CBZ release 
of CBZ-SAC cocrystals was complex: the CBZ release profile in a lower HPMC dissolution 
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medium of 0.5 mg/ml was higher than those in both in water and a higher HPMC concentration 
solution of 2 mg/ml. A nonlinear CBZ release rate was also observed, both for CBZ III in water and 
for cocrystals of CBZ-SAC and CBZ-CIN in various dissolution medium. This indicates that the 
solids changed their properties. However, in 0.5 mg/ml or 2 mg/ml HPMC dissolution medium, the 
CBZ release rate of CBZ III was nearly linear, as illustrated in Fig.6.4 (a) (The linear regression 
coefficients (R
2
) are 0.9762 and 0.9889 in 0.5 mg/ml and 2 mg/ml HPMC dissolution medium), 
indicating no change in the form of CBZ III solids.)  
CBZ-CIN cocrystals’ dissolution rate in various dissolution medium proved better (i.e. greater) than 
those for both CBZ III and CBZ-SAC cocrystals. In water, the amount of dissolved CBZ was 65% 
from CBZ-CIN cocrystal after 30 minutes, which was significantly higher than those of CBZ III 
(around 45%) and CBZ-SAC cocrystals (around 40%). CBZ-SAC cocrystals had the advantage 
over CBZ III in an improved dissolution rate in water for a very short period of around 15 minutes, 
after which the release percentage of CBZ from CBZ-SAC cocrystals was lower than that from 
CBZ III alone. In a 0.5 mg/ml HPMC solution, both CBZ-CIN and CBZ-SAC cocrystals showed 
similar dissolution profiles, which were significant higher than that of CBZ III. In the higher 2 
mg/ml HPMC solution, the dissolution rates of both CBZ III and CBZ-SAC cocrystals were lower 
than that of CBZ-CIN cocrystals, whose dissolution profile remained constant. Fig.6.4 (d) shows 
the change of the eutectic constant Keu of CBZ-SAC and CBZ-CIN cocrystals with various HPMC 












Fig.6.4 Comparison of powder dissolution profiles for various HPMC concentration solutions: (a) CBZ III release 




6.3.3 CBZ release from HPMC matrices 
Fig.6.5 (a) shows the CBZ release profiles of CBZ III, CBZ-SAC cocrystals, CBZ-CIN cocrystals 
and their physical mixtures from the 100 mg HPMC matrices. It was found that the physical 
mixture of CBZ III and SAC had the highest CBZ release rate. The rate of release of CBZ from the 
CBZ-CIN cocrystal formulation was significantly higher than that of their physical mixture of CBZ 
III and CIN (p<0.05). In the early stages of dissolution (up to 2 hours), the CBZ releases from both 
of the cocrystal formulations were similar (p>0.05). After that, the formulations of CBZ-SAC 
cocrystals and CBZ III exhibited similar CBZ release profiles, while the release rate for the CBZ-
CIN formulations was much lower.      
Fig.6.5 (b) shows that the CBZ release profiles of CBZ III, CBZ-SAC and CBZ-CIN cocrystals and 
their physical mixtures from the 200 mg HPMC matrices. It was observed that the CBZ release 
from the CBZ-CIN cocrystal formulation was much faster than those of the other four formulations. 
Interestingly, the CBZ release profiles of the three formulations of CBZ-SAC cocrystal and the 
physical mixtures of CBZ III and SAC, CBZ III and CIN were all similar (p>0.05), being lower 
than that of the CBZ III formulation. Fig.6.5 (c) illustrates the change of the eutectic constant Keu of 
CBZ-SAC and CBZ-CIN cocrystals in HPMC tablets during dissolution. It was found that the 
eutectic constant Keu of CBZ-SAC cocrystal tablets changed significantly during dissolution by 










Fig.6.5 Comparison of CBZ release profiles of CBZ III, physical mixtures and cocrystals in various percentages of 
HPMC matrices: (a) 100mg HPMC matrix; (b) 200mg HPMC matrix; (c) Eutectic constant 
The solid residuals of various formulations after the dissolution tests were analysed using XRPD 
are shown in Fig.6.6; the DSC analysis is shown in Fig.S6.2 in the Appendices. It was observed that 
CBZ DH crystals were precipitated from the CBZ-SAC cocrystal formulation during dissolution. 
There was no solid phase change for the other formulations, including the physical mixtures of CBZ 








Fig.6.6 XRPD patterns of solid residues of various formulations after dissolution tests: (a) CBZ-SAC cocrystals and 





It is well documented that pharmaceutical cocrystals can improve the solubility of both ionisable 
and noionizable drug compounds, in particular that of BCS II APIs with low aqueous solubility. 
However, the supersaturated solution generated from the dissolution of cocrystals is unstable. This 
results in the crystallisation of a stable solid phase with less solubility, and subsequently the loss of 
the solubility advantage offered by cocrystals [158]. It is believed that the addition of the excipients 
of polymers and/or surfactants in a formulation could inhibit the crystallisation of the parent drug 
from solution by the formation of a soluble complex of the drug and polymer to maintain the drug’s 
supersaturation [61, 159-161].  Unfortunately, most studies have not demonstrated the effectiveness 
of the polymers and/or surfactants in inhibiting the phase transformation of cocrystals [61, 157, 
161].  A possible reason for this could be the “rate difference between cocrystal dissolution and 
formation of the soluble complex”, as revealed in our previous study [157]. In order for the 
inhibition function of a selected polymer in a formulation to be activated, the cocrystal dissolution 
rate must be lower than the rate of formation of the soluble complex of the parent drug and polymer 
in solution. The present authors expected this to be achieved through selection of a coformer with 
low water solubility to form relative stable CBZ cocrystals, in contrast to CBZ-NIC cocrystals in 
solution. 
SAC is soluble (its apparent solubility is 23.4 mM at 37C, as shown in Fig.6.1 (b)), whereas CBZ 
is only a slightly soluble drug (its apparent solubility is 1.1 mM at 37C, as shown in Fig.6.1(a)). 
According to the theory of cocrystal solubility based on the transition concentration measurements 
of the parent drug and coformer [162], the solubility of CBZ-SAC cocrystals in water at 37C as 
calculated in the present study is 3.34 Mm, i.e. around 3.2 times the apparent solubility of CBZ III 
at equilibrium. This agrees well with the previous published data of 2.6 times. Because of CBZ-
SAC cocrystals’ improved solubility, CBZ-SAC cocrystals are thermodynamically unstable in 
various HPMC concentration solutions, and CBZ DH crystals have therefore crystallized from 
solution as shown in the DSC thermographs of the solid residues in Fig.6.2 (b). The effect of the 
various HPMC concentrations in solution on the stability of CBZ-SAC cocrystals in solution is 
indicated by the cocrystal eutectic constant Keu, which can be determined from the ratio of the 
concentrations of the coformer and drug at the eutectic point [163]. Fig.6.1 (c) shows the change of 
the eutectic constant Keu of CBZ-SAC cocrystals with the HPMC concentration in solution. Keu 
decreased with increasing HPMC concentration as a result of the reduced solubility difference 




cocrystals. However, the values of Keu at various concentrations of HPMC solution are well above 
the critical value of 1, so the conversion of CBZ-SAC cocrystals into CBZ DH duly occurs.  
CIN is slightly soluble, and its apparent solubility is 5 mM at 37C as shown in Fig.6.1 (b). By 
contrast to CBZ-SAC cocrystals, the solubility of CBZ-CIN cocrystals in water is 0.73 mM at 37C 
(around two-thirds of the apparent solubility of CBZ III at equilibrium as observed in this study). 
CBZ-CIN cocrystals are therefore thermodynamically stable in various HPMC concentration 
solutions, and no conversion of CBZ-CIN cocrystals occurrs, as confirmed by the sole feature of 
CBZ-CIN cocrystals in the DSC thermographs of the solid residues in Fig.6.2 (b). CBZ-CIN 
cocrystals’ eutectic constant Keu decreases slightly when HPMC is added in solution from 1.6 in 
water to 0.7 at various concentrations of HPMC, as shown in Fig.6.1 (c), confirming that HPMC 
can also slightly increase the stability of CBZ-CIN cocrystals in solution.  
Cocrystals’ dissolution behaviour is crucial for the prediction of absorption and efficient 
formulations, and in particular for those insoluble or lightly soluble BCS II drugs whose absorption 
is limited by the dissolution rate. Cocrystal dissolution involves many complex processes occurring 
simultaneously, such as the breakdown of the crystal lattice, the dissociation of the cocrystal into its 
individual components and the solvation and/or crystallisation of the individual components. The 
cocrystal dissolution rate is the result of a combination of the properties of the cocrystal itself, 
formulation including excipients and manufacturing conditions, and dissolution test conditions 
including dissolution medium, apparatus and hydrodynamics.  
The powder dissolution tests shown in Fig.6.4 can be regarded as composed of two consecutive 
stages: the cocrystal molecules are liberated from the solid phase (a process needed to break down 
the crystal lattice) and the drug molecules in the form of the pure parent drug or a complex (drug-
coformer or drug-additive) migrate through the boundary layers surrounding the solid crystals to the 
bulk of the solution. Whether the API crystallizes into its less soluble and most stable solid form 
depends on the gap between supersaturation and the apparent solubility of the drug. Although CBZ-
CIN cocrystals’ dissolution rate is significantly better than that of the parent drug, its solubility is 
lower than that of CBZ III. No supersaturation of CBZ in solution is therefore generated during the 
dissolution of CBZ-CIN cocrystals. The eutectic constant Keu of CBZ-CIN cocrystals in water is 
around 0.8, supporting the proposition that there is no precipitation of CBZ DH during the 
dissolution of CBZ-CIN cocrystals. CBZ-SAC cocrystal solubility is greater than that of the parent 
drug CBZ III. When it dissolves, unstable CBZ-SAC cocrystals can be dissociated into the two 




of seconds [61, 158], and results in the local supersaturation of CBZ in solution for the 
crystallization of CBZ DH. The eutectic constant Keu of CBZ-SAC cocrystal in water was observed 
as being around 1.5. It is interesting to note that the more soluble CBZ-SAC cocrystals do not 
exhibit a faster dissolution rate than less soluble CBZ-CIN ones as dissolution commences. This 
indicates that the initial rate of dissolution is not related to the stability of the cocrystals in solution.  
HPMC can inhibit the transformation of CBZ III to its dihydrate form CBZ DH in solution [149, 
157]. Fig.6.1 (a) shows the increased solubility of CBZ in solution. However, when HPMC is added 
to the dissolution medium, it slows down the dissolution of CBZ III, as shown in Fig.6.4, because 
the increased viscosity of a dissolution medium can suppress the dissolution of the crystals and slow 
the migration of the dissolved solute molecules to the bulk of the solution.  
The eutectic constants Keu of CBZ-SAC cocrystals at both 0.5 mg/ml and 2 mg/ml HPMC solutions 
are close to 1, as shown in Fig.6.4 (d), indicating that HPMC can solubilize CBZ in solution 
because of the formation of CBZ-HPMC complex. However, the selection of an appropriate 
concentration of HPMC in solution is essential to realise the improved dissolution rate of CBZ-SAC 
cocrystals by balancing the formation rate of the soluble complex of CBZ-HPMC in solution and 
the reduced cocrystal dissolution rate due to the increased viscosity of the dissolution medium. It 
was observed that the CBZ-SAC cocrystals’ dissolution rate in 0.5 mg/ml HPMC solution is higher 
than that in a 2 mg/ml HPMC solution. 
There is no significant change in the dissolution rate of CBZ-CIN cocrystals in various 
concentrations of HPMC solution due to the stability of the CBZ-CIN complex in solution, as 
shown by the eutectic constant Keu in Fig.6.4 (d). This indicates its potential as a lead cocrystal for 
further product development.   
In the 100 mg HPMC matrix, there was a delay in CBZ release from the CBZ III formulation 
because of HPMC’s hydration and gel layer formation process. The release of CBZ from the matrix 
was subsequently constant because of the inhibition of CBZ DH during the dissolution of CBZ III 
[157]. For the formulation of the physical mixture of CBZ III and SAC, the latter can be regarded as 
a channel agent to speed up the matrix’s wetting process, resulting in a higher CBZ release rate 
compared with CBZ III alone in the formulation. The slow dissolution of CIN in the formulation of 
the physical mixture of CBZ and CIN can result in the slowing of the HPMC matrix’s hydration and 
a reduction in CBZ III’s wetting surface areas. The formulation of the physical mixture of CBZ and 




both the CBZ-SAC and CBZ-CIN cocrystal formulations showed a higher CBZ release rate at the 
early stages of dissolution than that of the CBZ III formulation. As dissolution commenced, the 
CBZ was released from the surface of the matrix tablet, where the dissolution rate of CBZ-SAC 
cocrystals was higher than the formation rate of the soluble complex CBZ-HPMC because of a 
slower process of HPMC dissolution, resulting in the crystallisation of CBZ DH as shown in Fig.6.5 
(b), and a higher value for the eutectic constant Keu of CBZ-SAC cocrystals, as shown in Fig.6.5 (c). 
After the CBZ-SAC cocrystals were completely dissolved from the surface of the tablet, the 
dissolution medium had to diffuse into the matrix in order to dissolve the non-hydrated core. It can 
be seen that the soluble complex CBZ-HPMC was formed, as indicated by a reduced eutectic 
constant Keu of CBZ-SAC cocrystals as dissolution proceeded, as shown in Fig.6.5 (c). In the 
meantime, a higher concentration of HPMC inside the matrix (which can reduce the CBZ-SAC 
cocrystal dissolution rate) resulted in similar release rates for the CBZ-SAC cocrystals and the CBZ 
III formulation after three hours. 
CBZ-CIN cocrystals are stable in solution during dissolution of the CBZ-CIN cocrystal formulation, 
as shown by the eutectic constant Keu in Fig.6.5 (c). Inside the matrix, the dissolved CBZ-CIN 
complex had to travel to the surface for release. This process is controlled by diffusion, and the 
driving force is proportional to the solubility of CBZ-CIN cocrystals. After two hours the CBZ-CIN 
cocrystal formulation had a lower CBZ release rate compared with the CBZ III formulation due to 
its lower apparent solubility.  
In the higher-percentage 200 mg HPMC matrices, the rate of CBZ release from the formulations 
depended mainly on the erosion of the HPMC from the hydrated matrix, which can only take place 
at the outer surface of the tablets. Similarly to those of powder dissolution tests, the rate of CBZ 
release from CBZ-CIN was significantly higher than those of the other formulations. Increased 
viscosity in a higher HPMC percentage in the formulation can result in lower SAC dissolution rates, 
which cannot be treated as a channel agent to increase the hydration process of the matrix. The 
formulations of the physical mixtures of CBZ and SAC and of CBZ and CIN therefore exhibited a 
similar CBZ release profile. Furthermore, SAC and CIN can reduce the surface area of CBZ III with 
the dissolution medium, resulting in a lower release rate than the CBZ III formulation. CBZ-SAC 





6.5 Chapter conclusion 
The influence of HPMC on the phase transformation and release profiles of CBZ-SAC and CBZ-
CIN cocrystals in solution and in sustained release matrix tablets have been investigated. The 
authors have found that the selection of coformers of SAC and CIN affects the stability of the 
cocrystals in solution, resulting in significant differences in the apparent solubility of CBZ in 
solution. The dissolution advantage of CBZ-SAC cocrystals is only evident for a short period 
during dissolution because of its rapid conversion to its dihydrate form. HPMC can partly inhibit 
the crystallisation of CBZ DH during the dissolution of CBZ-SAC cocrystals, but it does not 
display an increased CBZ release rate from the cocrystal formulations at different percentages of 
HPMC because the increased viscosity can result in a reduction in CBZ-SAC cocrystal dissolution. 
By contrast, their stability means that CBZ-CIN cocrystals’ potential for improved dissolution rates 
can be realised in both solution and formulation. In conclusion, exploring and understanding the 
mechanisms of the phase transformation of pharmaceutical cocrystals in aqueous medium in order 





Chapter 7 Role of polymers in solution and tablet based 
carbamazepine cocrystal formulations 
7.1 Chapter overview 
In this chapter, the effects of three chemically diverse polymers on the phase transformations 
and release profiles of three CBZ cocrystals with significantly different solubility and 
dissolution rates, including CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals [114, 146, 161, 
164, 165], are evaluated. Three chemically diverse polymers (HPMCAS, PVP and PEG) were 
selected because they are widely used as precipitation inhibitors in other supersaturating drug 
delivery systems [166-168]. In order to evaluate the effectiveness of these polymers in 
inhibiting the phase transformation of cocrystals, the study has been carried out with 
polymers in both pre-dissolved solution and tablet formulations. Two types of dissolution 
testing experiment were therefore conducted: 1) cocrystal powder dissolution tests in the 
dissolution medium of pH 6.8 PBS in the absence and presence of pre-dissolved polymers to 
identify the mechanism by which drug precipitation is inhibited, and 2) dissolution tests for 
tablets consisting of a mixture of cocrystals (or physical mixtures of drug and coformers) and 
polymers in order to assess the effects of polymer release kinetics on the cocrystal release 
profiles. Both powder and tablet dissolution tests were carried out under sink conditions with 
the aim of identifying the rate of difference between cocrystal dissolution and interaction 
between the drug and the polymer in solution [164]. In the meantime, the equilibrium 
solubility of the CBZ cocrystals and the parent drug CBZ III in pH 6.8 PBS in both the 
absence and the presence of different concentrations of the selected polymers was measured 
so as to evaluate the polymer solubilization effects in solution formulations. By comparing 
the behaviour of cocrystals with that of physical mixtures or the pure parent drug, it was 
expected that the role of polymers in solution and tablet based cocrystal formulations would 
be elucidated. 
7.2 Materials and methods 
7.2.1 Materials 
Anhydrous CBZ III, NIC, SAC, CIN, EtOAc, methanol, SLS, HPMCAS, PVP, PEG, 
potassium dihydrogen phosphate (KH2PO4) and sodium hydroxide (NaOH) were used in this 





7.2.2.1 Formation of the CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals 
CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals were used in this chapter. The details of the 
formation methods can be found in Chapter 3. 
7.2.2.2 Preparation of pH 6.8 PBS 
The dissolution medium used for solubility and dissolution tests was pH 6.8 PBS, which was 
prepared according to British Pharmacopeia 2010. Details of this preparation can be found in 
Chapter 3. 
7.2.2.3 Preparation of tablets 
The formulations of the matrix tablets are provided in Table 7.1. The details of this method 
can be found in Chapter 3. 
7.2.2.4 Powder dissolution study 
The powder dissolution rates of CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals and CBZ III 
were studied in this chapter. The details of this method can be found in Chapter 3. The two 
dissolution medium used for the tests were pH 6.8 PBS and pH 6.8 PBS, with a pre-dissolved 
2 mg/ml polymer of HPMCAS, PVP or PEG.  
7.2.2.5 Solubility analysis of CBZ III, CBZ cocrystals and physical mixtures in pH 6.8 
PBS with a pre-dissolved polymer of HPMCAS, PVP or PEG 
The equilibrium solubility of the three cocrystals CBZ-NIC, CBZ-SAC and CBZ-CIN and 
their mixtures, CBZ III in pH 6.8 PBS or with a pre-dissolved polymer of HPMCAS, PVP or 
PEG were tested in this chapter. The details of this method can be found in Chapter 3. The 
concentrations of a pre-dissolved polymer of HPMCAS, PVP or PEG in pH 6.8 PBS were 0.5, 






Table 7.1 Matrix tablet composition (mg) 
Component   Formulation     
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
CBZ III 200       200       
CBZ-NIC 
cocrystal  




  304       304     
CBZ-SAC 
cocrystal 




    355       355   
CBZ-CIN 
cocrystal 
     325       325  
equal molar 
mixture of 
CBZ III-CIN  




100 100 100 100 100 100 100 200 200 200 200 200 200 200 
7.2.2.6 Dissolution studies of formulated HPMCAS, PEG and PVP tablets 
The dissolution studies of CBZ-NIC, CBZ-SAC and CBZ-CIN cocrystals, their physical 
mixtures of CBZ III and coformers and CBZ III in 100 mg and 200 mg HPMCAS, PVP or 
PEG tablets were investigated in this study. Details can be found in Chapter 3. The 
dissolution medium was 700 ml, 1% (w/v) SLS pH 6.8 PBS. 
7.2.2.7 Physical property characterisation techniques 
HPLC and statistical analysis were used to study the solubility, powder dissolution rates and 
dissolution behaviours of the tablets. SEM, XRPD and DSC were used in this chapter for 





7.3.1 Solubility studies 
Fig.7.1 (a)-(d) shows the CBZ concentrations after the solubility tests of CBZ III and cocrystals of 
CBZ-NIC, CBZ-SAC, and CBZ-CIN in both the absence and the presence of the different 
concentrations of a pre-dissolved polymer of HPMCAS, PVP or PEG in pH 6.8 PBS at equilibrium 
after 24 hours.  
 
(a)                                                                              (b) 
 
                                                   (c)                                                                               (d) 
 






Fig.7.1 CBZ concentrations in the absence and presence of the different concentrations of pre-dissolved polymers in pH 
6.8 PBS at equilibrium after 24 hours: (a)  CBZ III; (b) CBZ-NIC cocrystal; (c) CBZ-SAC cocrystal;  (d) CBZ-CIN 
cocrystal; (e) eutectic constant for CBZ-NIC cocrystal; (f) eutectic constant for CBZ-SAC cocrystal; (g) eutectic 
constant for CBZ-CIN cocrystal 
The findings demonstrate that the three polymers HPMCAS, PVP and PEG can all enhance the 
solubility of CBZ III, as shown in Fig.7.1 (a). The equilibrium concentration of CBZ in solution 
increases with the increase in polymer concentration, its maximum at 1mg/ml for all three polymers, 
after which point it remained constant. The polymers’ solubility enhancement was limited to a 1.5-
fold increase for HPMCAS and PEG and a slightly higher increase of 1.6-fold for PVP. This 
enhancement of solubility is due to formation of the soluble complex through hydrogen bonding 
between CBZ and the polymers. However, these polymers show significantly different precipitation 
inhibition abilities. HPMCAS can completely inhibit the transformation of CBZ III into CBZ DH, 
whereas PVP and PEG can only partially inhibit such transformation. This is confirmed by DSC 
thermographs of the solid residues retrieved from the solubility tests. 
Fig.7.2 shows the comparison of DSC thermographs of original samples and the solid residues 
obtained from the solubility tests in the absence and the presence of a 2 mg/ml polymer in pH 6.8 
PBS. In pH 6.8 PBS without a polymer, the solid residues of the CBZ III test consisted of CBZ DH 
crystals, showing that the dehydration process occurred between 80 to 120C under DSC heating. 
After dehydration, CBZ DH converted back to CBZ III, which melted around 175C and then 
recrystallized in the more stable form of CBZ I, which melted at around 196C [164]. In the 
presence of 2 mg/ml PVP or PEG in pH 6.8 PBS, CBZ DH crystals were found in the solid residues 
of the CBZ III test, showing a DSC thermograph similar to that of solid residues in pH 6.8 PBS in 
the absence of a polymer. However, the dehydration peak of the test’s DSC thermograph in the 




polymer, indicating that the solid residues comprised a mixture of CBZ DH and CBZ III. PVP or 
PEG can therefore partially inhibit the transformation of CBZ III into CBZ DH. In the presence of 2 
mg/ml HPMCAS in pH 6.8 PBS, the DSC thermograph of the solid residues was the same as that of 
CBZ III, the material used at the start, due to the HPMCAS inhibition effect. In a similar fashion to 
HPMC, the hydroxyl groups of HPMCAS can attach to CBZ at the site of water binding to form 
stable CBZ-HPMCAS complexes, result in an inhibition of CBZ transformation to the dihydrate 
form CBZ DH [164, 165]. 
SEM photographs of solid residues obtained from the tests in Fig.7.3 further support these analyses. 
The original CBZ III samples appeared to be irregular. They were mixtures of prismatic- and rock-
shaped particles, and they became CBZ DH crystals after the test in the absence of a polymer 
showing a needle-like shape. The solid residues in the presence of 2 mg/ml HPMCAS in pH 6.8 
PBS had a shape similar to that of the original CBZ III, indicating the absence of a phase 
transformation. The solid residues left when the test was conducted in the presence of 2 mg/ml PVP 
or PEG consisted of a mixture of needle-like (CBZ DH) and prismatic/rock (CBZ III) particles. 
Similar results can be found in the other solubility tests conducted in the presence of different 
concentrations of a polymer of HPMCAS, PVP or PEG, including 0.5 mg/ml, 1 mg/ml and 5 mg/ml 
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Fig.7.2 DSC thermographs of original samples and solid residues retrieved from solubility studies in the absence and presence of 2 mg/ml polymer in pH 6.8 PBS 
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Fig.7.3 SEM photographs of original samples and solid residues retrieved from solubility studies in the absence and the presence of 2 mg/ml polymer in pH 6.8 PBS 
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For CBZ-NIC cocrystals, the apparent CBZ concentration was the same as that of CBZ III in pH 
6.8 PBS in the absence of a polymer. This concentration rose slightly with an increase in the 
concentration of HPMCAS up to 1 mg/ml in pH 6.8 PBS, subsequently remaining constant. A pre-
dissolved polymer of PVP or PEG in pH 6.8 PBS at any of the concentrations tested did not affect 
the apparent CBZ concentration of CBZ-NIC cocrystals, which was the same as the solubility of 
CBZ III in pH 6.8 PBS in the absence of a polymer, although the apparent CBZ concentration fell 
slightly in a low polymer concentration as shown in Fig.7.1 (b). The DSC thermographs and SEM 
photographs of solid residues after the solubility tests were conducted are shown in Fig.7.2 and 
Fig.7.3. Figs S7.1 and S7.2 show the results of the other polymer concentrations in the 
supplementary materials. It was evident that the original CBZ-NIC cocrystals were completely 
transformed into needle-like CBZ DH crystals, indicating that none of the polymers HPMCAS, 
PVP and PEG can inhibit the crystallisation of CBZ DH from solution. This is similar to the case of 
the polymer HPMC. The solubility test of the physical mixture of CBZ III-NIC demonstrates that 
NIC does not affect the apparent solubility of CBZ III in the either the absence or the presence of a 
polymer in pH 6.8 PBS, as shown in Fig.S7.3 in the supplementary material. Pre-dissolved 
HPMCAS in pH 6.8 PBS can inhibit the transformation of CBZ into CBZ DH for the physical 
mixture of CBZ III-NIC, as confirmed by the DSC thermographs and SEM photographs in Figs.7.2 
and 7.3 (Figs.S7.1 and S7.2 in the supplementary material show the results for the other polymer 
concentrations).  
The apparent CBZ concentration of CBZ-SAC cocrystals (about 0.35 mg/ml) in pH 6.8 PBS in the 
absence of a polymer was 1.4 times that of CBZ III (0.25 mg/ml), indicating the enhanced solubility 
advantage of the cocrystal. The SEM photograph of the solid residues after the test in Fig.7.3 shows 
that some of the CBZ-SAC cocrystals had transformed into needle-like CBZ DH crystals. When 
HPMCAS was pre-dissolved in pH 6.8 PBS, the apparent CBZ solubility of CBZ-SAC cocrystals 
increased significantly, reaching their maximum 0.74 mg/ml at 2 mg/ml of HPMCAS concentration. 
This was 2.1 times the solubility of CBZ III in the same polymer solution and three times the 
solubility of CBZ III in pH 6.8 PBS in the absence of HPMCAS. Although the CBZ DH crystals 
were found in the solid residues of the tests shown in the DSC thermographs in Fig.7.2 (other 
results are given in Fig.S7.1 in the supplementary material), their percentage was significantly 
lower than those for the absence of HPMCAS in pH 6.8 PBS, as shown in the SEM photographs in 
Fig.7.3 (other results are given in Fig.S7.2 in the supplementary material), indicating that HPMCAS 
can partially inhibit the precipitation of CBZ from solution. Pre-dissolved PVP in pH 6.8 PBS did 




concentration remains constant irrespective of the concentration of PVP, as shown in Fig.7.1. 
However, the solid residues consisted of a mixture of CBZ-SAC cocrystals and CBZ DH crystals, 
as confirmed by the DSC analysis in Fig.7.2 (other results are given in Fig.S7.1 in the 
supplementary material) and the SEM photographs in Fig.7.3 (other results are given in Fig.S7.2 in 
the supplementary material). This indicates that the pre-dissolved PVP can partially inhibit the 
crystallisation of CBZ DH, but less effectively than HPMCAS. Pre-dissolved PEG in pH 6.8 PBS 
slightly lowered the apparent CBZ concentration of CBZ-SAC cocrystals by comparison with that 
of CBZ-SAC cocrystals in the absence of the polymer, demonstrating that PEG enhances the 
precipitation of CBZ DH from solution. This is confirmed by the SEM photographs in Fig.7.3 
(other results are given in Fig.S7.2 in the supplementary material), in which a large amount of 
needle-like CBZ DH crystals was found in the solid residues after the tests. The solubility of SAC 
in pH 6.8 PBS decreased slightly when a polymer of HPMCAS, PVP or PEG was pre-dissolved in 
solution as shown in Fig.S7.3 (a) in the supplementary material. In the absence of a polymer in pH 
6.8 PBS, the CBZ concentration of the physical mixture of CBZ III-SAC was the same as that of 
CBZ-SAC cocrystals and higher than that of CBZ III, indicating that SAC can enhance the 
solubility of CBZ III. The CBZ concentration of physical mixture of CBZ III-SAC decreased in the 
presence of HPMCAS in solution,, as shown in Fig.S7.3 (b) in the supplementary material. By 
contrast, the apparent CBZ concentration of the physical mixture of CBZ III-SAC in the presence of 
a polymer of PVP or PEG in solution was similar to that of CBZ III in the same condition, as shown 
in Fig.S7.3 (b) in the supplementary material. 
Fig.7.1 (d) shows the apparent CBZ concentration of CBZ-CIN cocrystals in both the absence and 
the presence of a polymer in solution. The apparent CBZ concentration of CBZ-CIN cocrystals in 
pH 6.8 PBS was same as that of CBZ III. When HPMCAS was pre-dissolved in the solution, the 
apparent CBZ concentration of CBZ-CIN cocrystals increased significantly. At a concentration of 2 
mg/ml of HPMCAS, the solubility of CBZ-CIN cocrystals can rise to 2.7 times that of CBZ III in 
pH 6.8 PBS, which is slightly lower than that of CBZ-SAC cocrystals in the same condition. In the 
presence of PVP in pH 6.8 PBS, it is evident that PVP has a profound effect on the apparent CBZ 
concentration of CBZ-CIN cocrystals. At a lower concentration of 0.5 mg/ml PVP, the apparent 
CBZ concentration of CBZ-CIN cocrystals was significantly lower than that of CBZ III, while at a 
higher PVP concentration (2 mg/ml or 5 mg/ml) the CBZ concentration of CBZ-CIN cocrystals 
increased to the same level of solubility as CBZ III. PEG pre-dissolved in solution did not 
significantly affect the apparent CBZ concentration of CBZ-CIN cocrystals, displaying a nearly 




cocrystals in pH 6.8 PBS in the absence and presence of a polymer of HPMCAS, PVP, or PEG 
consisted of physical mixtures of CBZ DH and CBZ-CIN cocrystals, as confirmed by DSC analysis 
in Fig.7.2 and SEM photographs in Fig.7.3. The CBZ concentration of the physical mixture of CBZ 
III-CIN was constant in both the absence and the presence of a polymer in pH 6.8 PBS, as shown in 
Fig.S7.3 in the supplementary material, which was lower than CBZ III or CBZ-CIN cocrystals. 
However, the components of the solid residuals from the tests were different. In the absence of a 
polymer, these residuals contained mixtures of CBZ DH, CIN and CBZ-CIN cocrystals. In the 
presence of HPMCAS in solution, the solid residuals were CBZ III, indicating that HPMCAS 
completely inhibits the transformation of CBZ III to CBZ DH. By contrast, both CBZ DH and 
CBZ-CIN cocrystals were found in the solid residuals when in the presence of PVP or PEG in 
solution. DSC analysis in Fig.7.2 and SEM photographs in Fig.7.3 support these conclusions. 
Fig.7.1 (e)-(g) shows the ratios of CBZ and its corresponding coformer concentrations for the three 
CBZ cocrystals. This parameter is also called the cocrystal eutectic constant Keu, which can be used 
as an indicator of the stability of cocrystals in solution [61, 165]. Details will be given in the 
discussion section. 
7.3.2 Powder dissolution studies 
Fig.7.4 represents the effect of a pre-dissolved 2 mg/ml concentration of HPMCAS, PVP and PEG 
on the powder dissolution profiles of CBZ III and cocrystals of CBZ-NIC, CBZ-SAC and CBZ-
CIN. It was found that a pre-dissolved polymer did not improve the dissolution rate of CBZ III. 
Actually a pre-dissolved polymer of HPMCAS or PVP decreased CBZ III’s release rate, while the 
pre-dissolved PEG did not affect CBZ III’s dissolution rate. Although the final CBZ concentration 
of 0.1 mg/ml in solution was well below its solubility (0.25 mg/ml) in the experiments, a nonlinear 
release profile of CBZ III was observed, demonstrating that an increased concentration of CBZ in 
solution can decrease the release rate of the solids due to the reduced dissolution driving force. This 
reduction is most likely caused by the reduced diffusion coefficient of CBZ in solution due to the 
change of the bulk solution properties, in particular the increased viscosity of the solution with a 
pre-dissolved polymer.  
By contrast, all three pre-dissolved polymers in pH 6.8 PBS could increase the dissolution rates of 
the three CBZ cocrystals. PEG was least able to do so, while the performances of HPMCAS and 
PVP were similar to each other in this regard. Although the physicochemical properties of CBZ-




similar in the absence or the presence of a polymer of 2 mg/ml concentration in pH 6.8 PBS, both 
of those profiles being faster than those of CBZ-SAC cocrystals. In the meantime, all three 
cocrystals display a significant advantage in a better dissolution rate than that of CBZ III. In the 
presence of a 2 mg/ml HPMCAS in pH 6.8 PBS, the cocrystals of CBZ-NIC and CBZ-CIN can be 
approximately 80% dissolved within five minutes, compared to 10% of CBZ III over the same time.      
 
(a)                                                                             (b) 
 
                                                     (c)                                                                                 (d) 
Fig.7.4 Powder dissolution profiles in the absence and the presence of a 2 mg/ml pre-dissolved polymer in pH 6.8 PBS: 
(a) CBZ III; (b) CBZ-NIC cocrystal; (c) CBZ-SAC cocrystal; (d) CBZ-CIN cocrystal 
7.3.3 CBZ release profiles from HPMCAS, PVP and PEG based tablets 
Fig.7.5 presents the comparisons of CBZ release profiles from different polymer-based tablets. The 
performance of none of the cocrystal formulations was observed to be better than the CBZ III 
formulation.  
Depending on coformer, the dissolution profile of a physical mixture formulation can vary 
significantly. Generally, a physical mixture of a CBZ III-NIC formulation had a similar release 
performance to that of a CBZ III formulation. The dissolution performance of a physical mixture of 




III and CBZ-SAC cocrystals. For the PEG based tablets, the release profiles of the physical mixture 
of CBZ III-SAC were better than those of CBZ III-based formulations. The dissolution performance 
of a physical mixture of CBZ III-CIN varied by polymers. In HPMCAS or PVP based tablets, CIN 
reduced the release rate of CBZ III, indicating that the release profile of a physical mixture of CBZ 
III-CIN was lower than that of CBZ III alone. In a HPMCAS-based tablet, the physical mixture of 
CBZ III-CIN had a lower release profile than that of the cocrystal formulation for up to four hours. 
In a PVP based tablet, CBZ III-CIN’s physical mixture had a lower release profile than that of the 
cocrystal formulation over the whole dissolution period, while in a PEG-based tablet, the same 
mixture had a higher one. For any period of dissolution of up to three hours, the physical mixture of 
the CBZ III-CIN formulation shows a lower rate profile than that of CBZ III alone.  
The drug release profile is also affected by the percentage of a polymer in the tablet, a percentage 
that varies with different polymers. PEG’s effects on formulation performance differ from those of 
HPMCAS and PVP. Increasing the percentage of PEG in a formulation increased the drug’s 










Fig.7.5 CBZ release profiles of CBZ III and cocrystals of CBZ-NIC, CBZ-SAC and CBZ-CIN from 100 mg and 200 
mg polymer based tablets: (a) HPMC-based tablets; (b) PVP-based tablets; (c) PEG-based tablets 
The solid residuals of different formulations after the dissolution tests (if any reasonable amounts of 
the solids can be collected for testing) have been analysed by DSC in Fig.7.6, XRPD in Fig.7.7 and 
SEM in Fig.S7.4 in the supplementary material. It has been shown that all cocrystal formulations 
had solid residues left after six hours dissolution except the 100 mg PVP-based CBZ-SAC cocrystal 
formulation. The solid residues from these cocrystal formulations comprised a mixture of CBZ 
cocrystals and CBZ DH crystals, as confirmed by XRPD patterns in Fig.7.7 and DSC analyses in 
Fig.7.6. This indicated that the CBZ DH crystals were precipitated during dissolution. Tablets of the 
CBZ III formulations and the physical mixture of CBZ III-NIC had dissolved completely. The solid 
residues collected from the 200 mg HPMCAS-based physical mixture of CBZ III-SAC consisted of 
CBZ III, indicating that HPMCAS can completely inhibit the transformation of CBZ III into CBZ 
DH during tablet dissolution. For the HPMCAS-based physical mixture of CBZ III-CIN 
formulations, the solid residues consisted of a mixture of the original materials of CBZ III and CIN, 
as shown in XRPD patterns in Fig.7.7 and DSC analyses in Fig.7.6. However, for the PVP-based 
physical mixture of CBZ III-CIN formulation, the solid residuals comprised a the mixture of the 
three components of CBZ III, CIN and CBZ DH, indicating that PVP cannot inhibit the 
transformation of CBZ III into CBZ DH during tablet dissolution. No solid residual was collected 
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Fig.7.6 DSC thermographs of solid residues retrieved from various formulations after dissolution tests (X: no solid residues collected) 
 



















































note: solid residues are physical mixture of CBZ-NIC cocrystal and CBZ DH
CBZ DH
CBZ-NIC cocrystal in PVP 100mg
CBZ-NIC cocrystal in HPMCAS 200mg













Fig.7.7 XRPD patterns of solid residues of various formulation after dissolution tests: (a) CBZ-NIC cocrystal 
formulations (b) CBZ-SAC cocrystal and physical mixture formulations; (c) CBZ-CIN cocrystal and physical mixture 
formulations 
7.4 Discussion 
Theoretically, cocrystals can significantly improve the solubility of drug compounds with 
solubility-limited bioavailability through the selection of suitable coformers [162]. In reality, 
however, such solubility cannot be sustained in the supersaturated solution generated because of the 
solution-medted phase transformation, which results in the precipitation of a less soluble solid form 
of the parent drug. The drug precipitation process can occur simultaneously with the dissolution of 
the cocrystals, demonstrating that the apparent drug solubility of cocrystals has not been improved 
by comparison with that of the stable form of the parent drug. Further research on maintaining the 




Cocrystals in pre-dissolved polymer solutions 
In pH 6.8 PBS in the absence of a polymer, the solubility advantage of CBZ cocrystals was not in 
evidence: both CBZ-NIC and CBZ-CIN cocrystals generated the same apparent CBZ 
concentrations as that of the parent drug CBZ III while CBZ-SAC cocrystals generated a slightly 
higher value, as shown in Fig.7.1. This was due to crystallisation of CBZ DH from the 
supersaturated solution generated by the dissolution of CBZ cocrystals, as seen in the DSC and 
SEM analyses in Figs.7.2 and Fig.7.3. When HPMCAS with a concentration of 2 mg/ml or higher 
was pre-dissolved in solution, both CBZ-SAC and CBZ-CIN cocrystals could generate significantly 
higher CBZ supersaturated solutions with approximately three times the solubility of CBZ III. This 
supersaturated state had been maintained for more than 24 hours, so therefore it could certainly 
allow sufficient CBZ absorption for increasing bioavailability. Based on the powder dissolution 
studies, all three cocrystals showed at least a two-fold increase in drug release compared with that 
of CBZ III in pH 6.8 PBS in the absence of a polymer at five minutes. In the presence of 2 mg/ml 
HPMCAS in pH 6.8 PBS, the drug release of CBZ-NIC or CBZ-CIN cocrystals rose to around eight 
times of that of CBZ III in the same condition. These results are much better than those of previous 
work based on the solid dispersion approaches [170, 171]. The implication of these observations is 
therefore of significance because it demonstrates that cocrystals can be easily formulated through a 
simple solution or powder formulation to generate supersaturated concentrations and faster 
dissolution rates to overcome those drugs whose solubility and/or dissolution is limited. This 
conclusion is supported by a recent similar study of the development of an enabling danazol-
vanillin cocyrstal formulation, although this research used a relatively complicated approach 
involving both a surfactant and polymer in the formulation [169]. As regards the formulation of 
drug compounds whose solubility and/or dissolution is limited, the cocrystal approach should be 
considered just as seriously as many other successfully supersaturating drug delivery approaches 
such as solubilized formulations, solid dispersions, nanoparticles and crystalline salt forms and 
particle size reduction [166].  
In order to develop an enabling cocrystal formulation, a mechanistic understanding of the role of a 
polymer in inhibiting the phase transformation of cocrystals is required. This study and the authors’ 
previous work [164, 165] has found that the key factors in controlling the maintenance of the 
apparent parent drug supersaturating level of a cocrystal include the cocrystal stability in solution, 
the rate difference between the cocrystal dissolution/dissociation and formation of a soluble 
complex between the parent drug and polymer, and the stability of the complexes of the drug and 




cocrystals. It can be seen that when the cocrystal molecules are dissolved into solution, they are 
completely or partially dissociated into the parent drug and coformer molecules depending on the 
stability of the cocrystals in solution. If a pre-dissolved polymer in solution cannot form soluble 
complexes with the drug molecules, the solid crystals will certainly precipitate from solution due to 
its supersaturated states. On the other hand, although a pre-dissolved polymer can form soluble 
complexes with the API in solution, precipitation of the drug crystals can also occur if the rate of 
cocrystal dissolution and dissociation is faster than the rate at which the soluble complexes are 
formed. Finally, the stability of the soluble complex of the drug and polymer formed in solution is 
another factor by which to determine the precipitation of the drug’s solid forms from solution. Two 
approaches can therefore be used to completely inhibit the crystallisation of the stable solid form of 
the parent drug in a formulation:     
Scheme 1: Selecting cocrystals which are stable in solution. This can be achieved by selecting a 
suitable coformer. Because most cocrystals have faster dissolution rates, this scheme is particularly 
suitable for the formulation of drug compounds whose dissolution bioavailability is limited, 
although the apparent solubility of the parent drug has not been improved.   
Scheme 2: Balancing the rate difference between cocrystal dissolution and the formation of a 
soluble complex between drug and polymer in solution. This can be realised by selecting both a 
polymer and a coformer. Because a stable supersaturated drug concentration can be generated to 
enhance drug absorption, the scheme is a particularly suitable one by which to formulate drug 





Fig.7.8 Illustration of factors affecting the phase transformation of cocrystals 
It must be stressed that when a polymer is pre-dissolved in solution, both the dissolution rate of the 
solid cocrystals and the stability of the cocrystals in solution will be affected because of the change 
in the bulk properties of the dissolution medium and the solubility of both parent drug and coformer. 
The cocrystals in solution intend to be stable if the solubility difference between the drug and 
coformer in a pre-dissolved polymer solution becomes smaller, forming a congruent system.  
Based on the solubility tests of CBZ III in this study, it was found that all three polymers 
(HPMCAS, PVP and PEG) can interact with CBZ in solution to form soluble complexes through 
hydrogen bonding. This indicates the increased solubility of CBZ III in pH 6.8 PBS in the presence 
of a pre-dissolved polymer, as shown in Fig.7.1 (a). However, the stability of the formed soluble 
complexes is different. Due to the rigorous structure and rich hydrogen-bond acceptors of 




supersaturated CBZ solution can therefore be stabilized, indicating that HPMCAS can completely 
inhibit the precipitation of CBZ from solution, as shown in the DSC and SEM analyses of the solid 
residues of the tests in Fig.7.2 and Fig.7.3.  
The solubility tests in pH 6.8 PBS in the absence of a polymer show that all three CBZ cocrystals 
(CBZ-NIC, CBZ-SAC and CBZ-CIN) are not stable, indicating that the eutectic constants Keu in 
Fig.7.1 (e)-(g) are significantly higher than the critical value of 1 [61, 165]. When they are 
dissolved, therefore, the cocrystal molecules are dissociated into CBZ and coformers in solution, 
resulting in the crystallisation of CBZ DH crystals from solution. This is confirmed by the DSC and 
SEM analyses in Fig.7.2 and Fig.7.3. Because the value of the eutectic constant is smaller than 
CBZ-NIC and CBZ-CIN cocrysatls, CBZ-SAC cocrystals in solution are relatively more stable than 
them, resulting in a higher apparent CBZ concentration.  
A pre-dissolved polymer in pH 6.8 PBS can significantly improve the stability of CBZ-SAC and 
CBZ-CIN cocrystals because of the reduced solubility differences between CBZ and coformers 
(coformer solubility is shown in Fig.S7.3 (a) in the supplementary material), indicating decreases in 
the eutectic constants Keu, as shown in Fig.7.1 (f)-(g). HPMCAS is also the best polymer to stabilize 
CBZ-SAC or CBZ-CIN cocrystals in solution because of the smallest value of the eutectic constant 
Keu, pointing to the significant improvement of the supersaturating level of CBZ in solution shown 
in Fig. 7.1 (c)-(d). The values of Keu in different concentrations of HPMCAS solutions are, however,  
e is a small change of the eutectic constants Keu for CBZ-NIC cocrystals in the presence of 
HPMCAS, PVP or PEG in solution so that the apparent concentration of CBZ is almost constant, as 
shown in Fig.7.1 (b).   
All three CBZ cocrystals exhibit significantly improved dissolution rates compared with that of 
CBZ III, based on the powder dissolution tests in pH 6.8 PBS in both the absence and the presence 
of a polymer, as Fig.7.4 shows. Selection of a coformer is the key factor that affects cocrystal 
dissolution rate. Although there is a significant difference between NIC and CIN in term of 
solubility, it was found that both CBZ-NIC and CBZ-CIN cocrystals have similar dissolution rates, 
both of them higher than that of CBZ-SAC cocrystals. A pre-dissolved polymer in the dissolution 
medium of pH 6.8 PBS can further improve this dissolution rate. One reasonable explanation is that 
the presence of a polymer in solution can increase the solubility of the cocrystals, resulting in faster 
dissolution. In the meantime, because of the improved stability of cocrystals in solution in the 
presence of a pre-dissolved polymer, the dissolved cocrystal will be stable in solution to avoid 




value of 1 as shown in Fig.S7.5 in the supplementary material. Generally, the experiments show 
that HPMCAS is the best excipient to be included in solution to improve the dissolution rates as 
well as solubility of the cocrystals. In contract, the presence of HPMCAS or PVP in solution 
decreased the dissolution rate of CBZ III, which is the similar to our previous work on HPMC [165]. 
This could be caused by the slightly increased viscosity of the dissolution medium, resulting in a 
reduction in CBZ III’s molecular mobility. In the meantime, the polymers HPMCAS and PVP can 
also be adsorbed on the surfaces of CBZ III particles to hinder the latter’s dissolution. 
Cocrystals in polymer-based matrix tablets 
A polymer-based cocrystal tablet formulation has not demonstrated any advantage in increasing 
CBZ’s release rate by comparison with the formulation of CBZ III or physical mixtures of CBZ III 
and coformers, as shown in Fig.7.5. This is contrary to the solution behaviours of CBZ cocrystals 
studied in the solubility and powder dissolution tests. A tablet’s drug release performance is 
complex and highly dependent not only on each individual component’s properties (such as 
solubility, dissolution rate, particle size, and wettability) but also on manufacturing factors (e.g. 
compression forces, tablet shape and drug loads). These factors affect the kinetic processes of tablet 
dissolution, including the polymer dissolution kinetics, drug dissolution kinetics and kinetics of the 
physical form change of the tablet. Both this study and our previous work [164, 165] indicate that 
the polymer hydration process is the critical factor in determining cocrystal release performance.   
PEG as used in this study is highly soluble and exhibits good wettability. Their poor gelling ability 
meant that all PEG-based tablets eroded quickly and eventually disintegrated completely, thus 
leaving no solid residue after dissolution. PEG-based CBZ III tablets and physical mixtures of CBZ 
III and coformers exhibited complete drug release because of the sink conditions. The PEG-based 
cocrystal tablets had an incomplete release profile, which was believed to be caused by the 
precipitation of CBZ DH. Once the tablet was immersed into the dissolution medium, the PEG 
dissolved quickly to form channels that allowed water to penetrate the tablet. Because of the faster 
dissolution rate, dissolution of the cocrytstal started immediately inside the tablet before its erosion 
and disintegration, resulting in crystallisation of CBZ DH from the micro-environmentally 
supersaturated states.     
Similarly to PEG, PVP can dissolve quickly in water. However, PVP, which is a good gelling agent, 
can form a gel matrix to modify the drug release profile in an extended release formulation. Due to 




inside the tablet to dissolve the drug. The highly viscous environment inside the matrix prevented 
the dissolved drug from immediately diffusing into the bulk solution. When the drug concentration 
was built up to exceed its solubility, a stable, solid form of the drug crystallized. The three CBZ 
cocrystals used in this study had significantly improved dissolution rates compared with that of 
CBZ III, so the concentration of the cocrystals inside the tablets quickly exceeded their solubility. 
In the meantime, the formation of the soluble complexes between the drug and polymer was slower. 
PVP-based cocrystal formulation release is slower and incomplete compared with that of CBZ III or 
physical mixture formulations because of the crystallisation of CBZ DH inside the tablet, as shown 
in Fig.7.5 (b) and analyses of the DSC in Fig.7.6 and XRPD in Fig.7.7. The formulation of the 
physical mixture of CBZ III and CIN resulted in significantly slower release rates for CBZ. It is 
believed that poor solubility and a slow CIN dissolution rate retarded the hydration and dissolution 
of CBZ III.  
HPMCAS-based cocrystal formulations display improved release rates at the early stage of the 
tablet dissolution test, which is similar to the authors’ previous work on HPMC-based cocrystal 
formulations [164, 165]. This is caused by HPMCAS’ slower hydration property. At the beginning 
of the dissolution test, cocrystal dissolution can only take place at the surface of the tablet, and the 
dissolved cocrystal can therefore diffuse into the bulk of the dissolution medium directly so as to 
avoid the supersaturated states of the drug concentration. This is similar to the powder dissolution 
tests. Once the gel layer has formed, water can penetrate into the inside tablet to dissolve the 
cocrystals, resulting in crystallisation of CBZ DH inside the tablet.   
7.5 Chapter conclusion 
The influence of the three chemically diverse polymers (HPMCAS, PVP and PEG) on the phase 
transformation of the three CBZ cocrystals (CBZ-NIC, CBZ-SAC and CBZ-CIN) in solution and 
tablet-based formulations has been investigated. This study has shown that the improved CBZ 
solubility of the three CBZ cocrystals cannot be sustained in the supersaturated solution generated 
due to the solution mediated phase transformation, resulting in precipitation of a less soluble solid 
form of CBZ DH. When HPMCAS with a concentration of 2 mg/ml or higher was pre-dissolved in 
solution, both CBZ-SAC and CBZ-CIN cocrystals could generate significantly higher CBZ 
supersaturated solutions with an approximate three-fold increase in CBZ III’s solubility that can be 
sustained for more than 24 hours. All three cocrystals at least doubled the drug release compared 
with CBZ III in pH 6.8 PBS in the absence of a polymer at five minutes. In the presence of 2 mg/ml 




around eight times of that of CBZ III in the same condition. These results demonstrate that 
cocrystals can easily be formulated through a simple solution or powder formulation to generate 
supersaturated concentrations and faster dissolution rates to overcome those drugs whose solubility 
and/or dissolution bioavailability is limited. The cocrystal approach should therefore be taken just 
as seriously for formulating drug compounds with limited solubility and/or dissolution 
bioavailability as many other successfully supersaturating drug delivery approaches such as 
solubilized formulations, solid dispersions, nanoparticles and crystalline salt forms and particle size 
reduction. As regards improved CBZ release rates, however, a polymer tablet-based CBZ cocrystal 
formulation did not reveal any advantage compared with CBZ III formulations or physical mixtures 
of CBZ III and coformers. These findings contradict the solution behaviours of CBZ cocrystals 
studied in the solubility and powder dissolution tests because crystallization of the stable solid form 
of CBZ DH within the tablet has taken place, leading to a reduced drug release rate and incomplete 











Chapter 8 Quality by Design approach for developing an optimal 
CBZ-NIC cocrystal sustained-release formulation 
8.1 Chapter overview 
This chapter discusses the QbD principles and tools used to develop a CBZ-NIC cocrystal 
formulation that ensures the quality, safety and efficacy of CBZ sustained-release tablets. Self-made 
tablets are compared with the CBZ commercial tablet, the 200 mg Tegretol Prolonged Release 
Tablet. 
8.2 Materials and methods 
8.2.1 Materials 
CBZ, NIC, HPMC, HPMCP, EtOAc, methanol, SLS, potassium dihydrogen phosphate (KH2PO4) 
and sodium hydroxide (NaOH), double distilled water, microcrystalline (MCC), lactose, stearic acid, 
colloidal silicon dioxide and 200 mg CBZ Tegretol Prolonged Release Tablets, were used in the 
tests discussed in this chapter. Details of these materials can be found in Chapter 3. 
8.2.2 Methods 
8.2.2.1 Formation of CBZ-NIC cocrystal 
CBZ-NIC cocrystals were used for the tests described in this chapter. The details of the formation 
method can be found in Chapter 3. 
8.2.2.2 Tablet preparation 
Tablets were prepared, the details of which can be found in Chapter 3. The total weight of each 
tablet was 500 mg. All tablets contained the equivalent of 304 mg CBZ-NIC cocrystals (equal to 
200 mg CBZ III).  
8.2.2.3 Physical tests of tablets 
The tablets’ diameter, hardness, thickness and friability were tested. Details can be found in 





8.2.2.4 Dissolution studies of tablets  
The details of the dissolution studies on formulated tablets can be found in Chapter 3. The 
dissolution medium was 700 ml, 1% SLS pH 6.8 PBS. 
8.3 Preliminary experiments 
CBZ sustained-release oral tablets were formulated and tested in the early stages of development. 
The pharmaceutical target profile for CBZ is a safe efficacious convenient dosage form, preferably 
a tablet, which facilitates patient compliance. The tablet should be of appropriate size. The 
manufacturing process for the tablet should be robust and reproducible and should result in a 
product that meets the appropriate critical quality attributes. These pharmaceutical Quality Target 
Product Profiles (QTPPs) are summarized in Table 8.1. 
Table 8.1 Quality Target Product Profile 
Quality Attribute Target 
Dosage form Oral sustained-release Carbamazepine Tablet 
Potency 200 mg 
Identity Positive to Carbamazepine 
Appearance White round tablets 
Thickness 3-3.5 mm 
Diameter 12.5-13.0 mm 
Friability  Not more than 1% 
Release percentage 
 
15-30% at 0.5 hours 
40-60% at 2 hours 
not less than 75% at 6 hours 
 
Fig.8.1 shows the CBZ release profiles of CBZ-NIC cocrystals (304 mg) in 100mg MCC or 100 mg 
HPMCP tablets. The CBZ release percentages of CBZ-NIC cocrystals in 100 mg MCC tablets at 
0.5, 1, 2, 3, 4, 5 and 6 hours are 5.9, 9.8, 18.8, 24.7, 33.1, 38.4 and 45.0 respectively. The CBZ 
release percentages of CBZ-NIC cocrystals in 100 mg HPMCP tablets at 0.5, 1, 2, 3 and 4 hours are 
53.9, 74.6, 90.8, 95.0 and 96.4 respectively. The results indicate that CBZ releases more slowly 
from MCC tablets than from HPMCP ones. Therefore, HPMCP and MCC were both used in the 
preliminary experiments for CBZ sustained-release tablets in order to obtain reliable dissolution 






Fig.8.1 Dissolution profiles of CBZ-NIC cocrystal in 100 mg MCC and 100 mg HPMCP tablets 
Four pharmaceutical formulations of CBZ sustained-release tablets have initially been developed 
for preliminary studies. The formulations were evaluated for their physical properties and 
dissolution profiles.  HPMCP was used as a disintegrant, lactose as a dissolution enhancer, MCC as 
a filler, stearic acid as a lubricant and silica as a glidant. The drug release profiles of the four 
formulations were used to find the parameter ranges for the final design of experiments. Table 8.2 
shows the composition of the four preliminary formulations (the total weight of tablet is 500 mg). 
 
Table 8.2 Preliminary formulations in percentage and mass in milligrams 
Raw 
material  


























































The results of the thickness, hardness, diameter and friability tests on the four preliminary 
formulations are shown in Table 8.3. 
Table 8.3 Physical tests of preliminary formulations 








Friability %  
1 0.499±0.013 3.510±0.010 12.673±0.015 77.967±1.686 0.335 
2 0.500±0.006 3.510±0.010 12.690±0.010 92.233±0.352 0.306 
3 0.504±0.012 3.460± 0.030 12.670±0.020 114.600±1.442 0.398 
4 0.498±0.003 3.420±0.100 12.676±0.006 122.833±4.80 0.245 
 
Standard deviation of the four preliminary formulations diameter was less than 1, which is close to 
the actual die diameter used (13 mm). The average thickness of tablets with a standard deviation of 
0.01, 0.01, 0.03 and 0.10 separately, indicates good reproducibility. The hardness results showed 
higher standard deviation compared to the 
other measurements. This could be due to poor mixing and/or different particle size distribution of 
the excipients. 
The dissolution profiles of the four preliminary formulations and the commercial product CBZ 






Fig.8.2 Dissolution profiles of four preliminary formulations and CBZ commercial tablet. R: (reference) 
The dissolution profiles shown in Fig.8.2 indicate that, with an increase of dissolution enhancer 
lactose, the drug’s release rate increased (F4>F3; F2>F1). The release rates of all four preliminary 
formulations were faster than those of the reference (i.e. commercial) tablets, signifying that when 
HPMCP is used in MCC tablets, they disintegrate rapidly so as to increase the surface area of their 
fragments and so promote rapid drug release. The pharmaceutical excipient MCC thus cannot 
sustain the release of CBZ from the tablets. The dissolution profiles of the four preliminary 
formulations suggest that a high-viscosity polymer should be used in the formulations in order to 
make the tablets sustained-release. Based on the previous experiments, HPMC was selected as a 





8.4 Risk assessments 
Risk assessment aims to obtain all the potential high impact factors to be subjected to a Design of 
Experiment (DoE) study that establishes a product or process design space. A fish-bone diagram 
identifies the potential risks and corresponding causes. Friability and hardness of tablets are 
identified as the Critical Quality Attributes (CQAs). Based on the preliminary work, factors thought 
to affect dissolution are assessed and the critical attributes identified. These factors are shown in the 
following fish bone diagram (Fig.8.3). 
 
Fig.8.3 Fish bone diagram showing the possible factors that could affect CBZ’s dissolution rate  
8.5 Design of Experiment (DoE) [69]  
The Box-Behnken experimental design was used to optimise and evaluate the main effects of 
HPMC, HPMCP and lactose together with their interaction effects. A three-factor, three-level 
design was used because it was suitable for exploring quadratic response surfaces and constructing 
second order polynomial models for optimisation. The independent factors and dependent variables 
used in this design are listed in Table 8.4. Selection of the low, medium and high levels of each 
independent factor was based on the results of the preliminary experiments. HPMC was used as 






















channel agent and lactose as its dissolution enhancer. For the response surface methodology 
involving the Box-Behnken design, a total of 15 experiments were constructed for the three factors 
at the three levels of each parameter, as shown in Table 8.4. Each factor was tested at three levels 
designated as -1, 0 and +1. HPMCP’s weight percentage ranged from 5% (-1) to 15% (+1), 
HPMC’s weight percentage from 5% (-1) to 15% (+1) and lactose’s weight percentage from 2% (-1) 
to 6% (+1).  The design was equal to the three replicated centre points and the set of points lying at 
the midpoint of each surface on the cube defining the region of interest of each parameter. The non-
linear quadratic model generated by the design is  
𝑌 = 𝑏0 + 𝑏1𝑥1 + 𝑏2𝑥2 + 𝑏3𝑥3 + 𝑏12𝑥1 𝑥2+𝑏13𝑥1𝑥3 + 𝑏23𝑥2𝑥3 + 𝑏11𝑥1
2 + 𝑏22𝑥2
2 + 𝑏33𝑥3
2         Equ.8.1 
where Y is a measured response associated with each factor level combination,  𝑏0 is an intercept, 
𝑏1 to 𝑏33 are regression coefficients calculated from the observed experimental values of Y, and 
𝑥1,𝑥2 and 𝑥3 are the coded levels of independent variables. The terms 𝑥1 𝑥2, 𝑥1𝑥3, 𝑥2𝑥3  and 𝑥𝑖 
2 (i=1, 
2 and 3) represent the interaction and quadratic terms respectively. The response surface and 
analysis were carried out using JMP 11 software (SAS, SAS Institute, Cary, NC, USA). 
Table 8.4 Variables and levels in the Box-Behnken experimental design 
In dependent variables level 
Low (-1) Medium(0) High(+1) 
𝑥1 : weight percentage of HPMCP 5 10 15 
𝑥2: weight percentage of HPMC 5 10 15 
𝑥3 : weight percentage of lactose 2 4 6 
Dependent responses Goal lower limit upper limit 
𝑌1: drug release percentage at 0.5 hours Match 
Target 
15 30 
𝑌2: drug release percentage at 2 hours Match 
Target 
40 60 




The Box-Behnken design was applied in this study to optimise CBZ sustained-release tablets. A 





optimisation was to determine the design space of excipients range in order to obtain a target 
product which releases the drug at rates of 15-30% at 0.5 hours, 40-60% at 2 hours and no less than 
75% at 6 hours.  The observed responses for the 15 experiments are given in Table 8.5. 
Tablets produced were white, smooth, flat faced and circular. No cracks were observed. Physical 
tests for the 15 formulations were carried out to study the average mass, thickness, diameter, 
hardness and friability of the tablets. Six tablets of each formulation were tested for mass and 
friability, and three of each for thickness, diameter and hardness. 
Table 8.5 The Box-Behnken experimental design and responses 
Run Independent variables Dependent variables Hardness Friability 
mode 𝑿𝟏 𝑿𝟐 𝑿𝟑 𝒀𝟏 𝒀𝟐 𝒀𝟑 𝒀𝟒 𝒀𝟓 
1 --0 5 5 4 57.45 82.70 87.96 141.27 0.143 
2 -0- 5 10 2 33.23 60.20 80.73 135.30 0.219 
3 -0+ 5 10 6 31.79 53.93 79.58 152.90 0.213 
4 -+0 5 15 4 16.01 31.21 60.37 157.53 0.080 
5 0-- 10 5 2 63.98 85.72 89.11 140.27 0.195 
6 0-+ 10 5 6 66.47 88.52 89.19 134.67 0.293 
7 000 10 10 4 22.16 47.80 79.43 115.97 0.253 
8 000 10 10 4 29.47 52.31 88.24 140.80 0.213 
9 000 10 10 4 27.51 54.94 86.18 140.73 0.207 
10 0+- 10 15 2 14.17 31.83 67.15 159.40 0.040 
11 0++ 10 15 6 10.51 35.19 67.76 137.77 0.482 
12 +-0 15 5 4 72.23 85.80 88.80 123.63 0.290 
13 +0- 15 10 2 29.36 51.49 75.96 159.43 0.182 
14 +0+ 15 10 6 28.38 58.60 81.73 144.43 0.274 
15 ++0 15 15 4 13.13 32.86 64.84 129.37 0.404 
Notes: “-” indicates low (-1) level; “0” indicates medium (0) level; “+” indicates high (+1) level. 
The average masses of all formulations ranged between 0.501 g and 0.506 g. The average thickness 
of the tablets ranged from 3.307 mm to 3.563 mm. The average diameters of the tablets ranged from 
12.657 mm to 12.790 mm. Friability tests showed vales less than 1% for all the formulations range 
between 0.080% and 0.482%.  The lowest average hardness was 115.97 N and the highest was 





The standard deviation calculated for the average masses, thickness and diameters was less than 1%. 
This indicated that the reproducibility process for the tablets was good. The friability was less than 
1%, which showed that the tablets’ mechanical resistance was likewise good.   
The hardness of Formulation 1 (HPMCP 5%, HPMC 5%, lactose 4%) was 141.27 N. Increasing the 
percentage of HPMCP in Formulation 12 (HPMCP 15%, HPMC 5%, lactose 4%) resulted in a 
hardness value of 123.63 N. This decrease in hardness can be attributed to HPMCP’s poor 
compressibility properties, a quality which is also attested by the friability of Formulations 1 and 12, 
of 0.143 N and 0.290 N respectively.  
The effect of HPMC on the mechanical strength of the tablets was studied by comparing 
Formulations 1 (HPMCP 5%, HPMC 5%, Lactose 4%) and 4 (HPMCP 5%, HPMC 15%, lactose 
4%). Increasing the percentage of HPMC from 5% in the former to 15% in the latter resulted in an 
increase in hardness from 141.27 N to 157.53 N and a corresponding decrease in friability from 
0.143 to 0.080. These two effects can be attributed to the binding property of HPMC, that tends to 
hold the particles together, resulting in a stronger tablet. These results accord with those of the 
published paper [172]. Investigation of the various polymers’ structures and dry binding activities 
revealed that hardness and friability improved with increasing the percentage of binger  HPMC.  
Formulations 2 (HPMCP 5%, HPMC 10%, lactose 2%), 3 (HPMCP 5%, HPMC 10%, lactose 6%), 
5 (HPMCP 10%, HPMC 5%, lactose 2%) and 6 (HPMCP 10%, HPMC 5%, lactose 6%) were 
compared, with no significant effect of lactose on mechanical properties being observed.  
Table 8.6 Physical test showing average of tested masses, thicknesses and diameters of the 15 formulations 






1 0.501±0.003 3.307±0.038 12.757±0.055 
2 0.501±0.004 3.373±0.031 12.697±0.031 
3 0.502±0.001 3.337±0.049 12.660±0.017 
4 0.502±0.013 3.467±0.170 12.677±0.006 
5 0.502±0.003 3.353±0.021 12.710±0.010 
6 0.502±0.001 3.407±0.071 12.690 ±0.010 





8 0.500±0.004 3.387±0.025 12.683±0.015 
9 0.501±0.003 3.400±0.020 12.657±0.049 
10 0.502±0.003 3.453±0.035 12.743±0.055 
11 0.502±0.005 3.403±0.083 12.683±0.006 
12 0.506±0.006 3.457±0.015 12.677±0.015 
13 0.502±0.004 3.563±0.160 12.790±0.090 
14 0.502±0.003 3.350±0.050 12.697±0.025 
15 0.502±0.008 3.470±0.026 12.703±0.035 
Mass N=6 tablets, thickness, diameter N=3 tablets 
8.7 Discussion 
8.7.1 Fitting data to model 
Using a fitted full quadratic model, a response surface regression analysis for each of response𝑌1-
𝑌3was performed using JMP 11 software. Table 8.7 shows the values calculated for the coefficients 
and the P-value. Using a 5% significance level, a factor is considered to have a significant effect on 
the response if the coefficients markedly differ from zero and the P-value is less than 0.05 (p<0.05). 
A positive coefficient before a factor in the polynomial equation means that the response increases 
with the factor, while a negative one means that the relationship between response and factor is 
reciprocal. Higher order terms or more than one factor term in the regression equation represents 
nonlinear relationships between responses and factors. 
Table 8.7 Regression coefficients and associated probability values (P-value) for responses of 𝑌1, 𝑌2, 𝑌3 
Term   release percentage at 0.5h     release percentage at 2h     release percentage at 6h 
 Coefficient P-value  Coefficient P-value  Coefficient P-value 
Constant  26.38 <0.0001*  51.68 <0.0001*  84.62 <0.0001* 
X1  0.58 0.6968  0.09 0.9329  0.34 0.7956 
X2  -25.79 <0.0001*  -26.46 <0.0001*  -11.87 0.0002* 
X3  -0.45 0.7613  0.88 0.4229  0.66 0.6128 
X1*X2  -4.42 0.0759  -0.36 0.8085  0.91 0.6244 
X1*X3  0.12 0.9559  3.35 0.0649  1.73 0.3659 
X2*X3  -1.54 0.4721  0.14 0.9252  0.13 0.9423 
X1*X1  2.62 0.2597  1.10 0.4899  -3.96 0.0803 
X2*X2  10.78 0.0035*  5.36 0.0151*  -5.16 0.0359* 
X3*X3  1.69 0.4481  3.27 0.0775  -1.15 0.5524 

































It is quite evident that the factor of weight percentage of HPMC (𝑋2) and (𝑋2
2) had significant 
effects (P-value <0.05) on the drug release percentage at 0.5 hours (𝑌1), 2 hours (𝑌2) and 6 hours 
(𝑌3).  The weight percentage of HPMC (𝑋2) negatively affected the drug release percentage at 0.5 
hours, 2 hours and 6 hours. As expected, increasing HPMC’s weight percentage resulted in a 
decrease in the drug’s release percentage, as has already been reported in the literature [99, 157]. 
When a matrix tablet is immersed in the dissolution medium, wetting occurs at the surface and then 
progresses into the matrix to form an entangled three-dimensional gel structure in HPMC. 
Molecules undergoing chain entanglement are characterized by strong viscosity dependence on the 
concentration. An increase in the HPMC percentage in the formulation can lead to an increase in the 
gel viscosity, suppressing the dissolution of the drug [157]. The interaction effect of 𝑋1 and 𝑋2 
favoured a decrease in the drug’s release percentage at 0.5 hours (𝑌1) and 2 hours (𝑌2) while 
increasing it at 6 hours (𝑌3). The interaction effect of 𝑋1and 𝑋3 led to an increase in the drug’s 
release percentage at 0.5 hours (𝑌1), 2 hours (𝑌2) and 6 hours (𝑌3). The interaction effect of 𝑋2 and 
𝑋3 resulted in a decrease in the drug’s release percentage at 0.5 hours (𝑌1) and an increase in that 
percentage at 2 hours (𝑌2) and 6 hours (𝑌3). The interaction effect of 𝑋1
2 favoured an increase in the 
drug’s release percentage at 0.5 hours (𝑌1) and 2 hours (𝑌2) while decreasing it at 6 hours (𝑌3). The 
interaction effect of 𝑋2
2 resulted in an increase in the drug’s release percentage at 0.5 hours (𝑌1) and 
2 hours (𝑌2) and a decrease at 6 hours (𝑌3).  It is also evident that the interaction effect of 𝑋2
2 
significantly affects the drug’s release percentage at 0.5 hours (𝑌1), 2 hours (𝑌2) and 6 hours (𝑌3). 
The interaction effect of 𝑋3
2 favoured an increase in this percentage at 0.5 hours (𝑌1) and 2 hours (𝑌2) 
while decreasing it at 6 hours (𝑌3).   
Repeatability of the formulation experiments was studied by examining the results of Experiments 
7 to 9. The values of the dependent responses (𝑌1 , 𝑌2  and  𝑌3 ) were similar, indicating good 





8.7.2 Response contour plots 
The relationship between the inputs and outputs are further elucidated using response contour plots, 
which are very useful in the study of the effects of two factors on a response at the same time as a 
third factor is kept at a constant level. The focus was to study the effects of the weight percentages 
of HPMCP, HPMC and lactose, and of their interactions, on the responses of the drug release 
percentages at 0.5 hours (𝑌1), 2 hours (𝑌2) and 6 hours ( 𝑌3). 
The effect of X1 and X2 and their interaction on the drug release percentage at 0.5 hours (𝑌1), 2 
hours (𝑌2) and 6 hours ( 𝑌3) at medium level of 𝑋3 is given in Fig.8.4. In the contour plots shown in 
Fig.8.4 (d), the white areas show the formulation spaces which can meet the required dissolution 
profiles: drug release between 15 to 30% at 0.5 hours; 40 to 60% at 2 hours; above 75% at 6 hours.  
 
                (a)                                                                           (b)                           
 





Fig.8.4 Response contour plots showing the effect of weight percentages of HPMCP (X1) and HPMC (X2), (a) on the 
drug release percentage at 0.5 hours (Y1) at a medium weight percentage of lactose (X3); (b) on the drug release 
percentage at 2 hours (Y2) at a medium weight percentage of lactose (X3); (c) on the drug release percentage at 6 hours 
(Y3) at a medium weight percentage of lactose (X3); (d) on the drug release percentage at 0.5 hours (Y1), 2 hours (Y2) and 
6 hours (Y3) at a medium weight percentage of lactose (X3). 
The effect of the input variables on the output variable Y1, Y2 and Y3 is summarised using a pareto 
chart and interaction plot in Figs.8.5–8.7. The interaction plots in Fig.8.5 show that, at a low and 
high level of weight percentage of HPMCP, the drug’s release percentage at 0.5 hours decreased 
with an increase of the weight percentage of HPMC, and that the drug’s release percentage at 0.5 
hours remained constant with changes in the weight percentage of lactose. At a low HPMC weight 
percentage, the drug’s release percentage at 0.5 hours increased slightly with an increase in HPMCP. 
At a high weight percentage of HPMC, however, the drug’s release percentage at 0.5 hours was 
nearly constant. Its release percentage at 0.5 hours remained constant with changes in the weight 
percentage of lactose at both low and high levels of HPMC weight percentage. There was not much 
difference in the drug’s release percentage at 0.5 hours, irrespective of lactose’s weight percentage. 
 
Fig.8.5 Interaction plot showing the quadratic effects on the interactions between factors on Y1 
As Fig.8.6 shows, at both low and high HPMCP weight percentages, the drug’s release percentage 
at 2 hours remained nearly constant with increased HPMC, indicating that HPMCP was not the 
main influence on that percentage. At both high (15%) and low (5%) HPMCP weight percentages, 





and high HPMC weight percentages, there was not much difference in the drug’s release percentage 
at 2 hours with increased HPMCP or lactose. At a high (6%) lactose weight percentage, the drug’s 
release percentage at 2 hours increased slightly with an increase of HPMCP, while at a low level 
(2%), it decreased slightly with an increase in HPMCP. The figures for the drug’s release 
percentage at 2 hours at both low and high lactose weight percentages were parallel, which 
indicates that lactose was the dissolution enhancer in the formulation.  
 
Fig.8.6 Interaction plot showing the quadratic effects on the interactions between factors on Y2 
Fig.8.7 shows that, at both low and high HPMCP weight percentages, the drug’s release percentage 
at 6 hours was similar; it decreased with an increase in HPMC weight percentage.  At a high 
HPMCP weight percentage, the drug’s release percentage at 6 hours increased slightly with an 
increase of lactose, but remained constant at a low percentage. At both low and high HPMC weight 
percentages, the drug’s release percentage at 6 hours remained largely unaffected by the change in 
either HPMCP or lactose, while at both low and high levels of lactose, the drug’s release percentage 
at 6 hours increased slightly and then decreased with an increase in HPMCP. The drug’s release 
percentage at 6 hours at both low and high lactose weight percentages were parallel, indicating that 






Fig.8.7 Interaction plot showing the quadratic effects on the interactions between factors on Y3 
8.7.3 Establishment and evaluation of the Design Space (DS) 
Design Space (DS) is defined by ICH Q8 as “the multidimensional combination and interaction of 
input variables (material attributes) and process parameters that have been demonstrated to provide 
assurance of quality. Working within the design space is not considered as a change; however the 
movement out of the design space is considered a change and would normally initiate a regulatory 
post approval change process. Design space is proposed by the applicant and is subject to the 
regulatory assessment and approval” [67].  
Based on the response surface models, a design space should define the ranges of the formulation, 
in which final tablet quality can be ensured. The objective of optimization is to maximize the range 
of input variables for meeting a goal. The desired response values were 15%<Y1<30%, 40%<Y2<60% 
and Y3>75%. When lactose was at the medium level set for the experiment, Fig.8.4 (a), (b) and (c) 
show the proposed design space of Y1, Y2 and Y3. As depicted in Fig.8.4(d), the blank region 
satisfied both 15%<Y1<30%, 40%<Y2<60% and Y3>75%.  
In order to evaluate the accuracy and robustness of the derived model, two further experiments were 
carried out with all three factors in the ranges of design space. Table 8.8 shows the three factors, the 
experimental and predicted values of all the response variables and their percentage errors. The 





the anticipated values was small. The prediction error varied between 1.74% and 4.46% for Y1, 0.48% 
and 1.46% for Y2 and 0.28% and 1.04% for Y3. 


















(6%, 10.5%, 2%) drug released % 
at 0.5 hours (Y1) 
28.35 27.86 1.74 
drug released % 
at 2 hours (Y2) 
54.02 54.81 1.46 
drug released % 
at 6 hours (Y3) 
79.82 80.05 0.28 
(14%, 12%, 6%) drug released % 
at 0.5 hours (Y1) 
20.12 19.22 4.46 
drug released % 
at 2 hours (Y2) 
49.26 49.50 0.48 
drug released % 
at 6 hours (Y3) 
78.83 78.01 1.04 
8.8 Chapter conclusion 
In this chapter, the influence factors of the HPMCP, HPMC and lactose weight percentages of the 
CBZ-NIC cocrystal sustained-release tablet formulation were studied using the Box-Behnken 
experimental design method. The results show that the level of HPMC (𝑋2) and (𝑋2
2) have a 
significant effect (P-value <0.05) on the drug’s release percentage at 0.5 hours (𝑌1), 2 hours (𝑌2) 
and 6 hours (𝑌3).  The weight percentage of HPMC (𝑋2) has negative effects on the drug’s release 
percentage at 0.5 hours, 2 hours and 6 hours. As expected, increasing HPMC’s weight percentage 
resulted in a decrease in the drug’s release percentage. 
Different mathematical models were developed to predict the drug’s release percentage at 0.5 hours, 
2 hours and 6 hours. The validation of the mathematical model showed that the variation between 
experimental value and model prediction was from 1.74% to 4.46% for 𝑌1, 1.46% to 0.48% for 𝑌2 
and 0.28% to1.04% for 𝑌3. The high degree of prediction obtained from validation experiments has 
demonstrated the reliability and effectiveness of the Box-Behnken experimental design method for 





Chapter 9 Conclusion and Future Work 
This chapter summarizes the work and its main findings. The limitations of the research are briefly 
discussed, along with potential areas for further research. 
9.1 Summary of the work 
This research has investigated the effect of coformers and polymers on the phase transformation 
and release profiles of CBZ cocrystals, which can explain the mechanism by which CBZ cocrystals 
dissolve in polymer solutions and tablets.  
The research commenced by reviewing some of the strategies to overcome poor water solubility. 
One of these, pharmaceutical cocrystals, was introduced in detail, including discussion of cocrystals 
design, formation and characterization methods, physicochemical properties, theoretical 
development on stability prediction and recent progress. Secondly, the formulation of tablets by the 
QbD method was introduced, and the drug delivery system-tablets and some definitions and basics 
of QbD were discussed. Finally, CBZ was briefly reviewed, a CBZ pharmaceutical cocrystal case 
study was presented and CBZ sustained/controlled release formulations were summarized. 
This research subsequently studied the effects of polymer HPMC on the phase transformation and 
release profiles of CBZ-NIC cocrystals. Solution-mediated phase transformation of CBZ-NIC 
cocrystals, which could greatly reduce the enhancement of its apparent solubility, was discussed in 
this part of the research. 
The effect of coformers on the phase transformation and release profiles of CBZ-SAC and CBZ-
CIN cocrystals in HPMC-based matrix tablets were further investigated.  
The polymer screening method was used to determine the polymers of HPMCAS, PVP, PEG that 
optimize the extent and stability supersaturation of CBZ cocrystals in solution. By comparing the 
behaviour of cocrystals with that of physical mixtures or the pure parent drug, the role of polymers 
in solution and tablet-based cocrystal formulations was investigated.  
This research finally studied the QbD approach to developing a CBZ-NIC cocrystal formulation 






This thesis investigated the effect of coformers and polymers on the phase transformation and 
release profiles of CBZ cocrystals in solution and in tablets, which can provide a comprehensive 
understanding of the mechanisms for phase transformation of CBZ cocrystals. 
The influence of HPMC on the phase transformation and release profiles of CBZ-NIC cocrystals in 
solution and in sustained release matrix tablets was investigated. The results indicate that HPMC 
cannot inhibit the transformation of CBZ-NIC cocrystals to CBZ DH in solution or in the gel layer 
of the matrix, as opposed to its ability to inhibit CBZ III phase transition to CBZ DH. HPMC’s 
inability to inhibit CBZ dihydrate during CBZ-NIC cocrystal dissolution is caused by the rate 
differences between CBZ-NIC cocrystal dissolution and formation of a CBZ-HPMC soluble 
complex in solution. 
The influence of HPMC on the phase transformation and release profiles of CBZ-SAC and CBZ-
CIN cocrystals in solution and in sustained release matrix tablets was also investigated, the finding 
being that the selection of different coformers of SAC and CIN affects the stability of the cocrystals 
in solution, resulting in significant differences in the apparent solubility of CBZ in solution. The 
dissolution advantage of CBZ-SAC cocrystals only lasts for a short period because of the speed of 
its conversion to its dihydrate form. HPMC can to some degree inhibit the crystallisation of CBZ 
DH during dissolution of CBZ-SAC cocrystals. By contrast, the improved dissolution rate of CBZ-
CIN cocrystals can be realised in both solution and formulation due to their stability. 
The influence of three polymers, HPMCAS, PVP and PEG, on the phase transformation of the three 
CBZ cocrystals CBZ-NIC, CBZ-SAC and CBZ-CIN in solution and tablet based formulations was 
also investigated. The study has shown that when HPMCAS with a concentration of 2 mg/ml or 
higher was pre-dissolved in solution, both CBZ-SAC and CBZ-CIN cocrystals can generate 
significantly higher CBZ supersaturated solutions with an increase of around three times the 
solubility of CBZ III, which can be sustained for more than 24 hours. All three cocrystals showed at 
least a two-fold increase in drug release compared with that of CBZ III in pH 6.8 PBS in the 
absence of a polymer at five minutes. These results demonstrate that cocrystals can be easily 
formulated through a simple solution formulation or powder formulation to generate a 
supersaturated concentration and faster dissolution rates to overcome those drugs with solubility- 





The CBZ-NIC cocrystal sustained release tablets were developed using the QbD method. Different 
mathematical models were developed to predict the drug release percentage at 0.5 hours, 2 hours 
and 6 hours. A high degree of predictiveness was obtained from validation experiments, 
demonstrating the reliability and effectiveness of QbD method in studying the CBZ sustained 
release tablet.  
9.3 Future work 
Future research into pharmaceutical cocrystals in the author’s laboratory will focus on preparation 
scale-up, a large amount of polymer screening and formulation, and the use of FTIR or Raman 
spectroscopy to characterize polymer-cocrystal and polymer-API interactions in solution. 
Although cocrystals can offer the advantage of providing a higher dissolution rate and greater 
apparent solubility to improve the bioavailability of a poorly water-soluble drug, a key limitation is 
that a stable form of the drug can be recrystallized during dissolution. The selection of both the 
cocrystal form and the excipients in formulations to maximise the benefit is an important part of 
successful product development. To achieve the target, it will first be necessary to scale up 
cocrystal preparation. The amount of cocrystal needed in the research, especially in the formulation 
study, is large, which makes it difficult to provide by slow evaporation and reaction crystallisation 
methods.  
More work on cocrystal formulation is then required. The recognition and adoption of cocrystals as 
an alternative formulation strategies for drugs’ low bioavailability faces several obstacles. More 
laboratory work should be done on long-term stability, coformer toxicity and regulatory issues. In 
particular, in vivo experiments should be done to demonstrate the cocrystals’ performance is 
comparable to other approaches. The author hopes to develop different cocrystal formulations such 
as solutions, immediate-release tablets or capsules and sustained-release tablets or capsules. In 
addition, the investigation of the in vitro-in vivo correlation (IVIVC) should be studied.   
There is still much to learn about how crystals actually grow: it is not clear how they change from a 
liquid to a solid state. This process is called “nucleation”. It is the first step in crystallisation, 
determining whether a crystal can form from a liquid state. Even though the present study has used 
sufficient instrumentation techniques, however, the mechanism by which polymers affect the phase 
transformation of cocrystals is based on the assumption of existing “API-polymer” or “cocrystal-





techniques such as FT-Raman microscopy should be used to provide insight into how molecules 
interact in solution and ultimately form crystals. 
The powder-stir method was used to investigate the powder dissolution rate of CBZ-SAC and CBZ-
CIN cocrystals. Even before experiments were conducted, all the powders were lightly ground and 
sieved through a 60 mesh sieve in order to reduce the effect of particle size on dissolution rates. 
This rate still depended on particle size. A rotating disk IDR apparatus, monitored in real time by an 
in situ dip-probe fiber optic UV method, could be used in future to investigate the powder 
dissolution rate. It would reduce the effects of particle size by supporting a constant surface area 
while requiring a much smaller sample size. Further advantages of this method are that any 
polymorph changes during dissolution can be recognized, and the longer incubation time needed to 
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Predict solubility of CBZ cocrystals 
Solubility of cocrystal is predicted by Equ.2.12. 









                                                 Equ.2.12 
Table S2.1 lists the transition concentration values ([drug]tr and [coformer]tr) for cocrystal measured 
at the in variant point where two solid phases (drug and coformer) are in equilibrium with aqueous. 
All cocrystal 𝐶𝑡𝑟 values were confirmed by XRPD analysis of the solid phase, isolated from 
equilibrium with solution [9]. 
Table S2.1 Cocrystal Transition Concentration ([drug]tr and [coformer]tr), Component Solubilities [9] 
Cocrystal solvent pH [coformer]tr (mM) [drug]tr (mM) Sdrug (mM)
a
 pKa % nonionized
b 
 
CBZ-NIC water 6.0 8.5×10-1 5.8×10-3 4.6×10-4 3.5 100 




 1.6 24 
a Solubility of hydrated forms are indicated for aqueous samples. b Calculated for the measured pH using referenced 
pKa values.  
For 1:1 CBZ-NIC cocrystal: 









                                                 
= √[𝐴]𝑡𝑟𝐵𝑡𝑟𝛿𝑑𝑟𝑢𝑔
2
= √[𝐶𝐵𝑍]𝑡𝑟[𝑁𝐼𝐶]𝑡𝑟 × 100%
2   
                                           =√8.5 × 10−1 × 8.6 × 10−3 × 100%
2





For 1:1 CBZ-SAC cocrystal: 


























For 1:1 CBZ-CIN cocrystal: 
CIN coformer is presented as HA, a monoprotic acid. The equilibrium reactions for cocrystal 
dissociation and coformer ionization are given below: 
𝐶𝐵𝑍𝐻𝐴𝑠𝑜𝑙𝑖𝑑 ⇌ 𝐶𝐵𝑍𝑠𝑜𝑙𝑛 + 𝐻𝐴𝑠𝑜𝑙𝑛                                                              
  𝐾𝑠𝑝=[CBZ][HA]                                                                 Equ.S2.1 




                                                                  Equ.S2.2 
Ksp  is the solubility product of the cocrystal, and Ka  is the acid ionization constant. Species 
without subscripts indicate solution phase. The sum of the ionized and non-ionized species, is 
given by: 
[𝐴]𝑇 = [𝐻𝐴] + [𝐴
−]                                                            Equ.S2.3 
While total drug, which is non-ionizable, is given by: 
[𝑅]𝑇 = [𝑅]                                                                    Equ.S2.4 
By substituting for [HA] and [A−] from equations from Equations S.2.1 and S.2.2, respectively. 







)                                                        Equ.S2.5 
For a 1:1 molar ratio binary cocrystal, the solubility is equal to the total concentration of either 




)                                                     Equ.S2.6 






Table S.2.1 CQAs of Example Sustained release tablets [173] 
Quality Attributes of the Drug 
Product 






Appearance Color and shape 
acceptable to the 
patient. No visual tablet 
defects observed. 
No Color, shape and appearance are not directly 
linked to safety and efficacy. Therefore, 
they are not critical. The target is set to 
ensure patient acceptability 
Odor No unpleasant odor No In general, a noticeable odor is not directly 
linked to safety and efficacy, but odor can 
affect patient acceptability and lead to 
complaints. For this product, neither the 
drug substance nor the excipients have an 
unpleasant odor. No organic solvents will 
be used in the drug product manufacturing 
process. 
Friability Not more than 1.0% 
w/w 
No A target of not more than 1.0% mean 
weight loss is set according to the 
compendial requirement and to minimize 
post-marketing complaints regarding tablet 
appearance. This target friability will not 
impact patient safety or efficacy. 
Identification Positive for drug 
substance 
Yes  Though identification is critical for safety 
and efficacy, this CQA can be effectively 
controlled by the quality management 
system and will be monitored at drug 
product release. Formulation and process  
variables do not impact identity. 
Assay 100.0% of label claim Yes Variability in assay will affect safety and 
efficacy; therefore, assay is critical. 
Content 
Uniformity 
Whole tablets Conforms to USP. 
Uniformity of dosage 
units 
Yes Variability in content uniformity will affect 
safety and efficacy. Content uniformity of 
whole and split tablets is critical. Split tablets 
Drug release Whole tablet Similar drug release 
profile as reference 
drug. 
Yes The drug release profile is important for 














water   
0.5 mg/ml HPMC   
1 mg/ml HPMC   





Fig.S5.1 SEM photographs of the sample compacts before and after dissolution tests at different HPMC concentration 
solutions 
 
20 um Mag=2.5KX 20 um Mag=2.5KX 
20 um Mag=2.5KX 20 um Mag=2.5KX 
20 um Mag=2.5KX 20 um Mag=2.5KX 
20 um Mag=2.5KX 20 um Mag=2.5KX 
20 um Mag=2.5KX 20 um Mag=2.5KX 






Fig.S5.2 DSC thermographs of gels of different formulations obtained after dissolution tests: (a) CBZ III formulations; 











Fig.S6.1 XRPD patterns of solid residues of solubility tests: (a) CBZ-SAC cocrystal; (b) CBZ-CIN cocrystal 







solid residues in water






solid residues in 1mg/ml HPMC
solid residues in 2mg/ml HPMC
note: solid residues are physical mixture of CBZ DH and CBZ-SAC cocrystal
CBZ-SAC cocrystal in different concentration of HPMC solutions
CBZ DH
solid residues in 5mg/ml HPMC











CBZ-CIN cocrystal in different concentration of HPMC solutions
solid residues in 1mg/ml HPMC
solid residues in 0.5mg/ml HPMC
solid residues in 2mg/ml HPMC
note:solid residues are pure CBZ-CIN cocrystal
CBZ-CIN cocrystal
















Fig.S6.2 DSC results of solid residues of different formulations after dissolution tests: (a) CBZ III formulations; (b) 





Polymer (mg/ml) CBZ III CBZ-NIC cocrystal CBZ III-NIC physical 
mixture 
CBZ-SAC cocrystal CBZ III-SAC 
physical  mixture 
CBZ-CIN cocrystal CBZ III-CIN physical 
mixture 
0.5 HPMCAS 
       
PVP 
       
PEG 
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Fig.S7.1 DSC thermographs of solid residues retrieved from solubility studies in the presence of different concentrations of a polymer in pH 6.8 PBS 



























































































































































































Polymer (mg/ml) CBZ III CBZ-NIC 
cocrystal 
CBZ-NIC mixture CBZ-SAC 
cocrystal 
CBZ-SAC mixture CBZ-CIN 
cocrystal 
CBZ-CIN mixture 
0.5 HPMCAS        
PVP        
PEG        
1.0 HPMCAS        
50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 





PVP        
PEG        
5.0 HPMCAS        
PVP  
 
      
PEG        
Fig.S7.2 SEM photographs of the solid residues retrieved from solubility studies in the presence of different concentrations of a polymer in pH 6.8 PBS
50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 
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50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 







 CBZ concentrations of CBZ 
III, CBZ-NIC cocrystal and 
physical mixture of CBZ III-
NIC 
CBZ concentrations of CBZ 
III, CBZ-SAC cocrystal and 
physical mixture of CBZ III-
SAC 
CBZ concentrations of CBZ 
III, CBZ-CIN cocrystal and 
physical mixture of CBZ III-
CIN 
HPMCAS 
   
PVP 
   
PEG 
   
(b) 
Fig.S7.3 Coformer concentrations and comparison of CBZ concentrations of CBZ III, CBZ cocrystals and physical 
mixtures in the absence and presence of the different concentrations of pre-dissolved polymers in pH 6.8 PBS at 
equilibrium after 24 hours: (a) coformer concentration; (b) comparisons of  CBZ concentrations of CBZ III, CBZ 














CBZ-SAC cocrystal CBZ-SAC mixture CBZ-CIN cocrystal CBZ-CIN mixture 
100mg 
HPMCAS 
       
200mg 
HPMCAS 
       
100mg  
PVP 
       
200mg  
PVP 
       
50 um Mag=1.0KX 
50 um Mag=1.0KX 
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50 um Mag=1.0KX 50 um Mag=1.0KX 
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200mg  
PEG 
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Fig.S7.4 SEM photographs of solid residues of different formulation after dissolution tests (, it indicated no solid left)
50 um Mag=1.0KX 
50 um Mag=1.0KX 
50 um Mag=1.0KX 








  (b)                                                                           (c) 
Fig.S7.5 Eutectic constant Keu of CBZ cocrystals in the absence and presence of a 2 mg/ml polymer in pH 6.8 PBS 
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